

Summary Table of Study Protocol

Title	Inpatient Constipation Among Migraine Patients Treated With Preventive Medications: A Retrospective Cohort Study in a United States Electronic Health Record Database
Protocol version identifier	20190501 Version 1.0
Date of last version of the protocol	Not applicable
EU Post Authorization Study (PAS) Register No	TBD after final protocol approval
Active Substance	erenumab-aooe
Medicinal Product	Aimovig® (erenumab-aooe)
Device	Not applicable
Product Reference	AMG 334
Procedure Number	Not applicable
Joint PASS	No
Research Question and Objectives	<p>This study protocol will address the following objectives:</p> <ul style="list-style-type: none">• To describe baseline characteristics of three cohorts of migraine patients initiating a migraine preventive treatment: erenumab, other calcitonin-gene related peptide (CGRP) antagonists, and standard of care (SOC) antiepileptic preventive medications.• To estimate the incidence proportion of inpatient constipation in migraine patients treated with erenumab, other CGRP antagonists, or SOC antiepileptic preventive medications.• To estimate the incidence proportion of serious complications of inpatient constipation (defined by occurrence of a complication within 30 days following the inpatient constipation event).• To assess the comparability of migraine patients treated with erenumab to migraine patients treated with other CGRP antagonists, and, separately, with SOC antiepileptic preventive medications, with respect to baseline patient characteristics.• [GATED ANALYSES] If the cohorts are comparable, compare the incidence proportion of inpatient constipation among migraine patients treated with erenumab to migraine patients treated with other CGRP antagonists and, separately, with SOC antiepileptic preventive medications.

Country of Study	United States
Author	<p><u>Optum:</u> PPD [REDACTED], MPH Senior Epidemiologist, Epidemiology Email: PPD [REDACTED]</p> <p>PPD [REDACTED], ScD Executive Director, Epidemiology Email: PPD [REDACTED]</p> <p><u>Amgen:</u> PPD [REDACTED], PhD Center for Observational Research Email: PPD [REDACTED]</p> <p>PPD [REDACTED], PhD Center for Observational Research Email: PPD [REDACTED]</p> <p>PPD [REDACTED], PhD Center for Observational Research Email: PPD [REDACTED]</p> <p><u>Novartis:</u> PPD [REDACTED], MD, PhD Email: PPD [REDACTED]</p>

Marketing Authorization Holder

Marketing authorization holder(s)	Amgen Inc.
MAH Contact	Amgen Inc.

Confidentiality Notice


This document contains confidential information of Amgen Inc.

This document must not be disclosed to anyone other than the site study staff and members of the Institutional Review Board/Independent Ethics Committee/Institutional Scientific Review Board or equivalent, as applicable.

The information in this document cannot be used for any purpose other than the evaluation or conduct of the research without the prior written consent of Amgen Inc.

If you have questions regarding how this document may be used or shared, call the Amgen Medical Information number: 1-800-77-AMGEN or 1-805-447-1000.

Study Design Schema Cohort Study*



*Figure is not drawn to scale

<p>Cohorts</p> <p>Three cohorts of patients treated with:</p> <ul style="list-style-type: none"> Erenumab-aooe (Aimovig) Other CGRP antagonist medications Standard of care (SOC) antiepileptic migraine prophylaxis medications 	<p>Covariates (assessed during the baseline period)</p> <ul style="list-style-type: none"> Demographics <i>A priori</i> covariates including comorbidities and risk factors for inpatient constipation Cohort descriptors identified empirically from the most prevalent diagnoses, procedures and prescriptions during the baseline period
<p>Date definitions</p> <ul style="list-style-type: none"> Beginning of study period: 17 May 2018 (date of US FDA approval for erenumab) End of study period: 31 March 2020 Index date: earliest date of meeting cohort eligibility criteria during the study period Baseline period: 12-month period prior to and including the index date, for assessment of covariates Follow-up period: starting on the day after the index date, for outcome ascertainment 	
<p>Analyses to address the study objectives</p> <ul style="list-style-type: none"> Characterize the cohorts according to baseline covariates using descriptive statistics. Estimate the incidence proportion of inpatient constipation in the cohorts. Estimate the incidence proportion of serious complications of inpatient constipation within 30 days following the inpatient constipation event. Assess the comparability of the erenumab cohort to the other CGRP antagonist and, separately, to the SOC antiepileptic preventive medication cohort, with respect to baseline confounders and risk factors for constipation using descriptive statistics prior to propensity score (PS) matching and after PS matching. Graphical distributions of the PS before and after matching will also be reviewed. [GATED] If the matched cohorts are comparable, compare the incidence proportion of inpatient constipation in the erenumab cohort to the other two cohorts with odds ratios obtained from logistic regression models. 	

1. Table of Contents

Summary Table of Study Protocol 1

Study Design Schema 4

1. Table of Contents 5

2. List of Abbreviations 8

3. Responsible Parties 9

4. Abstract 9

5. Amendments and Updates 13

6. Rationale and Background 13

6.1 Diseases and Therapeutic Area 13

6.2 Rationale 14

6.3 Statistical Inference (Estimation or Hypothesis[es]) 15

7. Research Question and Objectives 15

7.1 Primary 15

8. Research Methods 15

8.1 Study Design 15

8.2 Setting and Study Population 16

8.2.1 Study Period 16

8.2.2 Subject/Patient/Healthcare Professional Eligibility 16

8.2.2.1 Inclusion Criteria 16

8.2.2.2 Exclusion Criteria 17

8.2.3 Matching 17

8.2.4 Baseline Period 18

8.2.5 Study Follow-up 19

8.2.5.1 Erenumab Cohort 19

8.2.5.2 Other CGRP Antagonist Cohort 19

8.2.5.3 SOC Antiepileptic Preventive Medication Cohort 19

8.3 Variables 19

8.3.1 Exposure Assessment 19

8.3.2 Outcome Assessment 20

8.3.3 Covariate Assessment 20

8.3.3.1 Characterization of the Study Cohorts 20

8.3.3.2 Risk Factors for Inclusion in the PS Models 23

8.3.4 Validity and Reliability 26

8.4 Data Source 26

8.4.1	Extracting Free-text into Semi-structured Data: NLP Table.....	28
8.5	Study Size.....	29
8.6	Data Management.....	31
8.6.1	Obtaining Data Files.....	31
8.6.2	Linking Data Files.....	31
8.6.3	Review and Verification of Data Quality.....	32
8.7	Data Analysis.....	32
8.7.1	Planned Analyses.....	32
8.7.1.1	Primary Analysis.....	32
8.7.1.2	General Considerations.....	32
8.7.1.3	Missing or Incomplete Data and Lost to Follow-up.....	32
8.7.1.4	Descriptive Analysis.....	33
8.7.1.5	Analysis of the Primary, Secondary, and Exploratory Endpoint(s).....	36
8.7.1.6	Sensitivity Analysis.....	36
8.7.2	Analysis of Safety Endpoint(s)/Outcome(s).....	37
8.8	Quality Control.....	38
8.9	Limitations of the Research Methods.....	38
8.9.1	Internal Validity of Study Design.....	38
8.9.1.1	Measurement Error(s)/Misclassification(s).....	38
8.9.1.2	Information Bias.....	39
8.9.1.3	Selection Bias.....	39
8.9.1.4	Confounding.....	39
8.9.2	Limitations Due to Missing Data and/or Incomplete Data.....	40
8.10	Other Aspects.....	40
9.	Protection of Human Subjects.....	40
9.1	Institutional Review Board/Independent Ethics Committee (IRB/IEC).....	40
9.2	Patient Confidentiality.....	40
10.	Collection, Recording, and Reporting of Safety Information and Product Complaints.....	41
10.1	Safety Collection, Recording and Submission to Amgen Requirements.....	41
10.1.1	Safety Reporting Requirement to Regulatory Bodies.....	41
11.	Administrative and Legal Obligations.....	41
11.1	Protocol Amendments and Study Termination.....	41
12.	Plans for Disseminating and Communicating Study Results.....	41
12.1	Publication Policy.....	41

13. References	43
14. Appendices.....	44

List of Tables

Table 1. Covariates for Characterization of the Study Cohorts	20
Table 2. Risk Factors for Inclusion in the PS Models	24
Table 3. Demographics of the Optum EHR Database Through the Year 2018	27
Table 4. Distribution of Patients With a Migraine Preventive Treatment by Sex, Age Group, and Calendar Month/Year of the Index Date, Optum EHR Database, May 2018 through June 2019	29
Table 5. 95% CI Estimates and Half-widths for a Range of Constipation Values, Based on a Sample Size of 12,507 Erenumab Users, 6,785 Fremanezumab or Galcanezumab Users and 40,336 SOC Antiepileptic Preventive Medication Users.....	30
Table 6. Detectable Risk Ratios for Inpatient Constipation	31

List of Figures

Figure 1. Formation of Erenumab, Other CGRP Antagonist, and SOC Antiepileptic Preventive Medication Initiator Cohorts.....	34
---	----

List of Appendices

Appendix A. List of Stand-alone Documents.....	45
Appendix B. ENCePP Checklist for Study Protocols.....	46
Appendix C. NDCs for Identification of Erenumab, Other CGRP Antagonist, and SOC Antiepileptic Preventive Medication Cohorts.....	52
Appendix D. Inpatient Constipation and Serious Complications of Constipation Codes	169

2. List of Abbreviations

Term	Definition
AHS	American Headache Society
BMI	body mass index
CGRP	calcitonin gene-related peptide
CI	confidence interval
ED	emergency department
EHR	electronic health records
EMR	electronic medical records
ER	emergency room
FDA	Food and Drug Administration
ICD-10-CM	International Classification of Diseases, Tenth-Revision, Clinical Modification
IRB	institutional review board
mg	milligrams
NDC	National Drug Code
NLP	natural language processing
NSAIDs	nonsteroidal anti-inflammatory drugs
OR	odds ratio
OTC	over the counter
PS	propensity score
SD	standardized difference
SOC	standard of care
SOP	standard operating procedure
US	United States

3. Responsible Parties

Amgen Inc. Contacts (Study Sponsor):

PPD [REDACTED], PhD

Center for Observational Research

Email: PPD [REDACTED]

PPD [REDACTED], PhD

Center for Observational Research

Email: PPD [REDACTED]

Optum Contacts:

PPD [REDACTED], MPH

Senior Epidemiologist, Epidemiology

Email: PPD [REDACTED]

PPD [REDACTED], ScD

Executive Director, Epidemiology

Email: PPD [REDACTED]

4. Abstract

- Study Title
 - Inpatient Constipation Among Migraine Patients Treated With Preventive Medications: A Retrospective Cohort Study in a United States Electronic Health Record Database
- Study Background and Rationale
 - Erenumab was approved by the United States (US) FDA on 17 May 2018, followed by fremanezumab on 14 September 2018, galcanezumab on 27 September 2018, and eptinezumab on 21 February 2020, for the prevention of migraine in adults. This retrospective observational study will estimate the incidence proportion of inpatient constipation (constipation recorded during an inpatient hospital or emergency room [ED] visit), and estimate the incidence proportion of these inpatient constipation events with serious complications within 30 days, among migraine patients treated with calcitonin gene-related peptide (CGRP) antagonists and standard of care (SOC) antiepileptic preventive medications, to give context to events observed in real-world observations from post-marketing surveillance data.

- Research Question and Objective(s)
 - This study protocol will address the following objectives:

Objectives	Endpoints
<ul style="list-style-type: none"> • To describe baseline characteristics of three cohorts of migraine patients initiating a migraine preventive treatment: erenumab, other CGRP antagonists, or SOC antiepileptic preventive medications. 	<ul style="list-style-type: none"> • Not applicable
<ul style="list-style-type: none"> • To estimate the incidence proportion of inpatient constipation in migraine patients treated with erenumab, other CGRP antagonists, or SOC antiepileptic preventive medications. 	<ul style="list-style-type: none"> • Inpatient constipation
<ul style="list-style-type: none"> • To estimate the incidence proportion of serious complications of inpatient constipation (defined by occurrence of a complication within 30 days following the inpatient constipation event). 	<ul style="list-style-type: none"> • Serious complications of inpatient constipation
<ul style="list-style-type: none"> • To assess the comparability of migraine patients treated with erenumab to migraine patients treated with other CGRP antagonists and, separately, with SOC antiepileptic preventive medications with respect to baseline risk factors for constipation. 	<ul style="list-style-type: none"> • Not applicable
<ul style="list-style-type: none"> • [GATED ANALYSES] If the cohorts are comparable, compare the incidence proportion of inpatient constipation among migraine patients treated with erenumab to migraine patients treated with other CGRP antagonists and, separately, with SOC antiepileptic preventive medications. 	<ul style="list-style-type: none"> • Inpatient constipation

- Hypothesis(es)/Estimation
 - No formal hypotheses will be tested. We will: (1) estimate the incidence proportion (95% confidence interval [CI]) of inpatient constipation, and, separately, the incidence proportion (95% CI) of serious complications of inpatient constipation, in initiators of erenumab, other CGRP antagonists, and SOC antiepileptic preventive medications; and, (2) if the cohorts are comparable, this study will estimate the association between erenumab versus other CGRP antagonists initiators on the incidence proportion of inpatient constipation, and, separately, the association between erenumab versus SOC antiepileptic preventive medication initiators on the incidence proportion of inpatient constipation.

- Study Design/Type
 - Retrospective observational cohort study
- Study Population or Data Resource
 - Patients with migraine who initiate erenumab, other CGRP antagonists (fremanezumab, galcanezumab, and eptinezumab), and SOC antiepileptic preventive medications (carbamazepine, gabapentin, topiramate, valproate sodium/valproic acid/divalproex sodium, zonisamide) will be identified from Optum's Electronic Health Record (EHR) Research Database from 17 May 2018 (date of US FDA approval for erenumab) through 31 March 2020.
- Summary of Patient Eligibility Criteria
 - Cohort members will be required to have:
 - At least one prescription order for a study drug of interest
 - At least 18 years of age on the prescription order date
 - At least two diagnoses for migraine on different days in the 12 months prior to and including the prescription order date, or at least one prescription order for an acute migraine treatment (triptan or ergot) and at least one diagnosis for migraine in the 12 months prior to and including the prescription order date
 - At least one outpatient clinical visit at least 12 months prior to the prescription order date
 - Patients with missing/conflicting age and gender information will be excluded.
 - The three cohorts will be restricted to initiators of the study medications.
- Follow-up
 - Follow-up to evaluate outcomes will start on the day after the index date (cohort entry date) and continue until the first occurrence of the following: 1) for the erenumab and other CGRP antagonist cohorts, switching to an alternate CGRP antagonist, 2) for the SOC antiepileptic preventive medication cohort, initiation of a CGRP antagonist, 3) outcome of interest, or 4) end of the study period (31 March 2020).
- Variables
 - Outcome Variable(s)
 - Inpatient constipation (constipation recorded during an inpatient hospital or ED visit)
 - Serious complications of inpatient constipation (defined by occurrence of a complication during an inpatient hospital or ED visit within 30 days following the inpatient constipation event)

- Exposure Variable(s)
 - Erenumab, other CGRP antagonists, and SOC antiepileptic preventive medications
- Other Covariate(s)
 - Demographics, migraine preventive agents, comorbidities related to migraine, drugs that may cause constipation, drugs that treat constipation, gastrointestinal disorders, disorders that are associated with constipation, previous diagnosis of constipation or complications of constipation, family or personal history of constipation, and procedures related to constipation treatment. An *a priori* subset of these covariates will be considered in the assessment of the comparability of the cohorts.
 - Empirically identified covariates based on the most frequently occurring diagnoses, procedures, and medication class prescription orders.
- Study Sample Size
 - Within the Optum EHR database, a total of 12,507 erenumab users, 6,785 fremanezumab or galcanezumab users, and 40,336 users of select SOC antiepileptic preventive medications (carbamazepine, gabapentin, topiramate, valproate sodium/valproic acid/divalproex sodium, zonisamide) were identified from May 2018 through June 2019.
 - Based on these sample size estimates, the 95% CIs for an incidence proportion of inpatient constipation of 0.63% were (0.50, 0.77) for erenumab, (0.45, 0.83) for fremanezumab and galcanezumab, and (0.56, 0.71) for SOC antiepileptic preventive medication users. The final sample size for the study will change due to the criteria applied during the implementation of the protocol, including extension of the end of the study period through March 2020. We project this extension will result in cohorts of approximately 20,007 erenumab users, 14,285 other CGRP antagonist users, and 80,536 SOC antiepileptic preventive medication users through March 2020 (the number of eptinezumab users added to the other CGRP antagonist user cohort through March 2020 will be small given its' February 2020 approval date for marketed use in the US). We therefore expect to be able to estimate incidence proportion estimates of inpatient constipation with similar or greater precision.

- If a comparative analysis is conducted (assuming 1:1 matching of the erenumab cohort to the comparator cohort and an incidence of inpatient constipation of 0.63% in the comparator cohort), a risk ratio of 1.51 would be detected with 80% power with a sample size of 12,000 matched erenumab users (total matched study population of 24,000).
- Data Analysis
 - Data analyses will include a summary of baseline characteristics and risk factors for constipation, propensity score (PS) matching of the erenumab initiator cohort to the other CGRP antagonists and, separately, to the SOC antiepileptic preventive medication initiator cohorts, and an assessment of the comparability of the matched cohorts with respect to baseline patient characteristics. The incidence proportion of inpatient constipation and corresponding 95% CIs will be estimated within each cohort. The incidence proportion of serious complications of inpatient constipation within 30 days will also be estimated, along with associated 95% CIs. Incidence proportions of inpatient constipation will be estimated stratified by select baseline characteristics. If the comparative analysis is conducted, the incidence proportion of inpatient constipation in the erenumab cohort will be compared to those in the other CGRP antagonist cohort and, separately, to the SOC antiepileptic preventive medication cohort with odds ratios estimated from logistic regression models. Covariates that remain imbalanced following PS matching may be considered for multivariable adjustment.

5. Amendments and Updates

None

6. Rationale and Background

6.1 Diseases and Therapeutic Area

Migraine is a neurological disorder characterized by recurrent headache attacks of moderate to severe pain. Migraines affect up to 18% of the female population and 6% of the male population [[Katsarava et al, 2012](#)]. Treatment options include medications for acute episodes (ie, triptans and ergotamines) and preventive medications to reduce the frequency and severity of migraines. Medications including antiepileptics, beta blockers, calcium channel blockers, antidepressants, and botulinum toxins have been prescribed for preventive purposes, but also have primary indications for other conditions such as epilepsy, depression, and hypertension. Monoclonal antibodies targeting CGRP are the newest medicines that were developed specifically for the prevention of migraine. During

the study period, four CGRP antagonists were approved for this indication by the United States (US) Food and Drug Administration (FDA): erenumab-aooe (Aimovig®), fremanezumab-vfrm (Ajovy®), galcanezumab-gnlm (Emgality®), and eptinezumab-jjmr (Vyepiti™). Erenumab was approved by the US FDA on 17 May 2018, followed by fremanezumab on 14 September 2018, galcanezumab on 27 September 2018, and eptinezumab on 21 February 2020.

6.2 Rationale

The incidence of constipation from erenumab clinical trials was 1% with placebo, 1% with 70 milligrams (mg), and 3% with 140 mg in the three erenumab pivotal clinical trials during the 12-week double-blinded treatment phase [Dodick et al, 2018; Goadsby et al, 2017; Tepper et al, 2017]. In October 2019, an update of constipation with serious complications was added to the Warning and Precautions section of the product label for erenumab [Erenumab Prescribing Information, March 2019]. In a retrospective cohort study conducted within the MarketScan® Research Databases, the incidence of serious constipation (defined as a constipation claim in an emergency room [ER] or inpatient setting) in migraine patients initiating various acute and preventive migraine treatments was 0.63% [Chia et al, 2019].

In a companion retrospective observational study (Amgen Protocol 20200087), the incidence proportion of inpatient constipation (constipation recorded during an inpatient hospital or ED visit) and the proportion of inpatient constipation events with a serious complication within 30 days was described among migraine patients treated with erenumab, to give context to events observed in real-world observations from post-marketing surveillance data. Protocol 20200087 was developed in order to submit these descriptive results to the American Headache Society (AHS) 2020 conference with an abstract submission deadline of April 2020. When the AHS conference was cancelled due to the COVID-19 pandemic, the abstract was instead submitted to the Migraine Trust International Symposium virtual conference (presentation scheduled for October 2020). The current retrospective observational study will expand on the study described in Protocol 20200087 to estimate the incidence proportion of inpatient constipation as recorded during an inpatient hospital or ED visit among migraine patients treated with erenumab, other CGRP antagonists (galcanezumab, fremanezumab, and eptinezumab), and standard of care (SOC) antiepileptic preventive medications (carbamazepine, gabapentin, topiramate, valproate sodium/valproic acid/divalproex sodium, zonisamide). The five antiepileptic medications were selected for the SOC cohort as they are not

known to be associated with increased risk of constipation, while other SOC preventive medications, including antihypertensives and antidepressants, are associated with constipation [Wald, 2020].

6.3 Statistical Inference (Estimation or Hypothesis[es])

No formal hypotheses will be tested. We will: (1) estimate the incidence proportion (95% confidence interval [CI]) of inpatient constipation, and, separately, the incidence proportion (95% CI) of serious complications of inpatient constipation, in initiators of erenumab, other CGRP antagonists, and SOC antiepileptic preventive medications; and, (2) if the cohorts are comparable, this study will estimate the association between erenumab versus other CGRP antagonists initiators on the incidence proportion of inpatient constipation, and, separately, the association between erenumab versus SOC antiepileptic preventive medication initiators on the incidence proportion of inpatient constipation.

7. Research Question and Objectives

7.1 Primary

This study protocol will address the following objectives:

- To describe baseline characteristics of three cohorts of migraine patients initiating a migraine preventive treatment: erenumab, other CGRP antagonists, or SOC antiepileptic preventive medications.
- To estimate the incidence proportion of inpatient constipation in migraine patients treated with erenumab, other CGRP antagonists, or SOC antiepileptic preventive medications.
- To estimate the incidence proportion of serious complications of inpatient constipation (defined by occurrence of a complication within 30 days following the inpatient constipation event).
- To assess the comparability of migraine patients treated with erenumab to migraine patients treated with other CGRP antagonists, and, separately, to migraine patients treated with SOC antiepileptic preventive medications, with respect to baseline risk factors for constipation.
- [GATED ANALYSES] If the cohorts are comparable, compare the incidence proportion of inpatient constipation among migraine patients treated with erenumab to migraine patients treated with other CGRP antagonists, and, separately, to migraine patients treated with SOC antiepileptic preventive medications.

8. Research Methods

8.1 Study Design

This is a retrospective observational cohort study using secondary data from the Optum EHR database. Patients with migraine initiating erenumab will be identified through the presence of prescription orders within the EHR database. The following cohorts of

patients with migraine will also be identified: 1) patients initiating the other CGRP antagonists fremanezumab, galcanezumab, or eptinezumab, and 2) patients initiating SOC antiepileptic preventive medications. The primary outcome of interest is inpatient constipation, which will be identified following the index date using International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis codes within the EHR database (described in [Section 8.3.2](#)). Serious complications of inpatient constipation will also be identified using ICD-10-CM diagnosis codes (described in [Section 8.3.2](#)).

This study will estimate the incidence proportion of inpatient constipation among cohorts of erenumab, other CGRP antagonist, and SOC antiepileptic preventive medication initiators. If the erenumab cohort is comparable to the other CGRP antagonist and, separately, to the SOC antiepileptic preventive medication cohorts with respect to baseline characteristics (described in [Section 8.7.1.4.3](#)), the analysis will compare the incidence proportion of inpatient constipation among the erenumab cohort to the other 2 cohorts.

8.2 Setting and Study Population

The study population will be drawn from Optum's EHR database, a de-identified patient-level database that integrates multiple electronic medical record (EMR) data systems with medical claims, prescription, and practice management data. The database incorporates relevant clinical data on patients from both ambulatory and inpatient settings, including medical records, laboratory results, and drug prescription and administration data (including number of refills), as recorded during routine clinical practice. The study population includes patients identified as having migraine and who have a prescription order for a migraine treatment. The study cohorts will be identified based on a combination of National Drug Codes (NDC) and ICD-10-CM diagnosis codes for migraine.

8.2.1 Study Period

Study cohort members will be identified from 17 May 2018, which is the date of US FDA approval for erenumab, through 31 March 2020. Outcomes will be identified through 31 March 2020.

8.2.2 Subject/Patient/Healthcare Professional Eligibility

8.2.2.1 Inclusion Criteria

Initiators of erenumab, other CGRP antagonists, and SOC preventive medications will be identified during the cohort accrual period using NDCs as recorded in the prescription

order table within the EHR database. SOC preventive medications will include select antiepileptic migraine preventive agents. A list of these SOC antiepileptic preventive medications is provided in [Section 8.3.1](#). To select initiator cohorts, only the first prescription order for these medications that are identified during the study period will be assessed for the following criteria:

- At least 18 years of age on the prescription order date
- At least two diagnosis codes for migraine (ICD-10-CM G43.-) on two different days in the 12 months prior to and including the prescription order date, or at least one prescription order for an acute migraine treatment (triptan or ergot) and at least one diagnosis code for migraine in the 12 months prior to and including the prescription order date
- All cohorts will be required to have at least one outpatient clinical visit at least one year prior to the prescription order date to establish a 12-month baseline period for assessment of prevalent medication use, patient characteristics, and comorbidities. If sample size is a concern, we will also examine the number of patients who have a visit at least 6 and 9 months prior to their prescription order date.
- No prescription order for any CGRP antagonist during the 12-month baseline period.
- For the SOC antiepileptic preventive medication cohort only, no prescription order for any of the five antiepileptic medications during the 12-month baseline period.

The index date will be defined as the date of the earliest prescription order that meets all of the above criteria. Because it is expected that patients will have started erenumab or another CGRP antagonist after attempting treatment with an SOC preventive medication, the SOC antiepileptic preventive medication cohort will be selected from the remaining population of migraine preventive treatment users after the erenumab and CGRP antagonist cohorts are formed. Random sampling may be considered for the SOC antiepileptic preventive medication cohort if the sample size following implementation of the inclusion criteria is much larger than the size of the erenumab and the other CGRP antagonist cohorts.

8.2.2.2 Exclusion Criteria

Cohort members with missing or conflicting age or sex information will be excluded.

8.2.3 Matching

To address the fourth and fifth objectives of this study, the erenumab cohort will be matched to the other CGRP antagonist and, and, separately, to the SOC antiepileptic preventive medication cohorts using PS matching.

The following PS-matched comparisons will be assessed:

- Erenumab versus other CGRP antagonists
- Erenumab versus SOC antiepileptic preventive medications

PSs will be estimated by logistic regression models that incorporate risk factors for constipation, and *a priori* identified potential confounders. These confounders and risk factors for constipation will be the independent variables in the regression model with the group status (initiation of erenumab or comparator) as the dependent variable. The independent variables will be identified during the baseline period (12 months prior to and including the index date), without respect to group status. Because patterns of prescribing tend to change over time, prediction equations need to account for these secular changes. To accommodate changes in the way that migraine treatments are used over time, the PS model may include interaction terms for select risk factors by calendar time, as sample size allows. For a given risk factor pattern, the PS is the fitted value of the probability of being a member of the primary exposure cohort (erenumab), given membership in the study population and the covariate pattern.

Each erenumab cohort member will be matched to members of the two comparator cohorts (other CGRP antagonists or SOC antiepileptic preventive medications) using a standard matching algorithm, such as one with a variable caliper [Parsons, 2001; Parsons, 2004]. Each erenumab cohort member will be matched to the comparator cohort member in a 1:1 ratio, without replacement. Comparator members will be selected at random from all potential comparators who match sufficiently closely to the erenumab cohort member (ie, within the variable caliper applied by the matching algorithm that allows a maximum PS difference of 0.1). The PS matching process may result in some erenumab cohort members remaining unmatched. For transparency, characteristics of the unmatched cohort members will also be described.

8.2.4 Baseline Period

The baseline period for covariate assessment will be the 12 months prior to and including the index date. During this time frame, the study cohorts will be characterized with respect to demographics, comorbidities related to migraine, use of migraine preventive agents or drugs that may cause constipation, gastrointestinal disorders, disorders that are associated with constipation, previous diagnosis of constipation or complications of constipation, family or personal history of constipation, and procedures related to constipation treatment. A complete list of covariates that will be assessed

during the baseline period for cohort characterization and a complete list of constipation risk factors for inclusion in the PS model are provided in [Section 8.3.3](#).

8.2.5 Study Follow-up

Follow-up to evaluate the occurrence of inpatient constipation will start on the day after the index date and continue until the earliest occurrence of the following:

8.2.5.1 Erenumab Cohort

- Prescription for galcanezumab, fremanezumab, or eptinezumab
- Outcome of interest
- End of the study period (31 March 2020)

8.2.5.2 Other CGRP Antagonist Cohort

- Prescription for erenumab
- Outcome of interest
- End of the study period

8.2.5.3 SOC Antiepileptic Preventive Medication Cohort

- Prescription for erenumab, galcanezumab, fremanezumab, or eptinezumab
- Outcome of interest
- End of the study period

Since the SOC antiepileptic preventive medications may be prescribed for indications other than migraine, a prescription for an SOC antiepileptic preventive medication will not censor follow-up for any of the study cohorts. For each of the study cohorts, the number of patients receiving an SOC antiepileptic preventive medication during their follow-up will be tabulated. A sensitivity analysis that applies this censoring criterion to the erenumab and other CGRP antagonist cohorts will be conducted. Details of this sensitivity analysis are provided in [Section 8.7.1.6.4](#).

8.3 Variables

8.3.1 Exposure Assessment

The cohorts of erenumab (Amgen Protocol 20200087), other CGRP antagonist (fremanezumab, galcanezumab, and eptinezumab), and SOC antiepileptic preventive medication (carbamazepine, gabapentin, topiramate, valproate sodium/valproic acid/divalproex sodium and zonisamide) initiators will be identified as described in [Section 8.2](#). All medications will be identified with NDCs as recorded in the prescription order table within the EHR database. A list of NDCs that are available in the EHR database and used for cohort identification is provided in [Appendix C](#).

8.3.2 Outcome Assessment

The outcome of interest is inpatient constipation, which will be identified within the EHR database using ICD-10-CM diagnosis codes for constipation that are recorded during an emergency department (ED) or inpatient hospital stay. This may include events where constipation is the reason for the admission, where constipation is present on admission, and where constipation developed over the course of the stay.

Inpatient constipation will be assessed starting on the day after the index date through the earliest occurrence of switching of migraine preventive therapy or end of the study period (31 March 2020). Only the first (incident) event will be included in the analysis. The occurrence of serious complications of inpatient constipation will be assessed by the presence of at least one ICD-10-CM diagnosis code for fecal impaction, intestinal obstructions, anal fissures and/or fistulas as well as other symptoms identified in an ED or inpatient setting within 30 days following the inpatient constipation event. ICD-10-CM diagnosis codes for inpatient constipation and serious complications are provided in [Appendix D](#).

8.3.3 Covariate Assessment

8.3.3.1 Characterization of the Study Cohorts

The three study cohorts will be characterized with respect to the variables listed in [Table 1](#). A subset of these covariates that are confounders and risk factors for constipation will be included in the PS models. These confounders and risk factors are listed in [Section 8.3.3.2](#).

Table 1. Covariates for Characterization of the Study Cohorts

Demographics: <ul style="list-style-type: none">• Age• Gender• Body mass index• Geographic region
Migraine preventive agents: <ul style="list-style-type: none">• Antihypertensives (beta blockers, calcium channel blockers, candesartan, clonidine, lisinopril)• Antiepileptics (carbamazepine, gabapentin, levetiracetam, pregabalin, topiramate, valproate sodium/valproic acid/divalproex sodium, zonisamide)• Antidepressants (SNRIs, tricyclic antidepressants, SSRIs)• Botulinum toxins• Other migraine preventives (carisoprodol, cyproheptadine, guanfacine, memantine, methysergide, milnacipran, tizanidine)

Page 1 of 4

Footnotes defined on last page of the table

Table 1. Covariates for Characterization of the Study Cohorts

<p>Comorbidities related to migraine:</p> <ul style="list-style-type: none">• Asthma• Hypertension• Anxiety• Depression• Non-migraine headache• Chronic pain• Insomnia• Thyroid disorder• Epilepsy
<p>Drugs that may cause constipation:</p> <p><i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Opioids/opiates• Anticholinergics<ul style="list-style-type: none">○ Antipsychotics○ Antihistamines○ Antispasmodics○ Antiparkinsonian drugs○ Tricyclic antidepressants• NSAIDs (prescription and OTC)• Cation-containing agents<ul style="list-style-type: none">○ Iron supplements○ Aluminum (antacids, sucralfate)
<ul style="list-style-type: none">○ Barium• Ganglionic blockers• Vinca alkaloids• 5-HT₃ antagonists
<p>Prescription drugs that treat constipation:</p> <p><i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Prescription laxatives (lactulose, dulcolax)• Other prescription treatments (tegaserod, linaclotides, lubiprostone)
<p>OTC drugs that treat constipation:</p> <p><i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Magnesium citrate• Milk of magnesia (magnesium hydroxide)• Colace (docusate sodium)• Sennakot• Miralax (polyethylene glycol)

Footnotes defined on last page of the table

Table 1. Covariates for Characterization of the Study Cohorts

<p>Gastrointestinal disorders: <i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Irritable bowel syndrome• Crohn's disease• Ulcerative colitis• Diverticulitis/diverticulosis• Hemorrhoids (excluding pregnancy-induced)
<p>Disorders that are associated with constipation: <i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Diabetes mellitus• Autonomic neuropathy• Multiple sclerosis• Hirschsprung disease• Chagas disease• Spinal cord injury• Parkinson's disease• Hypothyroidism• Hypokalemia• Anorexia nervosa• Pregnancy• Panhypopituitarism• Systemic sclerosis• Myotonic dystrophy
<p>Constipation or complications of constipation during the 12-month baseline period: <i>To include all separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Any constipation (OP/IP/ED)• Inpatient constipation (IP/ED)• Complications of constipation (IP/ED)<ul style="list-style-type: none">○ Fecal impaction○ Impaction of intestine○ Bowel perforation○ Bowel/intestinal obstruction○ Megacolon○ Rectal prolapse○ Anal fissure○ Anal fistula○ Ulcer of anus and rectum○ Paralytic ileus○ Removal of impacted feces○ Intestinal pseudoobstruction• Idiopathic constipation (OP/IP/ED)<ul style="list-style-type: none">○ Normal colonic transit○ Slow transit constipation○ Dyssynergic defecation

Footnotes defined on last page of the table

Page 3 of 4

Table 1. Covariates for Characterization of the Study Cohorts

<p>History of constipation: <i>To include all as separate variables, may combine with baseline diagnosis of constipation if there is significant overlap between the variables</i></p> <ul style="list-style-type: none">• Family history of constipation• Personal history of constipation
<p>Procedures related to constipation treatment:</p> <ul style="list-style-type: none">• Removal of fecal impaction under anesthesia• Home visit fecal impaction management/enema• Irrigation of lower GI tract using irrigating substance, via natural or artificial opening• Extirpation of matter from rectum• Extirpation of matter from anus• Repair/ileum• Repair/anus• Mentions from the clinical notes:<ul style="list-style-type: none">○ Gastrografin enema○ Glycerin/fleet enema

Page 4 of 4

Abbreviations: ED: emergency department; GI: gastrointestinal; IP: inpatient; NSAIDs: nonsteroidal anti-inflammatory drugs; OP: outpatient; OTC: over the counter; SNRIs: serotonin norepinephrine reuptake inhibitors; SSRIs: selective serotonin reuptake inhibitors

Personal and family history of constipation and enemas used for the treatment of constipation (gastrografin, glycerin/fleet) will be identified using the semi-structured data in the natural language processing (NLP) table within the EHR database ([Section 8.4.1](#)). All other covariates in the table, including over the counter (OTC) medication use (per patient reported medication use), will be assessed with ICD-10-CM diagnosis codes, NDCs, and procedure codes derived from the structured data tables in the EHR database ([Section 8.4](#)). Covariates will also be identified empirically from the most prevalent diagnoses, procedures, and medication classes identified during the 12-month baseline period. Some of the covariates in the table may be collapsed into smaller groups within each covariate category based on cell sizes.

8.3.3.2 Risk Factors for Inclusion in the PS Models

The confounders and risk factors for constipation that will be included in the PS models are listed in [Table 2](#). These covariates were selected *a priori*, and are a subset of the covariates listed in [Table 1](#).

Table 2. Risk Factors for Inclusion in the PS Models

<p>Demographics:</p> <ul style="list-style-type: none">• Age• Gender• Body mass index• Geographic region
<p>Migraine preventive agents:</p> <ul style="list-style-type: none">• Antihypertensives (beta blockers, calcium channel blockers, candesartan, clonidine, lisinopril)• Antiepileptics (levetiracetam, pregabalin)• Antidepressants (SNRIs, tricyclic antidepressants, SSRIs)• Botulinum toxins• Other migraine preventives (carisoprodol, cyproheptadine, guanfacine, memantine, methysergide, milnacipran, tizanidine)
<p>Comorbidities related to migraine:</p> <ul style="list-style-type: none">• Anxiety• Depression• Chronic pain• Insomnia• Thyroid disorder
<p>Drugs that may cause constipation:</p> <p><i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Opioids/opiates• Anticholinergics<ul style="list-style-type: none">○ Antipsychotics○ Antihistamines○ Antispasmodics○ Antiparkinsonian drugs○ Tricyclic antidepressants• NSAIDs (prescription and OTC)• Cation-containing agents<ul style="list-style-type: none">○ Iron supplements○ Aluminum (antacids, sucralfate)○ Barium• Ganglionic blockers• Vinca alkaloids• 5-HT3 antagonists
<p>Prescription drugs that treat constipation:</p> <p><i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Prescription laxatives (lactulose, dulcolax)• Other prescription treatments (tegaserod, linaclotides, lubiprostone)

Table 2. Risk Factors for Inclusion in the PS Models

<p>OTC drugs that treat constipation: <i>To include all separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Magnesium citrate• Milk of magnesia (magnesium hydroxide)• Colace (docusate sodium)• Sennakot• Miralax (polyethylene glycol)
<p>Gastrointestinal disorders: <i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Irritable bowel syndrome• Crohn's disease• Ulcerative colitis• Diverticulitis/diverticulosis• Hemorrhoids (excluding pregnancy-induced)
<p>Disorders that are associated with constipation: <i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Diabetes mellitus• Autonomic neuropathy• Multiple sclerosis• Hirschsprung disease• Chagas disease• Spinal cord injury• Parkinson's disease• Hypothyroidism• Hypokalemia• Anorexia nervosa• Pregnancy• Panhypopituitarism• Systemic sclerosis• Myotonic dystrophy
<p>Constipation or complications of constipation during the 12-month baseline period: <i>To include all as separate variables, may collapse into fewer groups based on cell sizes</i></p> <ul style="list-style-type: none">• Any constipation (OP/IP/ED)• Inpatient constipation (IP/ED)• Complications of constipation (IP/ED)<ul style="list-style-type: none">○ Fecal impaction○ Impaction of intestine○ Bowel perforation○ Bowel/intestinal obstruction
<ul style="list-style-type: none">○ Megacolon○ Rectal prolapse○ Anal fissure○ Anal fistula

Table 2. Risk Factors for Inclusion in the PS Models

<ul style="list-style-type: none">○ Ulcer of anus and rectum○ Paralytic ileus○ Removal of impacted feces○ Intestinal pseudoobstruction● Idiopathic constipation (OP/IP/ED)<ul style="list-style-type: none">○ Normal colonic transit○ Slow transit constipation○ Dyssynergic defecation
<p>History of constipation: <i>To include all as separate variables, may combine with baseline diagnosis of constipation if there is significant overlap between the variables</i></p> <ul style="list-style-type: none">● Family history of constipation● Personal history of constipation
<p>Procedures related to constipation treatment:</p> <ul style="list-style-type: none">● Removal of fecal impaction under anesthesia● Home visit for fecal impaction management/enema● Irrigation of lower GI tract using irrigating substance, via natural or artificial opening● Extirpation of matter from rectum● Extirpation of matter from anus● Repair/ileum● Repair/anus● Mentions from the clinical notes:<ul style="list-style-type: none">○ Gastrografin enema○ Glycerin/fleet enema

Page 3 of 3

8.3.4 Validity and Reliability

Exposure to erenumab, the other CGRP receptor antagonists, and SOC antiepileptic preventives will be identified using NDCs from the prescription order table in the EHR database. Inpatient constipation events and subsequent serious complications will be identified on the basis of ICD-10-CM diagnosis codes that are present during an ED or inpatient stay. No information on the validity or reliability of these variables are available from the literature.

8.4 Data Source

The study population will be drawn from Optum's EHR database, which encompasses the EHR data of more than 88 million patients for the time period 2007-2018. For 2018, data relating to 31.6 million patients with at least one medical encounter are available. The data are collected from more than 92,000 providers and 195 hospitals representing 50 EMR-based provider/hospital networks across the US. The population captured in Optum's EHR database is geographically diverse and not specific to health insurance so that patients with commercial health insurance are present along with patients with

coverage through Medicare, Medicaid, and even patients with no health insurance. As compared with the overall US population, Optum’s EHR database includes a smaller proportion of children and adolescents (< 18 years of age) and a larger proportion of those age 65 + years. Select characteristics of the Optum EHR database population and US population are included in Table 3. Data are updated and fully synchronized into the research database on a regular basis. On average, approximately four years of longitudinal data per patient are available, though medical interactions occurring outside of the contributing provider may be absent, a reflection of the underlying data sources. Because the underlying population is covered by a diverse set of health plans, (and includes patients who have no health insurance) heterogeneity in pharmacy coverage/tier status is expected, a distinction from databases derived from a single health insurer.

Table 3. Demographics of the Optum EHR Database Through the Year 2018

Attributes	Optum EHR Population†	US Health Care Utilizers‡	US Population§
	N~31.6 million	N~270.9 million	N~318.9 million
Sex			
Male	43%	47%	49%
Female	57%	53%	51%
US Region			
Northeast	19%	N/A	17%
Midwest	48%	N/A	21%
South	24%	N/A	38%
West	9%	N/A	24%
Age Group (Years)			
0-9	10%	13%	13%
10-17	7%	10%	11%
18-24	8%	8%	9%
25-34	12%	13%	14%
35-44	12%	12%	12%
45-54	13%	13%	13%
54-64	16%	14%	13%
65-74	12%	10%	9%
75+	10%	8%	6%

Footnotes defined on next page of the table

Table 3. Demographics of the Optum EHR Database Through the Year 2018

Attributes	Optum EHR Population†	US Health Care Utilizers‡	US Population§
	N~31.6 million	N~270.9 million	N~318.9 million
Race			
White	72%	65%	61%
African American	10%	11%	12%
Asian	2%	5%	6%
Other	16%	3%	3%

Page 2 of 2

† Statistics current through 31 December 2018. Patients without sufficient clinical data to meet a minimum quality threshold are excluded. Includes patients with at least one clinical observation at any time in 2018.

‡ Source of U.S. estimate of healthcare utilizers by age & sex: U.S. Department of Health & Human Services, Agency for Healthcare Research & Quality, Medical Expenditure Panel Survey (MEPS), Projected Expenditure Data File for 2018. Percent of U.S. population with non-zero medical expenditures found from MEPS and applied to U.S. population estimate for 2018 from U.S. Census Bureau, Current Population Survey to obtain denominator. MEPS data accessed at https://meps.ahrq.gov/mepsweb/data_stats/download_data_files_detail.jsp?cboPufNumber=NHEA-Aligned%20MEPS. U.S. Census data accessed at <http://www.census.gov/cps/data/cpstablecreator.html>.

§ Source of estimate of U.S. population totals alone and by insurance type: U.S. Census Bureau, Current Population Survey, Annual Social and Economic Supplement, 2018. Health insurance questions asked respondents about their status in the previous year (2018). Accessed at <http://www.census.gov/cps/data/cpstablecreator.html>.

Optum Epidemiology uses the EHR database to conduct safety-related research, including studies requested by regulatory authorities as part of product launch and post-marketing commitments, and clinical epidemiology and pharmacoepidemiologic research.

8.4.1 Extracting Free-text into Semi-structured Data: NLP Table

Within the EHR systems from which the EHR database is derived, free-text information from inpatient and outpatient clinical notes of physicians and nurses, as well as visit summaries, follow-up and referral letters, reports from imaging services, pathology investigations, surgical procedures, and other sources are available. Optum uses a generalized NLP system developed to extract and organize concepts from free-text into semi-structured fields, along with pertinent attributes, sentiments, and other modifiers. The types of concepts included in the NLP table include medications, clinical measurements (eg, BMI, heart rate), personal and family history, diagnostic and therapeutic procedures; and signs, diseases, and symptoms. These concepts allow for the capture of patient, disease, and treatment attributes for which standard codes do not exist.

8.5 Study Size

The following patients with a migraine preventive treatment were identified within the Optum EHR database from May 2018 through June 2019:

- 12,507 erenumab users
- 6,785 fremanezumab or galcanezumab users
- 40,336 users of select SOC antiepileptic preventive medications (carbamazepine, gabapentin, topiramate, valproate sodium/valproic acid/divalproex sodium, zonisamide)

These migraine preventive treatment users were required to be at least 18 years of age, have at least one diagnosis for migraine (ICD-10-CM G43.-) or one prescription order for a triptan/ergot in the prior 12 months, and at least one outpatient visit at least one year prior to the index date. The SOC antiepileptic medication users were further required to have an additional diagnosis for migraine (ICD-10-CM G43.-) on a different date from the first migraine diagnosis. The distribution of these patients by sex, age group, and calendar month/year of index date are provided in [Table 4](#). These counts were generated before the February 2020 approval of eptinezumab.

Table 4. Distribution of Patients With a Migraine Preventive Treatment by Sex, Age Group, and Calendar Month/Year of the Index Date, Optum EHR Database, May 2018 through June 2019

	Erenumab	Fremanezumab or galcanezumab	SOC antiepileptic medications
	N	N	N
Overall	12,507	6,785	40,336
Sex			
Male	1,589	849	5,329
Female	10,918	5,936	35,007
Age group (years)			
18-34	2,282	1,347	8,532
35-49	5,063	2,764	14,691
50-64	4,213	2,221	12,469
65 +	949	453	4,644
Calendar month/year of index date			
May-August 2018	1,563	0	7,705
September-December 2018	5,281	1,529	10,645
January-March 2019	3,150	2,721	8,583
April-June 2019	2,513	2,535	13,403

Table 5 provides the 95% confidence interval estimates for various risks of constipation (0.5%, 0.63%, 1%, 3%, 5%, 10%, and 20%) based on starting samples of 12,507 erenumab users, 6,785 fremanezumab or galcanezumab users, and 40,336 SOC antiepileptic preventive medication users.

Table 5. 95% CI Estimates and Half-widths for a Range of Constipation Values, Based on a Sample Size of 12,507 Erenumab Users, 6,785 Fremanezumab or Galcanezumab Users and 40,336 SOC Antiepileptic Preventive Medication Users

Constipation (%)	Erenumab N = 12,507		Fremanezumab or Galcanezumab N = 6,785		SOC Antiepileptic Preventive Medications N = 40,336	
	95% CI	Half-width of CI	95% CI	Half- width of CI	95% CI	Half- width of CI
0.50	0.38 - 0.63	0.13	0.34 - 0.67	0.17	0.43 - 0.57	0.07
0.63	0.50 - 0.77	0.14	0.45 - 0.83	0.19	0.56 - 0.71	0.08
1.00	0.84 - 1.19	0.18	0.77 - 1.24	0.24	0.91 - 1.10	0.10
3.00	2.71 - 3.31	0.30	2.61 - 3.42	0.41	2.84 - 3.17	0.17
5.00	4.63 - 5.39	0.38	4.50 - 5.53	0.52	4.79 - 5.21	0.21
10.00	9.48 - 10.53	0.53	9.30 - 10.72	0.71	9.71 - 10.29	0.29
20.00	19.30 - 20.70	0.70	19.06 - 20.96	0.95	19.61 - 20.39	0.39

Abbreviations: CI: confidence interval; SOC: standard of care

The final sample size for the study will change due to the criteria applied during the implementation of the protocol, including extension of the end of the study period through March 2020. If patient accrual from July 2019 – March 2020 is consistent with the numbers reported in Table 4 from April – June 2019 (~2,500 patients in the erenumab and other CGRP antagonist (fremanezumab or galcanezumab) cohorts and ~13,400 patients in the SOC antiepileptic preventive medication cohort), we expect to accrue an additional 7,500 erenumab and other CGRP antagonist medication users and an additional 40,200 SOC antiepileptic medication users with the 9 extra months of data. This would result in cohorts of approximately 20,007 erenumab users, 14,285 other CGRP antagonist users, and 80,536 SOC antiepileptic preventive medication users through March 2020. The number of eptinezumab users added to the CGRP antagonist user cohort through March 2020 is expected to be small given the February 2020 approval date for its marketed use in the US. We therefore expect to be able to estimate

incidence proportion estimates of inpatient constipation with similar or greater precision than reported in [Table 5](#).

[Table 6](#) provides a range of detectable risk ratios of inpatient constipation for power levels of 80% and 90%, if a comparative analysis of the matched erenumab cohort to the comparator cohort (other CGRP antagonists or SOC antiepileptic preventive medications) is conducted. This assumes an incidence of inpatient constipation of 0.63% in the comparator cohort based on the findings in the study by [Chia et al \(2019\)](#).

Table 6. Detectable Risk Ratios for Inpatient Constipation

Unexposed: exposed ratio [§]	Total Matched Study Population [‡] (N) and Power (%)											
	N = 16,000		N = 20,000		N = 24,000		N = 28,000		N = 32,000		N = 36,000	
	80%	90%	80%	90%	80%	90%	80%	90%	80%	90%	80%	90%
3:1	1.72	1.86	1.64	1.76	1.58	1.68	1.53	1.63	1.50	1.59	1.47	1.55
2:1	1.66	1.79	1.59	1.69	1.53	1.63	1.49	1.58	1.46	1.53	1.43	1.50
1:1	1.63	1.74	1.56	1.65	1.51	1.59	1.47	1.54	1.43	1.51	1.41	1.48

[†] These estimates assume an incidence of inpatient constipation of 0.63% in the comparator cohort.

[‡] The total matched study population is the erenumab cohort plus the comparator cohort. For example, a total matched study population of 24,000 would comprise of 12,000 comparator and 12,000 erenumab with a 1:1 ratio, 16,000 comparator and 8,000 erenumab with a 2:1 ratio, and 18,000 comparator and 6,000 erenumab with a 3:1 ratio.

[§] Unexposed: comparator cohort; exposed: erenumab cohort

The estimates provided above are for informational purposes only. The final sample size for the study will change due to the criteria applied during the conduct of the protocol.

8.6 Data Management

8.6.1 Obtaining Data Files

The Optum EHR database incorporates relevant clinical data on patients from both ambulatory and inpatient settings, including medical records, laboratory results, and drug prescription and administration data, as recorded during routine clinical practice. These data tables can be linked to each other using unique de-identified patient identifiers. The Optum Epidemiology lead study analyst will extract the data from the EHR database according to study protocol and analytic specification requirements. Optum Epidemiology will conduct all analyses using SAS version 9.4 (SAS Institute Inc., Cary, NC). Data files will not be transferred to Amgen.

8.6.2 Linking Data Files

Encrypted project-specific patient and medical encounter identifiers are used to link tables within the de-identified EHR database.

8.6.3 Review and Verification of Data Quality

The conduct and reporting of this study follow Optum Epidemiology's standard operating procedures (SOPs) that are consistent with the International Society for Pharmacoepidemiology's Guidelines for Good Pharmacoepidemiology Practices (<http://www.pharmacoepi.org>). In particular, the SOPs in place at Optum prescribe that processes and deliverables are documented, reviewed, and validated in sufficient detail to allow for subsequent re-examination or replication.

The validation of analytic work typically involves a combination of a review of SAS program log and output files, independent coding, a review of program processes and documentation to ensure departmental SOPs are followed, and reconciliation of program code with the study analytic specifications to ensure populations and results are consistent with what is needed for the particular study. Individual programs are documented and revised as needed until sign-off by a validation analyst using a validation/programming log.

8.7 Data Analysis

8.7.1 Planned Analyses

8.7.1.1 Primary Analysis

The primary analysis will describe baseline characteristics of the erenumab (Amgen Protocol 20200087), other CGRP antagonists, and SOC antiepileptic preventive medication cohorts and estimate the incidence proportion of inpatient constipation within these three cohorts. The incidence proportion of serious complications of inpatient constipation (occurring within 30 days following the inpatient constipation event) will also be estimated.

8.7.1.2 General Considerations

Analyses comparing the risk of inpatient constipation in the PS-matched erenumab cohort to other CGRP antagonist and, separately, to the SOC antiepileptic preventive medication cohorts may be conducted if the cohorts are comparable with respect to baseline characteristics, including confounders and risk factors for constipation. Details of the PS matching, comparability assessment and comparative analysis are provided in [Sections 8.7.1.4.3](#) and [8.7.1.5](#)

8.7.1.3 Missing or Incomplete Data and Lost to Follow-up

For variables defined as presence or absence of a particular procedure, disease, or drug, absence of the associated information will be interpreted as indicating that the


procedure was not conducted, the disease was not present, or the drug was not prescribed.

8.7.1.4 Descriptive Analysis

8.7.1.4.1 Description of Study Enrollment

Selection of cohort members will begin by identifying all patients with at least one prescription order for erenumab, other CGRP antagonists, or an SOC antiepileptic preventive medication between 17 May 2018 through 31 March 2020. Cohort members will be checked to ensure that they are aged 18 years or older on the earliest study medication prescription date, meet all baseline migraine diagnosis/ treatment criteria as outlined in [Section 8.2.2.1](#), and have at least one outpatient clinical visit at least 12 months prior to the index date. Attrition for all three cohorts will be described in a flow chart ([Figure 1](#)).

Figure 1. Formation of Erenumab, Other CGRP Antagonist, and SOC Antiepileptic Preventive Medication Initiator Cohorts



* To restrict to initiators, only the first identified prescription order for a study drug during the study period will be assessed for cohort eligibility. A second check will be done after establishing the baseline period to ensure there is no prescription order for any of the four CGRP antagonists in all three initiator cohorts, and, for the SOC antiepileptic preventive medication initiator cohort only, no prescription for any of any of the five antiepileptic medications in the prior 12 months.

8.7.1.4.2 Description of Subject/Patient Characteristics

The baseline characteristics described in [Table 1](#) and the most prevalent diagnoses, procedures, and medication class prescriptions will be summarized for the three study cohorts prior to PS matching with frequencies and percentages or means and standard deviations. The confounders and risk factors for constipation described in [Table 2](#) (to be included in the PS models) will be summarized in a similar fashion for the cohorts before and after PS matching. The characteristics of the unmatched erenumab cohort will also be presented alongside those of the matched erenumab cohort.

The absolute standardized mean differences for continuous variables and the absolute standardized differences in proportions for binary variables will be reported in the PS-matched cohorts to assess the balance of each risk factor between the erenumab and other CGRP antagonist/SOC medication cohorts. Graphs of the distribution of the PS will be provided before and after PS matching for both comparisons.

Reasons for end of follow-up of the cohort members will be described.

8.7.1.4.3 Cohort Comparability Assessment

PS modeling and matching of the erenumab cohort to the other CGRP antagonist and, separately, to the SOC antiepileptic preventive medication cohorts will be conducted as described in [Section 8.2.3](#).

If there is sufficient overlap in the PS distributions to pursue matching as described in [Section 8.2.3](#), the distribution of the baseline risk factors and absolute SDs will be examined in the PS-matched cohorts (erenumab vs other anti CGRP antagonists; erenumab versus SOC antiepileptic preventive medications). An absolute SD > 0.1 for a given risk factor will be used as a measure of potential imbalance [[Austin, 2007](#); [Austin, 2009](#)]. Risk factors with an absolute SD > 0.1 in the PS-matched cohorts will be examined for potential inclusion in the outcome models for the comparative analysis. Graphs of the PS distribution before and after PS matching will also be examined to assess the extent of overlap between the cohorts.

The decision to move forward with the comparative analysis will be made after assessment of covariate balance and sample size confirmation. The PS models should [[Brookhart et al, 2006](#)]:

- Include all relevant confounders and risk factors for the outcome, based on subject-matter knowledge and causal diagrams

- Not include instrumental variables, intermediate variables, or colliders
- Result in cohort PS distributions that overlap

Furthermore, the sample size and number of outcome events in each cohort will be evaluated to determine the feasibility of proceeding with the comparative analysis [Austin et al, 2017]. If the decision is made to proceed with the comparative analysis, the adjusted outcome models will include no more than one covariate for every 20 events.

8.7.1.5 Analysis of the Primary, Secondary, and Exploratory Endpoint(s)

The incidence proportion (95% CIs) of the primary endpoint of inpatient constipation will be estimated in the cohorts by dividing the total number of patients with an event observed by the number of cohort members at risk at the start of follow-up. Other risk windows for outcome assessment (30, 60, and 90-day risk windows) may also be considered. Incidence proportions will be reported before and after PS matching (if PS matching for the given comparison is pursued). If a patient has more than one inpatient constipation event, only the earliest occurrence of the outcome will be included in the analysis. The incidence proportion of serious complications of inpatient constipation (occurring within 30 days following the inpatient constipation event) will be estimated in the same manner.

If the comparative analysis is conducted, the incidence proportion of inpatient constipation in the matched erenumab cohort will be compared to the other CGRP antagonist and, separately, to the SOC antiepileptic preventive medication cohorts with odds ratios obtained from logistic regression models. The odds ratio will approximate the estimate of interest, the risk ratio. Sample size permitting, the outcome models may be adjusted for risk factors that remain imbalanced following PS matching.

8.7.1.6 Sensitivity Analysis

8.7.1.6.1 Subgroup Analysis

Not applicable

8.7.1.6.2 Stratified Analysis

The incidence proportion of inpatient constipation within the study cohorts will be stratified by the presence of the following baseline characteristics:

- Use of constipation-causing medications. A list of constipation-causing medications is provided in [Table 1](#).
- Epilepsy diagnosis. If the comparative analysis is conducted, odds ratios stratified by the presence of epilepsy will be presented.

- (Erenumab cohort only) Use of any of the 5 SOC antiepileptic preventive medications. Estimating the incidence proportion inpatient constipation among erenumab initiators by prior use of these medications will allow for separate assessments of migraine patients initiating erenumab without prior use of an SOC antiepileptic medication and of migraine patients initiating erenumab after attempting an SOC antiepileptic medication. If the comparative analysis is conducted, the following comparisons will be presented:
 - Erenumab initiators with baseline SOC antiepileptic medication use versus SOC antiepileptic medication initiators
 - Erenumab initiators without baseline SOC antiepileptic medication use versus SOC antiepileptic medication initiators

8.7.1.6.3 Sensitivity Analysis for Residual Confounding and Bias

Not applicable

8.7.1.6.4 Other Sensitivity Analysis

As described in [Section 8.2.5](#), a prescription order for an SOC antiepileptic medication will not censor follow-up of the erenumab and other CGRP antagonist cohorts as these medications are also prescribed for purposes other than migraine prevention. As a sensitivity analysis, a prescription order for an SOC antiepileptic preventive medication will be added as a follow-up endpoint for the erenumab and the other CGRP antagonist cohorts, and the incidence proportion for inpatient constipation in these cohorts will be re-calculated. This sensitivity analysis will allow for an assessment of the incidence proportion of inpatient constipation with and without applying this end of follow-up criterion.

Inpatient constipation will be identified based on the presence of ICD-10-CM diagnosis codes during an ED or inpatient hospital stay. As reason for admission information is typically not complete or available in the EHR data, the outcomes in this study will include events where constipation is the reason for the admission, where constipation is present on admission and where constipation developed over the course of the stay. We will investigate if reason for admission information can be reliably determined for the inpatient constipation events included in the main analysis. If feasible, a sensitivity analysis will be conducted to restrict the outcomes to those that were the reason for the admission to the ED or hospital.

8.7.2 Analysis of Safety Endpoint(s)/Outcome(s)

Analysis methods for the primary endpoints are described in [Sections 8.7.1.5](#) and [8.7.1.6](#). The safety endpoint under study is inpatient constipation.

8.8 Quality Control

The following activities are conducted as part of the specific quality assurance and data handling processes for this study:

- The study protocol is reviewed by another epidemiologist and a senior scientist for overall clarity and validity of the study approach.
- Analytic specifications are reviewed by the lead study analyst and senior scientist prior to implementation.
- The lead study analyst extracts the data from the Optum EHR Research Database. Standard SAS programs are used to conduct the study analysis where possible.
- Data extracts and SAS programs are checked by a second analyst, who verifies that specifications for the data extracts are correct, that programs to determine cohort eligibility reflect study protocol requirements, that codes for creating variables match the study protocol, and that implementation of programs for analysis involve proper specification of programs and flags.
- The epidemiologist and study team, along with the senior scientist, review the preliminary and final output for consistency with expectations based on prior knowledge of drug use.
- The epidemiologist and study team confirm that report tables and content match the study protocol.
- The reports are reviewed by the senior scientist and an additional epidemiologist external to the project for accuracy and clarity.

8.9 Limitations of the Research Methods

8.9.1 Internal Validity of Study Design

As is true for most clinical record-keeping systems, Optum's EHR data do not include systematic information about enrollment and are based on information collected during clinical encounters (eg, outpatient physician visits, ED visits, inpatient hospital stays). Loss to follow-up therefore cannot be directly determined and we do not know exactly when patients are at risk for developing events. However, visit dates are available to determine when events of interest occurred. The baseline period also cannot be directly determined but is defined based on the presence of at least one outpatient clinical encounter during a time period of interest.

8.9.1.1 Measurement Error(s)/Misclassification(s)

While EHR data are valuable for the examination of clinical health care outcomes and treatment patterns, EHR and databases derived from EMR (such as Optum's EHR) have certain inherent limitations because the data are collected for the purpose of clinical patient management, not research. The presence of a diagnosis code in EHR data may not represent the actual presence of disease, as the diagnosis code may be incorrectly coded or included as rule-out criteria rather than actual disease. In addition, these

prescription data represent the intent of the prescriber through the written prescription for a medication, and do not indicate that a medication was filled, consumed, or that it was taken as prescribed.

8.9.1.2 Information Bias

There is the potential for the SOC antiepileptic preventive medication cohort to take their index medication for an indication other than migraine. To ensure these cohort members are migraine patients, a combination of two migraine diagnosis codes and/or prescription orders for migraine treatments will be required in the 12-month baseline period.

Analyses stratified by the presence of a diagnosis code for epilepsy during the baseline period will also be conducted.

8.9.1.3 Selection Bias

Because the EHR database is an open system, some patients may only receive a fraction of their care through a provider captured in the EHR data. As opposed to claims databases, where follow-up is defined based on start and end dates of health plan enrollment, it is not possible to directly determine length of follow-up in the EHR database. Although the end of follow-up could be defined in the EHR database using a proxy such as the date of last encounter (plus grace period), this approach would allow for sicker patients with more frequent medical visits to contribute more follow-up time than healthier patients with fewer medical visits. To avoid this form of selection bias, the incidence proportion, which is calculated using the number of cohort members as the denominator, will be estimated rather than the incidence rate, which is calculated using the person-time at risk as the denominator. Given the expectation that inpatient constipation events will occur within a relatively short time frame following study drug exposure (ie, approximately 90 days), the incidence proportion can serve as a proxy of the cumulative incidence.

8.9.1.4 Confounding

Although methods for confounding adjustment will be implemented through PS modelling and matching, residual confounding is always a concern. Migraine patients will likely have attempted an SOC preventive medication prior to attempting erenumab. The erenumab initiators may therefore be different from the SOC antiepileptic preventive medication initiators with respect to migraine severity, which may result in biased measures of association in this comparison if migraine severity is associated with constipation. The study cohorts will be assessed for comparability as described in

[Section 8.7.1.4.3](#). If the study cohorts are not comparable, then the comparative analysis will not be conducted.

8.9.2 Limitations Due to Missing Data and/or Incomplete Data

Clinical variables are missing for some individuals because of variation in care practices and potentially other factors. When these data are missing in systematic ways, care must be taken in selecting the study population, in the analytic methods employed, and in particular, with respect to how to account for the missing data. Health care encounters with medical providers who do not contract with Optum would not be observed. Because the EHR database is an open system, some patients may only receive a fraction of their care through a provider captured in the data, and medical encounters outside of the networks contributing data to the EHR database will not be observed. To mitigate the potential for missingness in the data, we will require that the study cohorts have evidence of routine care (ie, at least one outpatient visit at least 12 months prior to the index date) within the contributing EHR systems. Patients meeting this criterion likely have a reasonably high capture of medical encounters in the data. OTC medication data recorded in the structured fields of EHR database is based on what the patient has reported to their provider, and the capture of OTC medications may therefore be incomplete. Inpatient constipation will be identified based on the presence of ICD-10-CM diagnosis codes during an ED or inpatient hospital stay. As reason for admission information is not complete in the EHR data, the outcomes in this study will include events that were the reason for the admission, events that were present on admission, and events that occurred during the course of the stay.

8.10 Other Aspects

Not applicable

9. Protection of Human Subjects

9.1 Institutional Review Board/Independent Ethics Committee (IRB/IEC)

This observational study is designed as an analysis of de-identified EHR data derived from a large EHR data system and is considered secondary data. There will be no active enrollment or active follow-up of patients, and no data will be directly collected from patients. As the Optum EHR database is de-identified, this study is exempt from IRB oversight.

9.2 Patient Confidentiality

This study will comply with all applicable laws, regulations, and guidance regarding patient protection including patient privacy. All study reports will contain aggregated

results only and will not identify individual patients or physicians. At no time during the study will Amgen receive patient identifying information.

10. Collection, Recording, and Reporting of Safety Information and Product Complaints

10.1 Safety Collection, Recording and Submission to Amgen Requirements

This study is analyzing secondary data from an EHR research database. The safety outcomes that are listed in [Section 8.3.2](#) will be analyzed in this study. These will be reported in aggregate in the final study report as incidence proportion estimates. See [Section 8.3.2](#) for safety outcomes and definitions. Submission of safety outcomes as individual safety reports to Amgen is not required.

10.1.1 Safety Reporting Requirement to Regulatory Bodies

Reporting of individual adverse events is not applicable for secondary data collection studies.

11. Administrative and Legal Obligations

11.1 Protocol Amendments and Study Termination

Optum may amend the protocol only with the prior approval of both Amgen and Optum. Both Amgen and Optum reserve the right to terminate the study according to the contractual agreement.

12. Plans for Disseminating and Communicating Study Results

12.1 Publication Policy

The results of this study will be submitted for publication. Authorship of any publications resulting from this study will be determined on the basis of the International Committee of Medical Journal Editors (ICJME) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, which states:

- Authorship credit should be based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be published and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet conditions 1, 2, 3 and 4.
- When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship defined above.

- Acquisition of funding, collection of data, or general supervision of the research group alone does not justify authorship.
- All persons designated as authors should qualify for authorship, and all those who qualify should be listed.
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) based on this study must be submitted to Amgen for corporate review. The vendor agreement will detail the procedures for, and timing of, Amgen's review of publications.

13. References

Austin PC, Grootendorst P, and Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. *Stat Med* 2007; 26:734-753.

Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med*. 2009; 28(25):3083-107.

Austin PC, Steyerberg EW. Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models. *Stat Method Med Res* 2017;26(2):796-808.

Brookhart MA, Schneeweiss S, Rothman KJ et al. Variable selection for propensity score models. *Am J Epidemiol* 2006;163(12):1149-56.

Chia V, Park A, Goli V, et al. Incidence of constipation in patients treated with commonly used migraine medications. *Cephalalgia*. 2019;39(1_suppl):376.

Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. *Cephalalgia*. 2018;38(6):1026-1037

Erenumab FDA Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761077s001lbl.pdf. Accessed 29 January 2020.

Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. *N Engl J Med*. 2017;377:2123-2132.

Katsarava Z, Buse DC, Manack AN et al. Defining the differences between episodic migraine and chronic migraine. *Curr Pain Headache Rep* 2012; 16:86-92.

Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Paper 214-26 in Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Long Beach, California: SAS Institute, Inc; 2001. <http://www2.sas.com/proceedings/sugi26/p214-26.pdf>. Accessed 15 April 2020.

Parsons LS. Performing a 1: N Case-Control Match on Propensity Score. Paper 165-29 in Proceedings of the Twenty-Ninth Annual SAS Users Group International Conference. Montréal, Canada: SAS Institute, Inc; 2004. <http://www2.sas.com/proceedings/sugi29/165-29.pdf>. Accessed 15 April 2020.

Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomized, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol*. 2017;16:425-434.

Wald A. Etiology and evaluation of chronic constipation in adults. In: UpToDate, Talley NJ (Ed), UpToDate, Waltham, MA, 2020.

14. Appendices

Appendix A. List of Stand-alone Documents

None

Appendix B. ENCePP Checklist for Study Protocols

Study title: Inpatient Constipation Among Migraine Patients Treated With Preventive Medications: A Retrospective Cohort Study in a US Electronic Health Record Database

EU PAS Register® number: TBD
Study reference number (if applicable): N/A

Section 1: Milestones	Yes	No	N/A	Section Number
1.1 Does the protocol specify timelines for				
1.1.1 Start of data collection ¹	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
1.1.2 End of data collection ²	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
1.1.3 Progress report(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
1.1.4 Interim report(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
1.1.5 Registration in the EU PAS Register®	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
1.1.6 Final report of study results.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	

Comments:

Study milestones are TBD. This study will not have progress or interim reports.

Section 2: Research question	Yes	No	N/A	Section Number
2.1 Does the formulation of the research question and objectives clearly explain:				
2.1.1 Why the study is conducted? (eg, to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	6.2
2.1.2 The objective(s) of the study?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7.1
2.1.3 The target population? (ie, population or subgroup to whom the study results are intended to be generalised)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
2.1.4 Which hypothesis(-es) is (are) to be tested?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
2.1.5 If applicable, that there is no <i>a priori</i> hypothesis?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	6.3

Comments:

¹ Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.

² Date from which the analytical dataset is completely available.

Section 3: Study design	Yes	No	N/A	Section Number
3.1 Is the study design described? (eg, cohort, case-control, cross-sectional, other design)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.1
3.2 Does the protocol specify whether the study is based on primary, secondary or combined data collection?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.1, 9.1, 10.1
3.3 Does the protocol specify measures of occurrence? (eg, rate, risk, prevalence)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	6.3, 8.7
3.4 Does the protocol specify measure(s) of association? (eg, risk, odds ratio, excess risk, rate ratio, hazard ratio, risk/rate difference, number needed to harm (NNH))	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7
3.5 Does the protocol describe the approach for the collection and reporting of adverse events/adverse reactions? (eg, adverse events that will not be collected in case of primary data collection)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10

Comments:

--

Section 4: Source and study populations	Yes	No	N/A	Section Number
4.1 Is the source population described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2, 8.4
4.2 Is the planned study population defined in terms of:				
4.2.1 Study time period	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
4.2.2 Age and sex	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
4.2.3 Country of origin	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
4.2.4 Disease/indication	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
4.2.5 Duration of follow-up	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
4.3 Does the protocol define how the study population will be sampled from the source population? (eg, event or inclusion/exclusion criteria)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2

Comments:

--

Section 5: Exposure definition and measurement	Yes	No	N/A	Section Number
5.1 Does the protocol describe how the study exposure is defined and measured? (eg, operational details for defining and categorising exposure, measurement of dose and duration of drug exposure)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.3
5.2 Does the protocol address the validity of the exposure measurement? (eg, precision, accuracy, use of validation sub-study)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.9

Section 5: Exposure definition and measurement		Yes	No	N/A	Section Number
5.3	Is exposure categorised according to time windows?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
5.4	Is intensity of exposure addressed? (eg, dose, duration)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
5.5	Is exposure categorised based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	6
5.6	Is (are) (an) appropriate comparator(s) identified?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.3

Comments:

--

Section 6: Outcome definition and measurement		Yes	No	N/A	Section Number
6.1	Does the protocol specify the primary and secondary (if applicable) outcome(s) to be investigated?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.3
6.2	Does the protocol describe how the outcomes are defined and measured?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.3
6.3	Does the protocol address the validity of outcome measurement? (eg, precision, accuracy, sensitivity, specificity, positive predictive value, use of validation sub-study)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.9
6.4	Does the protocol describe specific outcomes relevant for Health Technology Assessment? (eg, HRQoL, QALYs, DALYS, health care services utilisation, burden of disease or treatment, compliance, disease management)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

--

Section 7: Bias		Yes	No	N/A	Section Number
7.1	Does the protocol address ways to measure confounding? (eg, confounding by indication)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7
7.2	Does the protocol address selection bias? (eg, healthy user/adherer bias)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.9
7.3	Does the protocol address information bias? (eg, misclassification of exposure and outcomes, time-related bias)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.9

Comments:

--

Section 8: Effect measure modification	Yes	No	N/A	Section Number
8.1 Does the protocol address effect modifiers? (eg, collection of data on known effect modifiers, sub-group analyses, anticipated direction of effect)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7

Comments:

--

Section 9: Data sources	Yes	No	N/A	Section Number
9.1 Does the protocol describe the data source(s) used in the study for the ascertainment of:				
9.1.1 Exposure? (eg, pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
9.1.2 Outcomes? (eg, clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
9.1.3 Covariates and other characteristics?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
9.2 Does the protocol describe the information available from the data source(s) on:				
9.2.1 Exposure? (eg, date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
9.2.2 Outcomes? (eg, date of occurrence, multiple event, severity measures related to event)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
9.2.3 Covariates and other characteristics? (eg, age, sex, clinical and drug use history, co-morbidity, co-medications, lifestyle)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
9.3 Is a coding system described for:				
9.3.1 Exposure? (eg, WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC) Classification System)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
9.3.2 Outcomes? (eg, International Classification of Diseases (ICD), Medical Dictionary for Regulatory Activities (MedDRA))	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
9.3.3 Covariates and other characteristics?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
9.4 Is a linkage method between data sources described? (eg, based on a unique identifier or other)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4

Comments:

--

Section 10: Analysis plan	Yes	No	N/A	Section Number
10.1 Are the statistical methods and the reason for their choice described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7
10.2 Is study size and/or statistical precision estimated?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.5
10.3 Are descriptive analyses included?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7
10.4 Are stratified analyses included?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7
10.5 Does the plan describe methods for analytic control of confounding?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7
10.6 Does the plan describe methods for analytic control of outcome misclassification?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.9
10.7 Does the plan describe methods for handling missing data?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7
10.8 Are relevant sensitivity analyses described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7

Comments:

--

Section 11: Data management and quality control	Yes	No	N/A	Section Number
11.1 Does the protocol provide information on data storage? (eg, software and IT environment, database maintenance and anti-fraud protection, archiving)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.6
11.2 Are methods of quality assurance described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.6
11.3 Is there a system in place for independent review of study results?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.8

Comments:

--

Section 12: Limitations	Yes	No	N/A	Section Number
12.1 Does the protocol discuss the impact on the study results of:				
12.1.1 Selection bias?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.9
12.1.2 Information bias?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.9
12.1.3 Residual/unmeasured confounding? (eg, anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods).	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.9
12.2 Does the protocol discuss study feasibility? (eg, study size, anticipated exposure uptake, duration of follow-up in a cohort study, patient recruitment, precision of the estimates)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.5

Comments:

--

Section 13: Ethical/data protection issues	Yes	No	N/A	Section Number
13.1 Have requirements of Ethics Committee/ Institutional Review Board been described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	9.1
13.2 Has any outcome of an ethical review procedure been addressed?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
13.3 Have data protection requirements been described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	9.2

Comments:

--

Section 14: Amendments and deviations	Yes	No	N/A	Section Number
14.1 Does the protocol include a section to document amendments and deviations?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	5

Comments:

This is the first version of the study protocol.
--

Section 15: Plans for communication of study results	Yes	No	N/A	Section Number
15.1 Are plans described for communicating study results (eg, to regulatory authorities)?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	12
15.2 Are plans described for disseminating study results externally, including publication?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	12

Comments:

--

Name of the main author of the protocol: _____

Date: dd/Month/year _____

Signature: _____

Appendix C. NDCs for Identification of Erenumab, Other CGRP Antagonist, and SOC Antiepileptic Preventive Medication Cohorts

Erenumab Cohort

NDC	Description
55513084101	AIMOVIG AUTOINJECTOR 70 MG/ML
55513084102	AIMOVIG AUTOINJECTOR (2 PACK) 70 MG/ML AUTO INJCT
55513084301	AIMOVIG AUTOINJECTOR 140 MG/ML AUTO INJCT
55513084001	AIMOVIG 70 MG/ML SINGLE-DOSE PREFILLED SYRINGE
55513084002	AIMOVIG 2 X 70 MG/ML SINGLE-DOSE PREFILLED SYRINGES

Other CGRP Antagonist Cohort

NDC	Description
51759020410	AJOVY 225 MG/1.5 SYRINGE
51759020411	AJOVY 225 MG/1.5 SYRINGE
00002143601	EMGALITY 120 MG/ML PEN INJCTR
00002143611	EMGALITY 120 MG/ML PEN INJCTR
00002237701	EMGALITY SYRINGE 120 MG/ML SYRINGE
00002237711	EMGALITY SYRINGE 120 MG/ML SYRINGE
00002311501	EMGALITY SYRINGE 100 MG/ML SYRINGE
00002311509	EMGALITY SYRINGE 100 MG/ML SYRINGE
00002143627	EMGALITY 120 MG/ML PEN INJCTR x 2
00002237727	EMGALITY 120 MG/ML SYRINGE x 2
06738613051†	VYEPTI 100MG/ML SINGLE DOSE VIAL

† Vyepti initiators will be considered for inclusion in the study if identified in the EHR database during the study period.

SOC Antiepileptic Preventive Medication Cohort

NDC	Description
00102362001	CARBAMAZEPINE 200 MG TABLET
11845035701	CARBAMAZEPINE 200 MG TABLET
11845035704	CARBAMAZEPINE 200 MG TABLET
13668026801	CARBAMAZEPINE 200MG TABLET
13668026805	CARBAMAZEPINE 200MG TABLET
13668026810	CARBAMAZEPINE 200MG TABLET
13668027101	CARBAMAZEPINE 100MG TAB CHEW
13668027105	CARBAMAZEPINE 100MG TAB CHEW
00143118125	CARBAMAZEPINE 200 MG TABLET
16590047530	CARBAMAZEPINE 200MG TABLET
16590047560	CARBAMAZEPINE 200MG TABLET

NDC	Description
16590047572	CARBAMAZEPINE 200MG TABLET
16590047590	CARBAMAZEPINE 200MG TABLET
17236035201	CARBAMAZEPINE 200MG TABLET
17236035205	CARBAMAZEPINE 200MG TABLET
17236035210	CARBAMAZEPINE 200MG TABLET
00182123300	CARBAMAZEPINE 200MG TABLET
00182123301	CARBAMAZEPINE 200MG TABLET
00182123310	CARBAMAZEPINE 200 MG TABLET
00182123389	CARBAMAZEPINE 200MG TABLET
00182133100	CARBAMAZEPINE 100MG TAB CHEW
00182133101	CARBAMAZEPINE 100MG TAB CHEW
00182133189	CARBAMAZEPINE 100MG TAB CHEW
18837031390	CARBAMAZEPINE 200MG TABLET
18837031398	CARBAMAZEPINE 200MG TABLET
21695072430	CARBAMAZEPINE 200 MG TABLET
21695072460	CARBAMAZEPINE 200 MG TABLET
00228214310	CARBAMAZEPINE 200MG TABLET
00228214350	CARBAMAZEPINE 200MG TABLET
00228214396	CARBAMAZEPINE 200MG TABLET
23490520001	CARBAMAZEPINE 200MG TABLET
00247035200	CARBAMAZEPINE 200MG TABLET
00247035207	CARBAMAZEPINE 200MG TABLET
00247035214	CARBAMAZEPINE 200MG TABLET
00247035230	CARBAMAZEPINE 200MG TABLET
00247035260	CARBAMAZEPINE 200MG TABLET
00247123130	CARBAMAZEPINE 100MG TAB CHEW
00247123160	CARBAMAZEPINE 100MG TAB CHEW
00258358701	CARBAMAZEPINE 200MG TABLET
00258358705	CARBAMAZEPINE 200 MG TABLET
00258358710	CARBAMAZEPINE 200MG TABLET
00028002701	TEGRETOL 200 MG TABLET
00028002710	TEGRETOL 200 MG TABLET
00028002761	TEGRETOL 200 MG TABLET
00028002765	TEGRETOL 200 MG TABLET

NDC	Description
00028003701	TEGRETOL 200 MG TABLET
00028003710	TEGRETOL 200 MG TABLET
00028003761	TEGRETOL 200 MG TABLET
00028003765	TEGRETOL 200 MG TABLET
00028004701	TEGRETOL 100 MG TAB CHEW
00028004761	TEGRETOL 100 MG TAB CHEW
00028005201	TEGRETOL 100 MG TAB CHEW
00028005261	TEGRETOL 100 MG TAB CHEW
00028006701	TEGRETOL 200 MG TABLET
00028006710	TEGRETOL 200 MG TABLET
00028006761	TEGRETOL 200 MG TABLET
00028006765	TEGRETOL 200 MG TABLET
00028701916	TEGRETOL 100 MG/5ML ORAL SUSP
29033000412	CARBAMAZEPINE 300 MG CPMP 12HR
29033001912	CARBAMAZEPINE 100 MG CPMP 12HR
29033002012	CARBAMAZEPINE 200 MG CPMP 12HR
00302051001	CARBAMAZEPINE 200 MG TABLET
00302051010	CARBAMAZEPINE 200 MG TABLET
00304166400	CARBAMAZEPINE 200 MG TABLET
00304166401	CARBAMAZEPINE 200 MG TABLET
00304166405	CARBAMAZEPINE 200 MG TABLET
30698041912	EQUETRO 100MG CPMP 12HR
30698042112	EQUETRO 200MG CPMP 12HR
30698042312	EQUETRO 300MG CPMP 12HR
00349851601	CARBAMAZEPINE 200 MG TABLET
00349851605	CARBAMAZEPINE 200 MG TABLET
00349851610	CARBAMAZEPINE 200 MG TABLET
00349892401	CARBAMAZEPINE 200 MG TABLET
00349897701	CARBAMAZEPINE 200MG TABLET
35470057501	CARBAMAZEPINE 200 MG TABLET
35470057509	CARBAMAZEPINE 200 MG TABLET
00364210601	CARBAMAZEPINE 200MG TABLET
00364210605	CARBAMAZEPINE 200 MG TABLET
00364230901	CARBAMAZEPINE 100MG TAB CHEW

NDC	Description
00367214310	CARBAMAZEPINE 200 MG TABLET
00367214350	CARBAMAZEPINE 200 MG TABLET
00367214396	CARBAMAZEPINE 200 MG TABLET
00405413001	CARBAMAZEPINE 100MG TAB CHEW
00405413101	CARBAMAZEPINE 200MG TABLET
42254039930	CARBAMAZEPINE 100 MG TAB CHEW
43063032812	CARBAMAZEPINE 200 MG TABLET
43353095330	CARBAMAZEPINE 200 MG TABLET
43353095353	CARBAMAZEPINE 200 MG TABLET
43353095360	CARBAMAZEPINE 200 MG TABLET
43353095380	CARBAMAZEPINE 200 MG TABLET
00440723528	CARBAMAZEPINE 100MG TAB CHEW
00440723590	CARBAMAZEPINE 100MG TAB CHEW
00440723591	CARBAMAZEPINE 100MG TAB CHEW
00440723620	CARBAMAZEPINE 200MG TABLET
00440723628	CARBAMAZEPINE 200MG TABLET
00440723690	CARBAMAZEPINE 200MG TABLET
00440723691	CARBAMAZEPINE 200MG TABLET
00047024224	CARBAMAZEPINE 100MG TAB CHEW
00047024324	CARBAMAZEPINE 200 MG TABLET
47202267701	CARBAMAZEPINE 200 MG TABLET
47202267702	CARBAMAZEPINE 200 MG TABLET
47202267703	CARBAMAZEPINE 200 MG TABLET
47202298601	CARBAMAZEPINE 100 MG TAB CHEW
47679057001	CARBAMAZEPINE 200 MG TABLET
47679057035	CARBAMAZEPINE 200 MG TABLET
49158050401	CARBAMAZEPINE 200MG TABLET
49158050410	CARBAMAZEPINE 200MG TABLET
49158050450	CARBAMAZEPINE 200MG TABLET
49452170501	CARBAMAZEPINE POWDER
49452170502	CARBAMAZEPINE POWDER
49648166401	CARBAMAZEPINE 200 MG TABLET
49648166405	CARBAMAZEPINE 200 MG TABLET
49999061600	CARBAMAZEPINE 200MG TABLET

NDC	Description
49999061601	CARBAMAZEPINE 200MG TABLET
49999061660	CARBAMAZEPINE 200MG TABLET
49999061690	CARBAMAZEPINE 200 MG TABLET
49999078201	CARBAMAZEPINE 100MG TAB CHEW
49999078260	CARBAMAZEPINE 100MG TAB CHEW
50090216100	CARBAMAZEPINE 200 MG TABLET
50090216103	CARBAMAZEPINE 200 MG TABLET
50111041001	CARBAMAZEPINE 200MG TABLET
50111041002	CARBAMAZEPINE 200 MG TABLET
50111041003	CARBAMAZEPINE 200 MG TABLET
50436341503	CARBAMAZEPINE 200 MG TABLET
50962022705	TEGRETOL 100MG/5ML ORAL SUSP
50962022710	TEGRETOL 100MG/5ML ORAL SUSP
50962022910	TEGRETOL 100MG/5ML ORAL SUSP
50962022960	TEGRETOL 100MG/5ML ORAL SUSP
51079038501	CARBAMAZEPINE 200MG TABLET
51079038517	CARBAMAZEPINE 200MG TABLET
51079038519	CARBAMAZEPINE 200MG TABLET
51079038520	CARBAMAZEPINE 200MG TABLET
51079038523	CARBAMAZEPINE 200MG TABLET
51079038524	CARBAMAZEPINE 200MG TABLET
51079087001	CARBAMAZEPINE 100MG TAB CHEW
51079087017	CARBAMAZEPINE 100MG TAB CHEW
51079087019	CARBAMAZEPINE 100MG TAB CHEW
51079087020	CARBAMAZEPINE 100MG TAB CHEW
51407021501	CARBAMAZEPINE ER 200 MG TAB ER 12H
51407021510	CARBAMAZEPINE ER 200 MG TAB ER 12H
51432005903	CARBAMAZEPINE 200 MG TABLET
51432005905	CARBAMAZEPINE 200 MG TABLET
51432088003	CARBAMAZEPINE 100 MG TAB CHEW
51552065304	CARBAMAZEPINE POWDER
51552065305	CARBAMAZEPINE POWDER
51552065306	CARBAMAZEPINE POWDER
51552065325	CARBAMAZEPINE POWDER

NDC	Description
51552065399	CARBAMAZEPINE POWDER
51655095352	CARBAMAZEPINE 200MG TABLET
51672126801	CARBAMAZEPINE 200 MG TABLET
51672126802	CARBAMAZEPINE 200 MG TABLET
51672126803	CARBAMAZEPINE 200 MG TABLET
51672400501	CARBAMAZEPINE 200MG TABLET
51672400502	CARBAMAZEPINE 200MG TABLET
51672400503	CARBAMAZEPINE 200MG TABLET
51672404101	CARBAMAZEPINE 100MG TAB CHEW
51672404102	CARBAMAZEPINE 100MG TAB CHEW
51672404709	CARBAMAZEPINE 100MG/5ML ORAL SUSP
51672412301	CARBAMAZEPINE ER 100 MG TAB ER 12H
51672412401	CARBAMAZEPINE XR 200MG TAB.SR 12H
51672412501	CARBAMAZEPINE XR 400MG TAB.SR 12H
51672414901	CARBAMAZEPINE 300 MG CPMP 12HR
51672415001	CARBAMAZEPINE 200 MG CPMP 12HR
51672415101	CARBAMAZEPINE 100 MG CPMP 12HR
51927217600	CARBAMAZEPINE POWDER
52372083101	CARBAMAZEPINE POWDER
52372083102	CARBAMAZEPINE POWDER
52372083103	CARBAMAZEPINE POWDER
52446007521	CARBAMAZEPINE 200 MG TABLET
52446007528	CARBAMAZEPINE 200 MG TABLET
52555013301	CARBAMAZEPINE 200 MG TABLET
52555013305	CARBAMAZEPINE 200 MG TABLET
52555013310	CARBAMAZEPINE 200 MG TABLET
52555021501	CARBAMAZEPINE 200 MG TABLET
52584023500	CARBAMAZEPINE 200 MG TABLET
52584023550	CARBAMAZEPINE 200 MG TABLET
52728021810	CARBAMAZEPINE 200 MG TABLET
52959017400	TEGRETOL 200MG TABLET
00005342523	CARBAMAZEPINE 200 MG TABLET
00005342531	CARBAMAZEPINE 200 MG TABLET
53445123301	CARBAMAZEPINE 200MG TABLET

NDC	Description
53489019101	CARBAMAZEPINE 200 MG TABLET
00536341101	CARBAMAZEPINE 100MG TAB CHEW
00536341501	CARBAMAZEPINE 200MG TABLET
00536341505	CARBAMAZEPINE 200 MG TABLET
00536341510	CARBAMAZEPINE 200 MG TABLET
54092017112	CARBATROL 100MG CAP.SR 12H
54092017212	CARBATROL 200MG CAP.SR 12H
54092017312	CARBATROL 300MG CAP.SR 12H
54092041912	EQUETRO 100MG CAP MPHASE
54092042112	EQUETRO 200MG CAP MPHASE
54092042312	EQUETRO 300MG CAP MPHASE
54124045660	CARBAMAZEPINE 200 MG TABLET
54274037810	CARBAMAZEPINE 200 MG TABLET
54274037830	CARBAMAZEPINE 200 MG TABLET
54274037850	CARBAMAZEPINE 200 MG TABLET
54274045210	CARBAMAZEPINE 200 MG TABLET
54274045230	CARBAMAZEPINE 200 MG TABLET
54274045250	CARBAMAZEPINE 200 MG TABLET
54569016300	TEGRETOL 200MG TABLET
54569016301	TEGRETOL 200MG TABLET
54569016302	TEGRETOL 200MG TABLET
54569016350	CARBAMAZEPINE 200 MG TABLET
54569016500	TEGRETOL 100MG TAB CHEW
54569016501	TEGRETOL 100MG TAB CHEW
54569016502	TEGRETOL 100MG TAB CHEW
54569265500	CARBAMAZEPINE 200MG TABLET
54569265501	CARBAMAZEPINE 200MG TABLET
54569265502	CARBAMAZEPINE 200MG TABLET
54569265503	CARBAMAZEPINE 200MG TABLET
54569265504	CARBAMAZEPINE 200MG TABLET
54569265505	CARBAMAZEPINE 200MG TABLET
54569279500	CARBAMAZEPINE 100 MG TAB CHEW
54569279501	CARBAMAZEPINE 100MG TAB CHEW
54569289700	TEGRETOL 100 MG/5ML ORAL SUSP

NDC	Description
54569662100	CARBAMAZEPINE 200 MG CPMP 12HR
54812004001	CARBAMAZEPINE 200 MG TABLET
54812004010	CARBAMAZEPINE 200 MG TABLET
54868014700	CARBAMAZEPINE 200MG TABLET
54868014701	CARBAMAZEPINE 200MG TABLET
54868014702	CARBAMAZEPINE 200MG TABLET
54868014704	CARBAMAZEPINE 200MG TABLET
54868014705	CARBAMAZEPINE 200MG TABLET
54868014706	CARBAMAZEPINE 200MG TABLET
54868014707	CARBAMAZEPINE 200 MG TABLET
54868123501	TEGRETOL 100MG TAB CHEW
54868123503	TEGRETOL 100MG TAB CHEW
54868197500	TEGRETOL 200MG TABLET
54868197501	TEGRETOL 200MG TABLET
54868246201	CARBAMAZEPINE 100MG TAB CHEW
54868246202	CARBAMAZEPINE 100MG TAB CHEW
54868246203	CARBAMAZEPINE 100MG TAB CHEW
54868386200	TEGRETOL XR 400MG TAB.SR 12H
54868406700	TEGRETOL XR 100MG TAB.SR 12H
54868406701	TEGRETOL XR 100MG TAB.SR 12H
54868543200	CARBATROL 300 MG CPMP 12HR
54868561000	TEGRETOL XR 200MG TAB.SR 12H
54868561001	TEGRETOL XR 200MG TAB.SR 12H
54868607400	CARBAMAZEPINE XR 400 MG TAB.SR 12H
55081075700	CARBAMAZEPINE 200 MG TABLET
55084075001	CARBAMAZEPINE 200 MG TABLET
55175607001	CARBAMAZEPINE 200MG TABLET
55289021030	CARBAMAZEPINE 200MG TABLET
55829017310	CARBAMAZEPINE 200MG TABLET
55887034560	CARBAMAZEPINE 200MG TABLET
55887034590	CARBAMAZEPINE 200MG TABLET
00056018270	CARBAMAZEPINE 100 MG TAB CHEW
00056018370	CARBAMAZEPINE 200 MG TABLET
56126035211	CARBAMAZEPINE 200MG TABLET

NDC	Description
57480030801	CARBAMAZEPINE 200MG TABLET
57480030806	CARBAMAZEPINE 200 MG TABLET
57664034213	CARBAMAZEPINE 100MG TAB CHEW
57664034288	CARBAMAZEPINE 100MG TAB CHEW
57664053313	CARBAMAZEPINE 200MG TABLET
57664053318	CARBAMAZEPINE 200MG TABLET
57664053388	CARBAMAZEPINE 200MG TABLET
57866341501	CARBAMAZEPINE 200MG TABLET
57866341502	CARBAMAZEPINE 200MG TABLET
57866341503	CARBAMAZEPINE 200MG TABLET
57866341504	CARBAMAZEPINE 200MG TABLET
00580149301	CARBAMAZEPINE 200 MG TABLET
00580149310	CARBAMAZEPINE 200 MG TABLET
58016050100	CARBAMAZEPINE 100MG TAB CHEW
58016050110	CARBAMAZEPINE 100MG TAB CHEW
58016050115	CARBAMAZEPINE 100MG TAB CHEW
58016050120	CARBAMAZEPINE 100MG TAB CHEW
58016050130	CARBAMAZEPINE 100MG TAB CHEW
58016050140	CARBAMAZEPINE 100MG TAB CHEW
58016050160	CARBAMAZEPINE 100MG TAB CHEW
58016050190	CARBAMAZEPINE 100MG TAB CHEW
58016096800	CARBAMAZEPINE 200MG TABLET
58016096802	CARBAMAZEPINE 200MG TABLET
58016096830	CARBAMAZEPINE 200MG TABLET
58016096860	CARBAMAZEPINE 200MG TABLET
58016096890	CARBAMAZEPINE 200MG TABLET
58469341130	CARBAMAZEPINE 100 MG TAB CHEW
58469341530	CARBAMAZEPINE 200 MG TABLET
58521017212	CARBATROL 200MG CAP.SR 12H
58521017312	CARBATROL 300MG CAP.SR 12H
58597800906	CARBAMAZEPINE POWDER
58597800907	CARBAMAZEPINE POWDER
58864063128	TEGRETOL 200MG TABLET
58864078830	TEGRETOL XR 200MG TAB.SR 12H

NDC	Description
58864084330	CARBAMAZEPINE 200MG TABLET
58887001976	TEGRETOL 100MG/5ML ORAL SUSP
58887002730	TEGRETOL 200MG TABLET
58887002732	TEGRETOL 200MG TABLET
58887002740	TEGRETOL 200MG TABLET
58887005230	TEGRETOL 100MG TAB CHEW
58887005232	TEGRETOL 100MG TAB CHEW
59075055410	ATRETOL 200MG TABLET
59075067112	CARBATROL 200MG CAP.SR 12H
59075067212	CARBATROL 300MG CAP.SR 12H
00603256321	CARBAMAZEPINE 200MG TABLET
60346077728	CARBAMAZEPINE 200MG TABLET
60346077730	CARBAMAZEPINE 200MG TABLET
60346077794	CARBAMAZEPINE 200MG TABLET
60429003201	CARBAMAZEPINE 200MG TABLET
60429003210	CARBAMAZEPINE 200MG TABLET
60429003212	CARBAMAZEPINE 200MG TABLET
60429012045	CARBAMAZEPINE 100 MG/5ML ORAL SUSP
60429025412	CARBAMAZEPINE 100 MG CPMP 12HR
60429025512	CARBAMAZEPINE 200 MG CPMP 12HR
60429025612	CARBAMAZEPINE 300 MG CPMP 12HR
60429093201	CARBAMAZEPINE 200MG TABLET
60429093210	CARBAMAZEPINE 200MG TABLET
60429093405	CARBAMAZEPINE 100 MG TAB CHEW
60432012916	CARBAMAZEPINE 100MG/5ML ORAL SUSP
60505018300	CARBAMAZEPINE 200MG TABLET
60505018301	CARBAMAZEPINE 200MG TABLET
60505018305	CARBAMAZEPINE 200MG TABLET
60505280507	CARBAMAZEPINE 100 MG CPMP 12HR
60505280607	CARBAMAZEPINE 200 MG CPMP 12HR
60505280707	CARBAMAZEPINE 300 MG CPMP 12HR
60760010960	CARBAMAZEPINE 200MG TABLET
60809012755	CARBAMAZEPINE 200MG TABLET
60809012772	CARBAMAZEPINE 200MG TABLET

NDC	Description
61392003830	CARBAMAZEPINE 200MG TABLET
61392003831	CARBAMAZEPINE 200MG TABLET
61392003832	CARBAMAZEPINE 200MG TABLET
61392003834	CARBAMAZEPINE 200MG TABLET
61392003839	CARBAMAZEPINE 200MG TABLET
61392003845	CARBAMAZEPINE 200MG TABLET
61392003851	CARBAMAZEPINE 200MG TABLET
61392003854	CARBAMAZEPINE 200MG TABLET
61392003856	CARBAMAZEPINE 200MG TABLET
61392003860	CARBAMAZEPINE 200MG TABLET
61392003890	CARBAMAZEPINE 200MG TABLET
61392003891	CARBAMAZEPINE 200MG TABLET
61392009730	CARBAMAZEPINE 100MG TAB CHEW
61392009731	CARBAMAZEPINE 100MG TAB CHEW
61392009732	CARBAMAZEPINE 100MG TAB CHEW
61392009739	CARBAMAZEPINE 100MG TAB CHEW
61392009745	CARBAMAZEPINE 100MG TAB CHEW
61392009751	CARBAMAZEPINE 100MG TAB CHEW
61392009754	CARBAMAZEPINE 100MG TAB CHEW
61392009760	CARBAMAZEPINE 100MG TAB CHEW
61392009790	CARBAMAZEPINE 100MG TAB CHEW
61392009791	CARBAMAZEPINE 100MG TAB CHEW
00615350513	CARBAMAZEPINE 200MG TABLET
00615350529	CARBAMAZEPINE 200MG TABLET
00615350543	CARBAMAZEPINE 200MG TABLET
00615350553	CARBAMAZEPINE 200MG TABLET
00615350563	CARBAMAZEPINE 200MG TABLET
00615350565	CARBAMAZEPINE 200MG TABLET
00615451529	CARBAMAZEPINE 100MG TAB CHEW
00615451543	CARBAMAZEPINE 100MG TAB CHEW
00615451553	CARBAMAZEPINE 100MG TAB CHEW
00615451563	CARBAMAZEPINE 100MG TAB CHEW
00615451565	CARBAMAZEPINE 100MG TAB CHEW
62584063901	CARBAMAZEPINE 100MG TAB CHEW

NDC	Description
62584063911	CARBAMAZEPINE 100MG TAB CHEW
62584063980	CARBAMAZEPINE 100MG TAB CHEW
62584063985	CARBAMAZEPINE 100MG TAB CHEW
62584064001	CARBAMAZEPINE 200MG TABLET
62584064033	CARBAMAZEPINE 200MG TABLET
62584095201	CARBAMAZEPINE 100MG TAB CHEW
62584095280	CARBAMAZEPINE 100MG TAB CHEW
62584095285	CARBAMAZEPINE 100MG TAB CHEW
62991102701	CARBAMAZEPINE POWDER
62991102702	CARBAMAZEPINE POWDER
62991102703	CARBAMAZEPINE POWDER
63304074701	CARBAMAZEPINE 100MG TAB CHEW
63629401801	CARBAMAZEPINE 200 MG TABLET
63629401802	CARBAMAZEPINE 200 MG TABLET
63739004501	CARBAMAZEPINE 200MG TABLET
63739004502	CARBAMAZEPINE 200MG TABLET
63739004503	CARBAMAZEPINE 200MG TABLET
63739004510	CARBAMAZEPINE 200MG TABLET
63739004515	CARBAMAZEPINE 200MG TABLET
63874049201	CARBAMAZEPINE 200MG TABLET
63874049202	CARBAMAZEPINE 200MG TABLET
63874049204	CARBAMAZEPINE 200MG TABLET
63874049210	CARBAMAZEPINE 200MG TABLET
63874049220	CARBAMAZEPINE 200MG TABLET
63874049230	CARBAMAZEPINE 200MG TABLET
63874049240	CARBAMAZEPINE 200MG TABLET
63874049245	CARBAMAZEPINE 200MG TABLET
63874049260	CARBAMAZEPINE 200MG TABLET
63874049290	CARBAMAZEPINE 200MG TABLET
65162035210	CARBAMAZEPINE 200MG TABLET
65162035211	CARBAMAZEPINE 200MG TABLET
65162035250	CARBAMAZEPINE 200MG TABLET
66336073130	CARBAMAZEPINE 200MG TABLET
66336084130	CARBAMAZEPINE 100MG TAB CHEW

NDC	Description
66689000560	CARBAMAZEPINE 200MG TABLET
66689032301	CARBAMAZEPINE 100MG/5ML ORAL SUSP
66689032350	CARBAMAZEPINE 100MG/5ML ORAL SUSP
66993040732	CARBAMAZEPINE 100 MG CPMP 12HR
66993040832	CARBAMAZEPINE 200 MG CPMP 12HR
66993040932	CARBAMAZEPINE 300 MG CPMP 12HR
67263034101	TEGRETOL XR 400MG TAB.SR 12H
67263045212	CARBATROL 300MG CPMP 12HR
67544024260	TEGRETOL 200MG TABLET
67544024270	TEGRETOL 200MG TABLET
67544024273	TEGRETOL 200MG TABLET
67544024280	TEGRETOL 200MG TABLET
67544024294	TEGRETOL 200MG TABLET
67544058353	CARBAMAZEPINE 200 MG TABLET
67544058360	CARBAMAZEPINE 200 MG TABLET
67544058380	CARBAMAZEPINE 200 MG TABLET
00677109901	CARBAMAZEPINE 200MG TABLET
00677176101	CARBAMAZEPINE 200MG TABLET
68084044401	CARBAMAZEPINE 200 MG TABLET
68084044411	CARBAMAZEPINE XR 200 MG TAB ER 12H
68084044421	CARBAMAZEPINE XR 200 MG TAB ER 12H
68084056111	CARBAMAZEPINE XR 200 MG TAB ER 12H
68084056121	CARBAMAZEPINE XR 200 MG TAB ER 12H
68084056211	CARBAMAZEPINE ER 400 MG TAB ER 12H
68084056221	CARBAMAZEPINE ER 400 MG TAB ER 12H
68094000759	CARBAMAZEPINE 100 MG/5ML ORAL SUSP
68094000762	CARBAMAZEPINE 100 MG/5ML ORAL SUSP
68094000859	CARBAMAZEPINE 200MG/10ML ORAL SUSP
68094000862	CARBAMAZEPINE 200MG/10ML ORAL SUSP
68094021459	CARBAMAZEPINE 100MG/5ML ORAL SUSP
68094021462	CARBAMAZEPINE 100MG/5ML ORAL SUSP
68094030159	CARBAMAZEPINE 100MG/5ML ORAL SUSP
68094030162	CARBAMAZEPINE 100MG/5ML ORAL SUSP
68115006130	CARBAMAZEPINE 100MG TAB CHEW

NDC	Description
68115006160	CARBAMAZEPINE 100MG TAB CHEW
68115006230	CARBAMAZEPINE 200MG TABLET
68115006260	CARBAMAZEPINE 200MG TABLET
68115006290	CARBAMAZEPINE 200MG TABLET
00693010901	CARBAMAZEPINE 200 MG TABLET
00693010905	CARBAMAZEPINE 200 MG TABLET
00693010910	CARBAMAZEPINE 200 MG TABLET
71205002590	CARBAMAZEPINE 200 MG TABLET
71610033630	CARBAMAZEPINE 200 MG TABLET
71610033653	CARBAMAZEPINE 200 MG TABLET
71610033660	CARBAMAZEPINE 200 MG TABLET
71610033680	CARBAMAZEPINE 200 MG TABLET
00719119310	CARBAMAZEPINE 200 MG TABLET
00719119313	CARBAMAZEPINE 200 MG TABLET
00719119410	CARBAMAZEPINE 100 MG TAB CHEW
00078049205	TEGRETOL 100MG TAB CHEW
00078049235	TEGRETOL 100MG TAB CHEW
00078050883	TEGRETOL 100MG/5ML ORAL SUSP
00078050905	TEGRETOL 200MG TABLET
00078051005	TEGRETOL XR 100MG TAB.SR 12H
00078051105	TEGRETOL XR 200MG TAB.SR 12H
00078051205	TEGRETOL XR 400MG TAB.SR 12H
00781508701	CARBAMAZEPINE XR 200MG TAB.SR 12H
00781508801	CARBAMAZEPINE XR 400MG TAB.SR 12H
00781598601	CARBAMAZEPINE ER 100 MG TAB ER 12H
00781598701	CARBAMAZEPINE ER 200 MG TAB ER 12H
00781598801	CARBAMAZEPINE ER 400 MG TAB ER 12H
00781801601	CARBAMAZEPINE ER 100 MG TAB ER 12H
00814147014	CARBAMAZEPINE 200MG TABLET
00083001976	TEGRETOL 100MG/5ML ORAL SUSP
00083002730	TEGRETOL 200MG TABLET
00083002732	TEGRETOL 200MG TABLET
00083002740	TEGRETOL 200MG TABLET
00083005230	TEGRETOL 100MG TAB CHEW

NDC	Description
00083005232	TEGRETOL 100MG TAB CHEW
00083006030	TEGRETOL XR 400MG TAB.SR 12H
00083006032	TEGRETOL XR 400MG TAB.SR 12H
00083006130	TEGRETOL XR 100MG TAB.SR 12H
00083006132	TEGRETOL XR 100MG TAB.SR 12H
00083006230	TEGRETOL XR 200MG TAB.SR 12H
00083006232	TEGRETOL XR 200MG TAB.SR 12H
00832023500	CARBAMAZEPINE 200 MG TABLET
00832023510	CARBAMAZEPINE 200 MG TABLET
00832023513	CARBAMAZEPINE 200 MG TABLET
00832023550	CARBAMAZEPINE 200 MG TABLET
00832061115	CARBAMAZEPINE 200 MG TABLET
00839717706	CARBAMAZEPINE 200MG TABLET
00839717712	CARBAMAZEPINE 200 MG TABLET
00839717716	CARBAMAZEPINE 200MG TABLET
00839741006	CARBAMAZEPINE 100MG TAB CHEW
00904385460	CARBAMAZEPINE 100MG TAB CHEW
00904385461	CARBAMAZEPINE 100MG TAB CHEW
00904385480	CARBAMAZEPINE 100 MG TAB CHEW
00904385540	CARBAMAZEPINE 200 MG TABLET
00904385560	CARBAMAZEPINE 200MG TABLET
00904385561	CARBAMAZEPINE 200MG TABLET
00904385580	CARBAMAZEPINE 200MG TABLET
00904617250	CARBAMAZEPINE 200 MG TABLET
00904617261	CARBAMAZEPINE 200 MG TABLET
00093009001	EPITOL 200MG TABLET
00093009005	EPITOL 200 MG TABLET
00093009010	EPITOL 200 MG TABLET
00093009093	EPITOL 200 MG TABLET
00093010901	CARBAMAZEPINE 200MG TABLET
00093010905	CARBAMAZEPINE 200 MG TABLET
00093010910	CARBAMAZEPINE 200MG TABLET
00093077801	CARBAMAZEPINE 100MG TAB CHEW
00093123319	CARBAMAZEPINE 200MG TABLET

NDC	Description
00093123393	CARBAMAZEPINE 200MG TABLET
00093551289	CARBAMAZEPINE 100 MG CPMP 12HR
00093551389	CARBAMAZEPINE 200 MG CPMP 12HR
00093551489	CARBAMAZEPINE 300 MG CPMP 12HR
10135064401	GABAPENTIN 100 MG CAPSULE
10135064405	GABAPENTIN 100 MG CAPSULE
10135064501	GABAPENTIN 300 MG CAPSULE
10135064505	GABAPENTIN 300 MG CAPSULE
10135064601	GABAPENTIN 400 MG CAPSULE
10135064605	GABAPENTIN 400 MG CAPSULE
10135064701	GABAPENTIN 600 MG TABLET
10135064705	GABAPENTIN 600 MG TABLET
10135064801	GABAPENTIN 800 MG TABLET
10135064805	GABAPENTIN 800 MG TABLET
10544031228	GABAPENTIN 100MG CAPSULE
10544031260	GABAPENTIN 100MG CAPSULE
10544031302	GABAPENTIN 300MG CAPSULE
10544031328	GABAPENTIN 300MG CAPSULE
10544031330	GABAPENTIN 300MG CAPSULE
10544031360	GABAPENTIN 300MG CAPSULE
10544031390	GABAPENTIN 300MG CAPSULE
10544033760	GABAPENTIN 600MG TABLET
10544033790	GABAPENTIN 600MG TABLET
10544043602	GABAPENTIN 300 MG CAPSULE
10544043630	GABAPENTIN 300 MG CAPSULE
10544043660	GABAPENTIN 300 MG CAPSULE
10544043681	GABAPENTIN 300 MG CAPSULE
10544043690	GABAPENTIN 300 MG CAPSULE
10544043902	GABAPENTIN 600 MG TABLET
10544043930	GABAPENTIN 600 MG TABLET
10544043960	GABAPENTIN 600 MG TABLET
10544043990	GABAPENTIN 600 MG TABLET
10544044702	GABAPENTIN 400 MG CAPSULE
10544044790	GABAPENTIN 400 MG CAPSULE

NDC	Description
10544044802	GABAPENTIN 800 MG TABLET
10544044890	GABAPENTIN 800 MG TABLET
12280007590	GABAPENTIN 400MG TABLET
12280007690	GABAPENTIN 100MG TABLET
12280007790	GABAPENTIN 300MG TABLET
12280007793	GABAPENTIN 300MG TABLET
12280007797	GABAPENTIN 300MG TABLET
12280014100	GABAPENTIN 600MG TABLET
12280024700	GABAPENTIN 400MG CAPSULE
12280024790	GABAPENTIN 400MG CAPSULE
13913000413	GRALISE 300 MG TAB SR 24H
13913000419	GRALISE 300 MG TAB ER 24H
13913000519	GRALISE 600 MG TAB SR 24H
13913000616	GRALISE 300-600MG TAB SR 24H
00143999201	GABAPENTIN 100MG CAPSULE
00143999301	GABAPENTIN 300MG CAPSULE
00143999401	GABAPENTIN 400MG CAPSULE
14550051102	GABAPENTIN 100 MG CAPSULE
14550051104	GABAPENTIN 100 MG CAPSULE
14550051202	GABAPENTIN 300 MG CAPSULE
14550051204	GABAPENTIN 300 MG CAPSULE
14550051302	GABAPENTIN 400 MG CAPSULE
14550051304	GABAPENTIN 400 MG CAPSULE
16590010110	GABAPENTIN 100 MG CAPSULE
16590010130	GABAPENTIN 100MG CAPSULE
16590010145	GABAPENTIN 100 MG CAPSULE
16590010160	GABAPENTIN 100MG CAPSULE
16590010186	GABAPENTIN 100 MG CAPSULE
16590010190	GABAPENTIN 100MG CAPSULE
16590010230	GABAPENTIN 300MG CAPSULE
16590010250	GABAPENTIN 300MG CAPSULE
16590010260	GABAPENTIN 300MG CAPSULE
16590010272	GABAPENTIN 300MG CAPSULE
16590010273	GABAPENTIN 300 MG CAPSULE

NDC	Description
16590010282	GABAPENTIN 300MG CAPSULE
16590010283	GABAPENTIN 300MG CAPSULE
16590010290	GABAPENTIN 300MG CAPSULE
16590010330	GABAPENTIN 600 MG TABLET
16590010342	GABAPENTIN 600 MG TABLET
16590010345	GABAPENTIN 600 MG TABLET
16590010356	GABAPENTIN 600MG TABLET
16590010360	GABAPENTIN 600 MG TABLET
16590010362	GABAPENTIN 600 MG TABLET
16590010371	GABAPENTIN 600 MG TABLET
16590010382	GABAPENTIN 600 MG TABLET
16590010383	GABAPENTIN 600 MG TABLET
16590010390	GABAPENTIN 600 MG TABLET
16590010415	GABAPENTIN 800MG TABLET
16590010430	GABAPENTIN 800MG TABLET
16590010460	GABAPENTIN 800MG TABLET
16590010462	GABAPENTIN 800 MG TABLET
16590010472	GABAPENTIN 800MG TABLET
16590010482	GABAPENTIN 800MG TABLET
16590010483	GABAPENTIN 800MG TABLET
16590010490	GABAPENTIN 800MG TABLET
16590049230	GABAPENTIN 400MG CAPSULE
16590049240	GABAPENTIN 400MG CAPSULE
16590049260	GABAPENTIN 400 MG CAPSULE
16590049262	GABAPENTIN 400 MG CAPSULE
16590049272	GABAPENTIN 400MG CAPSULE
16590049282	GABAPENTIN 400MG CAPSULE
16590049283	GABAPENTIN 400MG CAPSULE
16590049290	GABAPENTIN 400 MG CAPSULE
16590062773	NEURONTIN 600MG TABLET
16714033001	GABAPENTIN 600 MG TABLET
16714033002	GABAPENTIN 600 MG TABLET
16714033201	GABAPENTIN 800 MG TABLET
16714033202	GABAPENTIN 800 MG TABLET

NDC	Description
16714050301	GABAPENTIN 100 MG CAPSULE
16714050302	GABAPENTIN 100 MG CAPSULE
16714050401	GABAPENTIN 300 MG CAPSULE
16714050402	GABAPENTIN 300 MG CAPSULE
16714050501	GABAPENTIN 400 MG CAPSULE
16714050502	GABAPENTIN 400 MG CAPSULE
16714066101	GABAPENTIN 100 MG CAPSULE
16714066102	GABAPENTIN 100 MG CAPSULE
16714066201	GABAPENTIN 300 MG CAPSULE
16714066202	GABAPENTIN 300 MG CAPSULE
16714066301	GABAPENTIN 400 MG CAPSULE
16714066302	GABAPENTIN 400 MG CAPSULE
00172438100	GABAPENTIN 100MG CAPSULE
00172438110	GABAPENTIN 100MG CAPSULE
00172438160	GABAPENTIN 100MG CAPSULE
00172438170	GABAPENTIN 100MG CAPSULE
00172438184	GABAPENTIN 100MG CAPSULE
00172438200	GABAPENTIN 300MG CAPSULE
00172438210	GABAPENTIN 300MG CAPSULE
00172438260	GABAPENTIN 300MG CAPSULE
00172438270	GABAPENTIN 300MG CAPSULE
00172438288	GABAPENTIN 300MG CAPSULE
00172438300	GABAPENTIN 400MG CAPSULE
00172438310	GABAPENTIN 400MG CAPSULE
00172438360	GABAPENTIN 400MG CAPSULE
00172438370	GABAPENTIN 400MG CAPSULE
00172438378	GABAPENTIN 400MG CAPSULE
00172444060	GABAPENTIN 100MG TABLET
00172444070	GABAPENTIN 100MG TABLET
00172444160	GABAPENTIN 300MG TABLET
00172444170	GABAPENTIN 300MG TABLET
00172444260	GABAPENTIN 400MG TABLET
00172444270	GABAPENTIN 400MG TABLET
00172444300	GABAPENTIN 600MG TABLET

NDC	Description
00172444310	GABAPENTIN 600MG TABLET
00172444360	GABAPENTIN 600MG TABLET
00172444370	GABAPENTIN 600MG TABLET
00172444380	GABAPENTIN 600MG TABLET
00172444400	GABAPENTIN 800MG TABLET
00172444410	GABAPENTIN 800MG TABLET
00172444460	GABAPENTIN 800MG TABLET
00172444470	GABAPENTIN 800MG TABLET
00173080601	HORIZANT 600 MG TAB SR 24H
00182271801	GABARONE 100MG TABLET
00182271901	GABARONE 300MG TABLET
00182272001	GABARONE 400MG TABLET
00185009101	GABAPENTIN 100MG CAPSULE
00185009105	GABAPENTIN 100MG CAPSULE
00185009110	GABAPENTIN 100MG CAPSULE
00185009301	GABAPENTIN 300MG CAPSULE
00185009305	GABAPENTIN 300MG CAPSULE
00185009310	GABAPENTIN 300MG CAPSULE
00185009401	GABAPENTIN 400MG CAPSULE
00185009405	GABAPENTIN 400MG CAPSULE
00185009410	GABAPENTIN 400MG CAPSULE
00185010701	GABAPENTIN 600MG TABLET
00185011301	GABAPENTIN 800MG TABLET
18837005530	GABAPENTIN 100MG CAPSULE
18837005590	GABAPENTIN 100MG CAPSULE
18837005630	GABAPENTIN 300MG CAPSULE
18837005660	GABAPENTIN 300MG CAPSULE
18837005690	GABAPENTIN 300MG CAPSULE
18837005698	GABAPENTIN 300MG CAPSULE
18837005730	GABAPENTIN 400MG CAPSULE
18837005760	GABAPENTIN 400MG CAPSULE
18837005790	GABAPENTIN 400MG CAPSULE
18837005830	GABAPENTIN 600MG TABLET
18837005860	GABAPENTIN 600MG TABLET

NDC	Description
18837005890	GABAPENTIN 600MG TABLET
18837005898	GABAPENTIN 600MG TABLET
18837005960	GABAPENTIN 800MG TABLET
18837005990	GABAPENTIN 800MG TABLET
18837005998	GABAPENTIN 800MG TABLET
21695005500	GABAPENTIN 100MG CAPSULE
21695005530	GABAPENTIN 100MG CAPSULE
21695005560	GABAPENTIN 100MG CAPSULE
21695005590	GABAPENTIN 100MG CAPSULE
21695005600	GABAPENTIN 300MG CAPSULE
21695005630	GABAPENTIN 300MG CAPSULE
21695005642	GABAPENTIN 300MG CAPSULE
21695005660	GABAPENTIN 300MG CAPSULE
21695005672	GABAPENTIN 300MG CAPSULE
21695005678	GABAPENTIN 300MG CAPSULE
21695005687	GABAPENTIN 300MG CAPSULE
21695005690	GABAPENTIN 300MG CAPSULE
21695005700	GABAPENTIN 400MG CAPSULE
21695005790	GABAPENTIN 400MG CAPSULE
21695005800	GABAPENTIN 600MG TABLET
21695005830	GABAPENTIN 600MG TABLET
21695005842	GABAPENTIN 600MG TABLET
21695005860	GABAPENTIN 600MG TABLET
21695005872	GABAPENTIN 600 MG TABLET
21695005890	GABAPENTIN 600MG TABLET
21695005900	GABAPENTIN 800MG TABLET
21695005930	GABAPENTIN 800MG TABLET
21695005960	GABAPENTIN 800MG TABLET
21695005990	GABAPENTIN 800MG TABLET
21695034400	GABAPENTIN 400 MG CAPSULE
21695034430	GABAPENTIN 400 MG CAPSULE
21695034460	GABAPENTIN 400MG CAPSULE
21695034490	GABAPENTIN 400MG CAPSULE
00228263611	GABAPENTIN 600MG TABLET

NDC	Description
00228263650	GABAPENTIN 600MG TABLET
00228263711	GABAPENTIN 800MG TABLET
00228263750	GABAPENTIN 800MG TABLET
00228266511	GABAPENTIN 100MG CAPSULE
00228266550	GABAPENTIN 100MG CAPSULE
00228266611	GABAPENTIN 300MG CAPSULE
00228266650	GABAPENTIN 300MG CAPSULE
00228266711	GABAPENTIN 400MG CAPSULE
00228266750	GABAPENTIN 400MG CAPSULE
23490651301	GABAPENTIN 100MG CAPSULE
23490651302	GABAPENTIN 100MG CAPSULE
23490651306	GABAPENTIN 100MG CAPSULE
23490651307	GABAPENTIN 100MG CAPSULE
23490651308	GABAPENTIN 100MG CAPSULE
23490651401	GABAPENTIN 300MG CAPSULE
23490651402	GABAPENTIN 300MG CAPSULE
23490651403	GABAPENTIN 300MG CAPSULE
23490651404	GABAPENTIN 300MG CAPSULE
23490651405	GABAPENTIN 300MG CAPSULE
23490651406	GABAPENTIN 300MG CAPSULE
23490651407	GABAPENTIN 300MG CAPSULE
23490651501	GABAPENTIN 400MG CAPSULE
23490651502	GABAPENTIN 400MG CAPSULE
23490651506	GABAPENTIN 400MG CAPSULE
23490651507	GABAPENTIN 400MG CAPSULE
23490651509	GABAPENTIN 400MG CAPSULE
23490732500	GABAPENTIN 600MG TABLET
23490732502	GABAPENTIN 600MG TABLET
23490732503	GABAPENTIN 600MG TABLET
23490732504	GABAPENTIN 600MG TABLET
23490732506	GABAPENTIN 600MG TABLET
23490732509	GABAPENTIN 600MG TABLET
23490732600	GABAPENTIN 800MG TABLET
23490732602	GABAPENTIN 800MG TABLET

NDC	Description
23490732603	GABAPENTIN 800MG TABLET
23490732604	GABAPENTIN 800MG TABLET
23490732606	GABAPENTIN 800MG TABLET
23490732609	GABAPENTIN 800MG TABLET
23629013010	GABAPENTIN 100MG CAPSULE
23629013110	GABAPENTIN 300MG CAPSULE
23629013210	GABAPENTIN 300MG CAPSULE
24658012001	GABAPENTIN 600MG TABLET
24658012005	GABAPENTIN 600MG TABLET
24658012101	GABAPENTIN 800MG TABLET
24658012105	GABAPENTIN 800MG TABLET
31722022101	GABAPENTIN 100 MG CAPSULE
31722022105	GABAPENTIN 100 MG CAPSULE
31722022201	GABAPENTIN 300 MG CAPSULE
31722022205	GABAPENTIN 300 MG CAPSULE
31722022301	GABAPENTIN 400 MG CAPSULE
31722022305	GABAPENTIN 400 MG CAPSULE
31722040501	GABAPENTIN 600 MG TABLET
31722040505	GABAPENTIN 600 MG TABLET
31722040601	GABAPENTIN 800 MG TABLET
31722040605	GABAPENTIN 800 MG TABLET
33261005002	GABAPENTIN 400 MG CAPSULE
33261005010	GABAPENTIN 400 MG CAPSULE
33261005020	GABAPENTIN 400 MG CAPSULE
33261005030	GABAPENTIN 400 MG CAPSULE
33261005060	GABAPENTIN 400 MG CAPSULE
33261005090	GABAPENTIN 400 MG CAPSULE
33358015201	GABAPENTIN 100MG CAPSULE
33358015220	GABAPENTIN 100MG CAPSULE
33358015230	GABAPENTIN 100MG CAPSULE
33358015260	GABAPENTIN 100MG CAPSULE
33358015290	GABAPENTIN 100MG CAPSULE
33358015301	GABAPENTIN 300MG CAPSULE
33358015330	GABAPENTIN 300MG CAPSULE

NDC	Description
33358015360	GABAPENTIN 300MG CAPSULE
33358015390	GABAPENTIN 300MG CAPSULE
33358015430	GABAPENTIN 600MG TABLET
33358015460	GABAPENTIN 600MG TABLET
33358015490	GABAPENTIN 600MG TABLET
35356006130	NEURONTIN 800MG TABLET
35356070801	GABAPENTIN 300 MG CAPSULE
35356070830	GABAPENTIN 300 MG CAPSULE
35356070860	GABAPENTIN 300 MG CAPSULE
35356070890	GABAPENTIN 300 MG CAPSULE
35356070930	GABAPENTIN 100 MG CAPSULE
35356070960	GABAPENTIN 100 MG CAPSULE
35356070990	GABAPENTIN 100 MG CAPSULE
35356072730	GABAPENTIN 400 MG CAPSULE
35356072760	GABAPENTIN 400 MG CAPSULE
35356072790	GABAPENTIN 400 MG CAPSULE
35356085030	GABAPENTIN 600 MG TABLET
35356085060	GABAPENTIN 600 MG TABLET
35356085090	GABAPENTIN 600 MG TABLET
00378542401	GABAPENTIN 600 MG TABLET
00378542405	GABAPENTIN 600 MG TABLET
00378542501	GABAPENTIN 800 MG TABLET
00378542505	GABAPENTIN 800 MG TABLET
00378542601	GABAPENTIN 100 MG CAPSULE
00378542605	GABAPENTIN 100 MG CAPSULE
00378542701	GABAPENTIN 300 MG CAPSULE
00378542705	GABAPENTIN 300 MG CAPSULE
00378542801	GABAPENTIN 400 MG CAPSULE
00378542805	GABAPENTIN 400 MG CAPSULE
42192060816	GABAPENTIN 250 MG/5ML SOLUTION
42254004900	GABAPENTIN 300 MG CAPSULE
42254004921	GABAPENTIN 300 MG CAPSULE
42254004930	GABAPENTIN 300 MG CAPSULE
42254004960	GABAPENTIN 300 MG CAPSULE

NDC	Description
42254004964	GABAPENTIN 300 MG CAPSULE
42254004972	GABAPENTIN 300 MG CAPSULE
42254004978	GABAPENTIN 300 MG CAPSULE
42254004990	GABAPENTIN 300 MG CAPSULE
42254005400	GABAPENTIN 600 MG TABLET
42254005430	GABAPENTIN 600 MG TABLET
42254005460	GABAPENTIN 600 MG TABLET
42254005472	GABAPENTIN 600 MG TABLET
42254005490	GABAPENTIN 600 MG TABLET
42254010330	GABAPENTIN 100 MG CAPSULE
42254010360	GABAPENTIN 100 MG CAPSULE
42254010390	GABAPENTIN 100 MG CAPSULE
42254010930	GABAPENTIN 800 MG TABLET
42254010960	GABAPENTIN 800 MG TABLET
42254010990	GABAPENTIN 800 MG TABLET
42254011230	GABAPENTIN 400 MG CAPSULE
42254011260	GABAPENTIN 400 MG CAPSULE
42254011290	GABAPENTIN 400 MG CAPSULE
42254039330	GABAPENTIN 600 MG TABLET
42254039360	GABAPENTIN 600 MG TABLET
42254039390	GABAPENTIN 600 MG TABLET
42254039430	GABAPENTIN 800 MG TABLET
42254039490	GABAPENTIN 800 MG TABLET
42291030010	GABAPENTIN 100 MG CAPSULE
42291030018	GABAPENTIN 100 MG CAPSULE
42291030027	GABAPENTIN 100 MG CAPSULE
42291030050	GABAPENTIN 100 MG CAPSULE
42291030090	GABAPENTIN 100 MG CAPSULE
42291030110	GABAPENTIN 300 MG CAPSULE
42291030118	GABAPENTIN 300 MG CAPSULE
42291030127	GABAPENTIN 300 MG CAPSULE
42291030130	GABAPENTIN 300 MG CAPSULE
42291030150	GABAPENTIN 300 MG CAPSULE
42291030190	GABAPENTIN 300 MG CAPSULE

NDC	Description
42291030218	GABAPENTIN 400 MG CAPSULE
42291030227	GABAPENTIN 400 MG CAPSULE
42291030250	GABAPENTIN 400 MG CAPSULE
42291030290	GABAPENTIN 400 MG CAPSULE
42292002401	GABAPENTIN 600 MG TABLET
42292002420	GABAPENTIN 600 MG TABLET
42292002501	GABAPENTIN 800 MG TABLET
42292002508	GABAPENTIN 800 MG TABLET
42549031390	GABAPENTIN 300MG CAPSULE
42549033760	GABAPENTIN 600MG TABLET
42549051228	GABAPENTIN 100MG CAPSULE
42549051260	GABAPENTIN 100MG CAPSULE
42549051290	GABAPENTIN 100MG CAPSULE
42549051302	GABAPENTIN 300MG CAPSULE
42549051328	GABAPENTIN 300MG CAPSULE
42549051330	GABAPENTIN 300MG CAPSULE
42549051360	GABAPENTIN 300MG CAPSULE
42549051390	GABAPENTIN 300MG CAPSULE
42549053760	GABAPENTIN 600MG TABLET
42549053790	GABAPENTIN 600MG TABLET
42582011410	GABAPENTIN 100 MG CAPSULE
42582011418	GABAPENTIN 100 MG CAPSULE
42582011510	GABAPENTIN 300 MG CAPSULE
42582011518	GABAPENTIN 300 MG CAPSULE
42582011610	GABAPENTIN 400 MG CAPSULE
42582011618	GABAPENTIN 400 MG CAPSULE
42806050901	GABAPENTIN 100 MG CAPSULE
42806050910	GABAPENTIN 100 MG CAPSULE
42806051001	GABAPENTIN 300 MG CAPSULE
42806051010	GABAPENTIN 300 MG CAPSULE
42806051101	GABAPENTIN 400 MG CAPSULE
42806051110	GABAPENTIN 400 MG CAPSULE
43063022390	GABAPENTIN 400 MG CAPSULE
43063027190	GABAPENTIN 800 MG TABLET

NDC	Description
43063044130	GABAPENTIN 300 MG CAPSULE
43063044160	GABAPENTIN 300 MG CAPSULE
43063044186	GABAPENTIN 300 MG CAPSULE
43063044190	GABAPENTIN 300 MG CAPSULE
43063044193	GABAPENTIN 300 MG CAPSULE
43063044194	GABAPENTIN 300 MG CAPSULE
43063044198	GABAPENTIN 300 MG CAPSULE
43063049030	GABAPENTIN 100 MG CAPSULE
43063049045	GABAPENTIN 100 MG CAPSULE
43063049090	GABAPENTIN 100 MG CAPSULE
43063066430	GABAPENTIN 100 MG CAPSULE
43063066490	GABAPENTIN 100 MG CAPSULE
43063066510	GABAPENTIN 300 MG CAPSULE
43063066530	GABAPENTIN 300 MG CAPSULE
43063066590	GABAPENTIN 300 MG CAPSULE
43063067330	GABAPENTIN 300 MG CAPSULE
43063067345	GABAPENTIN 300 MG CAPSULE
43063067360	GABAPENTIN 300 MG CAPSULE
43063067390	GABAPENTIN 300 MG CAPSULE
43063068730	GABAPENTIN 100 MG CAPSULE
43063068745	GABAPENTIN 100 MG CAPSULE
43063068790	GABAPENTIN 100 MG CAPSULE
43063075630	GABAPENTIN 800 MG TABLET
43063075660	GABAPENTIN 800 MG TABLET
43063075683	GABAPENTIN 800 MG TABLET
43063075686	GABAPENTIN 800 MG TABLET
43063075690	GABAPENTIN 800 MG TABLET
43063075693	GABAPENTIN 800 MG TABLET
43063075694	GABAPENTIN 800 MG TABLET
43063075730	GABAPENTIN 600 MG TABLET
43063075760	GABAPENTIN 600 MG TABLET
43063075783	GABAPENTIN 600 MG TABLET
43063075786	GABAPENTIN 600 MG TABLET
43063075790	GABAPENTIN 600 MG TABLET

NDC	Description
43063075793	GABAPENTIN 600 MG TABLET
43063075794	GABAPENTIN 600 MG TABLET
43063075830	GABAPENTIN 400 MG CAPSULE
43063075860	GABAPENTIN 400 MG CAPSULE
43063075883	GABAPENTIN 400 MG CAPSULE
43063075886	GABAPENTIN 400 MG CAPSULE
43063075890	GABAPENTIN 400 MG CAPSULE
43063075893	GABAPENTIN 400 MG CAPSULE
43063075894	GABAPENTIN 400 MG CAPSULE
43063075928	GABAPENTIN 300 MG CAPSULE
43063075930	GABAPENTIN 300 MG CAPSULE
43063075945	GABAPENTIN 300 MG CAPSULE
43063075960	GABAPENTIN 300 MG CAPSULE
43063075983	GABAPENTIN 300 MG CAPSULE
43063075986	GABAPENTIN 300 MG CAPSULE
43063075990	GABAPENTIN 300 MG CAPSULE
43063075993	GABAPENTIN 300 MG CAPSULE
43063075994	GABAPENTIN 300 MG CAPSULE
43063076030	GABAPENTIN 100 MG CAPSULE
43063076045	GABAPENTIN 100 MG CAPSULE
43063076060	GABAPENTIN 100 MG CAPSULE
43063076083	GABAPENTIN 100 MG CAPSULE
43063076086	GABAPENTIN 100 MG CAPSULE
43063076090	GABAPENTIN 100 MG CAPSULE
43063076093	GABAPENTIN 100 MG CAPSULE
43063076094	GABAPENTIN 100 MG CAPSULE
43063077530	GABAPENTIN 300 MG CAPSULE
43063077560	GABAPENTIN 300 MG CAPSULE
43063077590	GABAPENTIN 300 MG CAPSULE
43063077630	GABAPENTIN 600 MG TABLET
43063077660	GABAPENTIN 600 MG TABLET
43063077690	GABAPENTIN 600 MG TABLET
43093010501	FANATREX 25 MG/ML ORAL SUSP
43353007530	GABAPENTIN 300 MG CAPSULE

NDC	Description
43353007553	GABAPENTIN 300 MG CAPSULE
43353007560	GABAPENTIN 300 MG CAPSULE
43353007580	GABAPENTIN 300 MG CAPSULE
43353007592	GABAPENTIN 300 MG CAPSULE
43353007594	GABAPENTIN 300 MG CAPSULE
43353007598	GABAPENTIN 300 MG CAPSULE
43353008160	GABAPENTIN 400 MG CAPSULE
43353008180	GABAPENTIN 400 MG CAPSULE
43353008192	GABAPENTIN 400 MG CAPSULE
43353019070	GABAPENTIN 800 MG TABLET
43353019092	GABAPENTIN 800 MG TABLET
43353037260	GABAPENTIN 400MG CAPSULE
43353037280	GABAPENTIN 400MG CAPSULE
43353037292	GABAPENTIN 400MG CAPSULE
43353059130	GABAPENTIN 300 MG CAPSULE
43353059153	GABAPENTIN 300 MG CAPSULE
43353059160	GABAPENTIN 300 MG CAPSULE
43353059170	GABAPENTIN 300 MG CAPSULE
43353059180	GABAPENTIN 300 MG CAPSULE
43353059192	GABAPENTIN 300 MG CAPSULE
43353059194	GABAPENTIN 300 MG CAPSULE
43353059198	GABAPENTIN 300 MG CAPSULE
43353060560	GABAPENTIN 400 MG CAPSULE
43353060580	GABAPENTIN 400 MG CAPSULE
43353060592	GABAPENTIN 400 MG CAPSULE
43353060595	GABAPENTIN 400 MG CAPSULE
43353061853	GABAPENTIN 100 MG CAPSULE
43353061860	GABAPENTIN 100 MG CAPSULE
43353061880	GABAPENTIN 100 MG CAPSULE
43353061945	GABAPENTIN 600 MG TABLET
43353061960	GABAPENTIN 600 MG TABLET
43353061974	GABAPENTIN 600 MG TABLET
43353061980	GABAPENTIN 600 MG TABLET
43353061992	GABAPENTIN 600 MG TABLET

NDC	Description
43353063045	GABAPENTIN 600 MG TABLET
43353063060	GABAPENTIN 600 MG TABLET
43353063080	GABAPENTIN 600 MG TABLET
43353063092	GABAPENTIN 600 MG TABLET
43353070930	GABAPENTIN 300 MG CAPSULE
43353070953	GABAPENTIN 300 MG CAPSULE
43353070960	GABAPENTIN 300 MG CAPSULE
43353070970	GABAPENTIN 300 MG CAPSULE
43353070980	GABAPENTIN 300 MG CAPSULE
43353070992	GABAPENTIN 300 MG CAPSULE
43353070994	GABAPENTIN 300 MG CAPSULE
43353070998	GABAPENTIN 300 MG CAPSULE
43353071060	GABAPENTIN 400 MG CAPSULE
43353071080	GABAPENTIN 400 MG CAPSULE
43353071092	GABAPENTIN 400 MG CAPSULE
43353071094	GABAPENTIN 400 MG CAPSULE
43353073192	GABAPENTIN 100 MG CAPSULE
43353073198	GABAPENTIN 100 MG CAPSULE
43353080445	GABAPENTIN 600 MG TABLET
43353080460	GABAPENTIN 600 MG TABLET
43353080480	GABAPENTIN 600 MG TABLET
43353080492	GABAPENTIN 600 MG TABLET
43353081080	GABAPENTIN 400 MG CAPSULE
43353081092	GABAPENTIN 400 MG CAPSULE
43353081094	GABAPENTIN 400 MG CAPSULE
43353082330	GABAPENTIN 300 MG CAPSULE
43353082360	GABAPENTIN 300 MG CAPSULE
43353082370	GABAPENTIN 300 MG CAPSULE
43353082392	GABAPENTIN 300 MG CAPSULE
43353082394	GABAPENTIN 300 MG CAPSULE
43353082398	GABAPENTIN 300 MG CAPSULE
43353086260	GABAPENTIN 100 MG CAPSULE
43353086280	GABAPENTIN 100 MG CAPSULE
43353086292	GABAPENTIN 100 MG CAPSULE

NDC	Description
43353086298	GABAPENTIN 100 MG CAPSULE
43353086330	GABAPENTIN 300 MG CAPSULE
43353086353	GABAPENTIN 300 MG CAPSULE
43353086360	GABAPENTIN 300 MG CAPSULE
43353086370	GABAPENTIN 300 MG CAPSULE
43353086380	GABAPENTIN 300 MG CAPSULE
43353086392	GABAPENTIN 300 MG CAPSULE
43353086394	GABAPENTIN 300 MG CAPSULE
43353086398	GABAPENTIN 300 MG CAPSULE
43353086460	GABAPENTIN 400 MG CAPSULE
43353086480	GABAPENTIN 400 MG CAPSULE
43353086492	GABAPENTIN 400 MG CAPSULE
43353086494	GABAPENTIN 400 MG CAPSULE
43353087245	GABAPENTIN 600 MG TABLET
43353087260	GABAPENTIN 600 MG TABLET
43353087273	GABAPENTIN 600 MG TABLET
43353087280	GABAPENTIN 600 MG TABLET
43353087292	GABAPENTIN 600 MG TABLET
43547026510	GABAPENTIN 100 MG CAPSULE
43547026550	GABAPENTIN 100 MG CAPSULE
43547026610	GABAPENTIN 300 MG CAPSULE
43547026650	GABAPENTIN 300 MG CAPSULE
43547026710	GABAPENTIN 400 MG CAPSULE
43547026750	GABAPENTIN 400 MG CAPSULE
43547033210	GABAPENTIN 600 MG TABLET
43547033250	GABAPENTIN 600 MG TABLET
43547033310	GABAPENTIN 800 MG TABLET
43547033350	GABAPENTIN 800 MG TABLET
43547038310	GABAPENTIN 100 MG CAPSULE
43547038350	GABAPENTIN 100 MG CAPSULE
43547038410	GABAPENTIN 300 MG CAPSULE
43547038450	GABAPENTIN 300 MG CAPSULE
43547038510	GABAPENTIN 400 MG CAPSULE
43547038550	GABAPENTIN 400 MG CAPSULE

NDC	Description
43547038910	GABAPENTIN 600 MG TABLET
43547038950	GABAPENTIN 600 MG TABLET
43547039010	GABAPENTIN 800 MG TABLET
43547039050	GABAPENTIN 800 MG TABLET
00440556205	GABAPENTIN 600 MG TABLET
00440556230	GABAPENTIN 600 MG TABLET
00440556260	GABAPENTIN 600 MG TABLET
00440556281	GABAPENTIN 600 MG TABLET
00440556290	GABAPENTIN 600 MG TABLET
00440556291	GABAPENTIN 600 MG TABLET
00440556292	GABAPENTIN 600 MG TABLET
00440556294	GABAPENTIN 600 MG TABLET
00440556305	GABAPENTIN 800 MG TABLET
00440556330	GABAPENTIN 800 MG TABLET
00440556360	GABAPENTIN 800 MG TABLET
00440556381	GABAPENTIN 800 MG TABLET
00440556390	GABAPENTIN 800 MG TABLET
00440556391	GABAPENTIN 800 MG TABLET
00440556392	GABAPENTIN 800 MG TABLET
00440556394	GABAPENTIN 800 MG TABLET
00440755892	GABAPENTIN 100MG CAPSULE
00440755960	GABAPENTIN 300MG CAPSULE
00440755990	GABAPENTIN 300MG CAPSULE
00440755992	GABAPENTIN 300MG CAPSULE
00440755994	GABAPENTIN 300MG CAPSULE
00440756192	GABAPENTIN 400MG CAPSULE
00440756199	GABAPENTIN 400MG CAPSULE
00440756292	GABAPENTIN 600 MG TABLET
45861001100	GABAPENTIN 300 MG CAPSULE
45861010801	ACTIVE-PAC 300MG-4-1% KIT GEL-CP
45963055511	GABAPENTIN 100 MG CAPSULE
45963055550	GABAPENTIN 100 MG CAPSULE
45963055611	GABAPENTIN 300 MG CAPSULE
45963055650	GABAPENTIN 300 MG CAPSULE

NDC	Description
45963055711	GABAPENTIN 400 MG CAPSULE
45963055750	GABAPENTIN 400 MG CAPSULE
47463270512	GABAPENTIN 400 MG CAPSULE
47463270590	GABAPENTIN 400 MG CAPSULE
49483060501	GABAPENTIN 100 MG CAPSULE
49483060550	GABAPENTIN 100 MG CAPSULE
49483060601	GABAPENTIN 300 MG CAPSULE
49483060650	GABAPENTIN 300 MG CAPSULE
49483060701	GABAPENTIN 400 MG CAPSULE
49483060750	GABAPENTIN 400 MG CAPSULE
49999025700	NEURONTIN 300MG CAPSULE
49999053901	GABAPENTIN 300MG CAPSULE
49999053918	GABAPENTIN 300MG CAPSULE
49999053930	GABAPENTIN 300MG CAPSULE
49999053960	GABAPENTIN 300MG TABLET
49999053990	GABAPENTIN 300MG TABLET
49999054015	GABAPENTIN 400MG CAPSULE
49999054030	GABAPENTIN 400MG CAPSULE
49999054060	GABAPENTIN 400 MG CAPSULE
49999054090	GABAPENTIN 400MG CAPSULE
49999056800	GABAPENTIN 100MG CAPSULE
49999056801	GABAPENTIN 100 MG CAPSULE
49999056830	GABAPENTIN 100MG CAPSULE
49999056860	GABAPENTIN 100MG TABLET
49999056890	GABAPENTIN 100MG CAPSULE
49999078401	GABAPENTIN 600MG TABLET
49999078430	GABAPENTIN 600MG TABLET
49999078460	GABAPENTIN 600MG TABLET
49999078490	GABAPENTIN 600MG TABLET
49999079901	GABAPENTIN 800MG TABLET
49999079930	GABAPENTIN 800 MG TABLET
49999079960	GABAPENTIN 800MG TABLET
49999079990	GABAPENTIN 800MG TABLET
50090089600	GABAPENTIN 300 MG CAPSULE

NDC	Description
50090089601	GABAPENTIN 300 MG CAPSULE
50090089602	GABAPENTIN 300 MG CAPSULE
50090089603	GABAPENTIN 300 MG CAPSULE
50090089604	GABAPENTIN 300 MG CAPSULE
50090089605	GABAPENTIN 300 MG CAPSULE
50090210700	GABAPENTIN 400 MG CAPSULE
50090253900	GABAPENTIN 600 MG TABLET
50090253902	GABAPENTIN 600 MG TABLET
50090256101	GABAPENTIN 100 MG CAPSULE
50090320000	GABAPENTIN 100 MG CAPSULE
50228017701	GABAPENTIN 600 MG TABLET
50228017705	GABAPENTIN 600 MG TABLET
50228017801	GABAPENTIN 800 MG TABLET
50228017805	GABAPENTIN 800 MG TABLET
50228017901	GABAPENTIN 100 MG CAPSULE
50228017905	GABAPENTIN 100 MG CAPSULE
50228018001	GABAPENTIN 300 MG CAPSULE
50228018005	GABAPENTIN 300 MG CAPSULE
50228018101	GABAPENTIN 400 MG CAPSULE
50228018105	GABAPENTIN 400 MG CAPSULE
50268034811	GABAPENTIN 300 MG CAPSULE
50268034815	GABAPENTIN 300 MG CAPSULE
50268034911	GABAPENTIN 400 MG CAPSULE
50268034915	GABAPENTIN 400 MG CAPSULE
50268035111	GABAPENTIN 600 MG TABLET
50268035115	GABAPENTIN 600 MG TABLET
50268035211	GABAPENTIN 800 MG TABLET
50268035213	GABAPENTIN 800 MG TABLET
50383031105	GABAPENTIN 250 MG/5ML SOLUTION
50383031106	GABAPENTIN 300 MG/6ML SOLUTION
50383031107	GABAPENTIN 250 MG/CUP SOLUTION
50383031109	GABAPENTIN 300 MG/6ML SOLUTION
50383031147	GABAPENTIN 250 MG/5ML SOLUTION
50436126203	GRALISE 600 MG TAB ER 24H

NDC	Description
50436126301	GABAPENTIN 100 MG CAPSULE
50436126302	GABAPENTIN 100 MG CAPSULE
50436126303	GABAPENTIN 100 MG CAPSULE
50436301101	GABAPENTIN 600 MG TABLET
50436301102	GABAPENTIN 600 MG TABLET
50436301103	GABAPENTIN 600 MG TABLET
50436728401	GABAPENTIN 400 MG CAPSULE
50436728402	GABAPENTIN 400 MG CAPSULE
50436728403	GABAPENTIN 400 MG CAPSULE
50436728501	GABAPENTIN 300 MG CAPSULE
50436728502	GABAPENTIN 300 MG CAPSULE
50436728503	GABAPENTIN 300 MG CAPSULE
50436728506	GABAPENTIN 300 MG CAPSULE
50436728601	GABAPENTIN 800 MG TABLET
50436728602	GABAPENTIN 800 MG TABLET
50436728603	GABAPENTIN 800 MG TABLET
50436728605	GABAPENTIN 800 MG TABLET
51079009701	GABAPENTIN 800 MG TABLET
51079009720	GABAPENTIN 800 MG TABLET
51079078501	GABAPENTIN 100MG CAPSULE
51079078517	GABAPENTIN 100MG CAPSULE
51079078519	GABAPENTIN 100MG CAPSULE
51079078520	GABAPENTIN 100MG CAPSULE
51079078601	GABAPENTIN 300MG CAPSULE
51079078617	GABAPENTIN 300MG CAPSULE
51079078619	GABAPENTIN 300MG CAPSULE
51079078620	GABAPENTIN 300MG CAPSULE
51138012128	GABAPENTIN 100 MG CAPSULE
51138012130	GABAPENTIN 100 MG CAPSULE
51138012228	GABAPENTIN 300 MG CAPSULE
51138012230	GABAPENTIN 300 MG CAPSULE
51138012328	GABAPENTIN 400 MG CAPSULE
51138012330	GABAPENTIN 400 MG CAPSULE
51138012428	GABAPENTIN 600 MG TABLET

NDC	Description
51138012430	GABAPENTIN 600 MG TABLET
51138012528	GABAPENTIN 800 MG TABLET
51138012530	GABAPENTIN 800 MG TABLET
51138012928	GABAPENTIN 600 MG TABLET
51138012930	GABAPENTIN 600 MG TABLET
51138013028	GABAPENTIN 800 MG TABLET
51138013030	GABAPENTIN 800 MG TABLET
51138014028	GABAPENTIN 100 MG CAPSULE
51138014030	GABAPENTIN 100 MG CAPSULE
51138014128	GABAPENTIN 300 MG CAPSULE
51138014130	GABAPENTIN 300 MG CAPSULE
51138014228	GABAPENTIN 400 MG CAPSULE
51138014230	GABAPENTIN 400 MG CAPSULE
51224002150	GABAPENTIN 600 MG TABLET
51224002160	GABAPENTIN 600 MG TABLET
51224012150	GABAPENTIN 800 MG TABLET
51224012160	GABAPENTIN 800 MG TABLET
51407004710	GABAPENTIN 100 MG CAPSULE
51407004718	GABAPENTIN 100 MG CAPSULE
51407004727	GABAPENTIN 100 MG CAPSULE
51407004790	GABAPENTIN 100 MG CAPSULE
51407004810	GABAPENTIN 300 MG CAPSULE
51407004818	GABAPENTIN 300 MG CAPSULE
51407004827	GABAPENTIN 300 MG CAPSULE
51407004830	GABAPENTIN 300 MG CAPSULE
51407004860	GABAPENTIN 300 MG CAPSULE
51407004890	GABAPENTIN 300 MG CAPSULE
51407004905	GABAPENTIN 400 MG CAPSULE
51407004927	GABAPENTIN 400 MG CAPSULE
51407004990	GABAPENTIN 400 MG CAPSULE
51655037925	GABAPENTIN 300 MG CAPSULE
51927330100	GABAPENTIN POWDER
51991033701	GABAPENTIN 100 MG CAPSULE
51991033705	GABAPENTIN 100 MG CAPSULE

NDC	Description
51991033801	GABAPENTIN 300 MG CAPSULE
51991033805	GABAPENTIN 300 MG CAPSULE
51991033901	GABAPENTIN 400 MG CAPSULE
51991033905	GABAPENTIN 400 MG CAPSULE
52343003001	GABAPENTIN 100 MG CAPSULE
52343003018	GABAPENTIN 100 MG CAPSULE
52343003027	GABAPENTIN 100 MG CAPSULE
52343003090	GABAPENTIN 100 MG CAPSULE
52343003099	GABAPENTIN 100 MG CAPSULE
52343003101	GABAPENTIN 300 MG CAPSULE
52343003118	GABAPENTIN 300 MG CAPSULE
52343003127	GABAPENTIN 300 MG CAPSULE
52343003130	GABAPENTIN 300 MG CAPSULE
52343003160	GABAPENTIN 300 MG CAPSULE
52343003190	GABAPENTIN 300 MG CAPSULE
52343003199	GABAPENTIN 300 MG CAPSULE
52343003201	GABAPENTIN 400 MG CAPSULE
52343003205	GABAPENTIN 400 MG CAPSULE
52343003227	GABAPENTIN 400 MG CAPSULE
52343003290	GABAPENTIN 400 MG CAPSULE
52959043400	NEURONTIN 300MG CAPSULE
52959043420	NEURONTIN 300MG CAPSULE
52959043430	NEURONTIN 300MG CAPSULE
52959043435	NEURONTIN 300MG CAPSULE
52959043445	NEURONTIN 300MG CAPSULE
52959043460	NEURONTIN 300MG CAPSULE
52959043490	NEURONTIN 300MG CAPSULE
52959050600	NEURONTIN 100MG CAPSULE
52959050602	NEURONTIN 100MG CAPSULE
52959050614	NEURONTIN 100MG CAPSULE
52959050620	NEURONTIN 100MG CAPSULE
52959050621	NEURONTIN 100MG CAPSULE
52959050630	NEURONTIN 100MG CAPSULE
52959050645	NEURONTIN 100MG CAPSULE

NDC	Description
52959050660	NEURONTIN 100MG CAPSULE
52959050690	NEURONTIN 100MG CAPSULE
52959064002	NEURONTIN 600MG TABLET
52959064030	NEURONTIN 600MG TABLET
52959064060	NEURONTIN 600MG TABLET
52959064090	NEURONTIN 600MG TABLET
52959075400	GABAPENTIN 300MG CAPSULE
52959075402	GABAPENTIN 300MG CAPSULE
52959075420	GABAPENTIN 300MG CAPSULE
52959075430	GABAPENTIN 300MG CAPSULE
52959075445	GABAPENTIN 300MG CAPSULE
52959075460	GABAPENTIN 300MG CAPSULE
52959075463	GABAPENTIN 300MG CAPSULE
52959075490	GABAPENTIN 300MG CAPSULE
52959075701	GABAPENTIN 100MG CAPSULE
52959075702	GABAPENTIN 100MG CAPSULE
52959075703	GABAPENTIN 100MG CAPSULE
52959075720	GABAPENTIN 100MG CAPSULE
52959075721	GABAPENTIN 100MG CAPSULE
52959075727	GABAPENTIN 100MG CAPSULE
52959075730	GABAPENTIN 100MG CAPSULE
52959075760	GABAPENTIN 100MG CAPSULE
52959075780	GABAPENTIN 100MG CAPSULE
52959075790	GABAPENTIN 100MG CAPSULE
52959077202	GABAPENTIN 800MG TABLET
52959077230	GABAPENTIN 800MG TABLET
52959077260	GABAPENTIN 800MG TABLET
52959077290	GABAPENTIN 800MG TABLET
52959078912	GABAPENTIN 600MG TABLET
52959078930	GABAPENTIN 600MG TABLET
52959078960	GABAPENTIN 600MG TABLET
52959078990	GABAPENTIN 600MG TABLET
52959081002	GABAPENTIN 400 MG CAPSULE
52959081030	GABAPENTIN 400 MG CAPSULE

NDC	Description
52959081060	GABAPENTIN 400MG CAPSULE
52959081080	GABAPENTIN 400MG CAPSULE
52959081090	GABAPENTIN 400MG CAPSULE
53451010101	HORIZANT 600 MG TAB ER 24H
53451010301	HORIZANT 300 MG TAB ER 24H
53489028401	GABAPENTIN 100MG CAPSULE
53489028405	GABAPENTIN 100MG CAPSULE
53489028410	GABAPENTIN 100MG CAPSULE
53489028501	GABAPENTIN 300MG CAPSULE
53489028505	GABAPENTIN 300MG CAPSULE
53489028510	GABAPENTIN 300MG CAPSULE
53489028601	GABAPENTIN 400MG CAPSULE
53489028605	GABAPENTIN 400MG CAPSULE
53489028610	GABAPENTIN 400MG CAPSULE
53746010101	GABAPENTIN 100MG CAPSULE
53746010105	GABAPENTIN 100MG CAPSULE
53746010110	GABAPENTIN 100MG CAPSULE
53746010201	GABAPENTIN 300MG CAPSULE
53746010205	GABAPENTIN 300MG CAPSULE
53746010210	GABAPENTIN 300MG CAPSULE
53746010301	GABAPENTIN 400MG CAPSULE
53746010305	GABAPENTIN 400MG CAPSULE
54569457600	NEURONTIN 100MG CAPSULE
54569457601	NEURONTIN 100MG CAPSULE
54569457700	NEURONTIN 300MG CAPSULE
54569457701	NEURONTIN 300MG CAPSULE
54569457702	NEURONTIN 300MG CAPSULE
54569457800	NEURONTIN 400MG CAPSULE
54569524900	NEURONTIN 600MG TABLET
54569563300	GABAPENTIN 300MG CAPSULE
54569563301	GABAPENTIN 300MG CAPSULE
54569563302	GABAPENTIN 300 MG CAPSULE
54569563303	GABAPENTIN 300 MG CAPSULE
54569563304	GABAPENTIN 300MG CAPSULE

NDC	Description
54569563305	GABAPENTIN 300 MG CAPSULE
54569573400	GABAPENTIN 100MG CAPSULE
54569573401	GABAPENTIN 100MG CAPSULE
54569573402	GABAPENTIN 100MG CAPSULE
54569595600	GABAPENTIN 600 MG TABLET
54569595601	GABAPENTIN 600 MG TABLET
54569595602	GABAPENTIN 600 MG TABLET
54569595603	GABAPENTIN 600 MG TABLET
54569598100	GABAPENTIN 400MG CAPSULE
54569630600	GABAPENTIN 800 MG TABLET
54569630601	GABAPENTIN 800 MG TABLET
54569630602	GABAPENTIN 800 MG TABLET
54569637100	GRALISE 300-600 MG TAB ER 24H
54569637200	GRALISE 600 MG TAB ER 24H
54868352900	NEURONTIN 100MG CAPSULE
54868352901	NEURONTIN 100MG CAPSULE
54868352902	NEURONTIN 100MG CAPSULE
54868352903	NEURONTIN 100MG CAPSULE
54868376801	NEURONTIN 300MG CAPSULE
54868376802	NEURONTIN 300MG CAPSULE
54868376803	NEURONTIN 300MG CAPSULE
54868376804	NEURONTIN 300MG CAPSULE
54868376805	NEURONTIN 300MG CAPSULE
54868393100	NEURONTIN 400MG CAPSULE
54868393101	NEURONTIN 400MG CAPSULE
54868393102	NEURONTIN 400MG CAPSULE
54868449100	NEURONTIN 600MG TABLET
54868449102	NEURONTIN 600MG TABLET
54868449103	NEURONTIN 600MG TABLET
54868449104	NEURONTIN 600MG TABLET
54868460000	NEURONTIN 800MG TABLET
54868460001	NEURONTIN 800MG TABLET
54868516400	GABAPENTIN 400MG TABLET
54868516403	GABAPENTIN 400MG TABLET

NDC	Description
54868516404	GABAPENTIN 400MG TABLET
54868516600	GABAPENTIN 300MG CAPSULE
54868516601	GABAPENTIN 300MG CAPSULE
54868516602	GABAPENTIN 300MG CAPSULE
54868516603	GABAPENTIN 300MG CAPSULE
54868516604	GABAPENTIN 300MG CAPSULE
54868516605	GABAPENTIN 300MG CAPSULE
54868516606	GABAPENTIN 300 MG CAPSULE
54868516607	GABAPENTIN 300 MG CAPSULE
54868519500	GABAPENTIN 800MG TABLET
54868519501	GABAPENTIN 800MG TABLET
54868519502	GABAPENTIN 800MG TABLET
54868519503	GABAPENTIN 800MG TABLET
54868519505	GABAPENTIN 800MG TABLET
54868521900	GABAPENTIN 600MG TABLET
54868521901	GABAPENTIN 600MG TABLET
54868521902	GABAPENTIN 600MG TABLET
54868521903	GABAPENTIN 600MG TABLET
54868521904	GABAPENTIN 600MG TABLET
54868521905	GABAPENTIN 600MG TABLET
54868521906	GABAPENTIN 600MG TABLET
54868522600	GABAPENTIN 100MG CAPSULE
54868522601	GABAPENTIN 100MG CAPSULE
54868522602	GABAPENTIN 100MG CAPSULE
54868522603	GABAPENTIN 100MG CAPSULE
54868522604	GABAPENTIN 100MG CAPSULE
54868522605	GABAPENTIN 100 MG CAPSULE
54868590100	GABAPENTIN 400 MG CAPSULE
54868590101	GABAPENTIN 400 MG CAPSULE
54868590102	GABAPENTIN 400 MG CAPSULE
54868590103	GABAPENTIN 400MG CAPSULE
54868590104	GABAPENTIN 400MG CAPSULE
55045254500	NEURONTIN 400MG CAPSULE
55045254508	NEURONTIN 400MG CAPSULE

NDC	Description
55045261600	NEURONTIN 300MG CAPSULE
55045261605	NEURONTIN 300MG CAPSULE
55045261606	NEURONTIN 300MG CAPSULE
55045261608	NEURONTIN 300MG CAPSULE
55045261609	NEURONTIN 300MG CAPSULE
55045269600	NEURONTIN 100MG CAPSULE
55045269606	NEURONTIN 100MG CAPSULE
55045269608	NEURONTIN 100MG CAPSULE
55045323402	GABAPENTIN 300MG CAPSULE
55045323406	GABAPENTIN 300MG CAPSULE
55045323409	GABAPENTIN 300MG CAPSULE
55045326401	GABAPENTIN 100MG CAPSULE
55045326408	GABAPENTIN 100MG CAPSULE
55045326409	GABAPENTIN 100MG CAPSULE
55045332201	GABAPENTIN 600MG TABLET
55045332206	GABAPENTIN 600MG TABLET
55045332208	GABAPENTIN 600MG TABLET
55045332209	GABAPENTIN 600MG TABLET
55045342101	GABAPENTIN 400MG CAPSULE
55045342106	GABAPENTIN 400MG CAPSULE
55045342108	GABAPENTIN 400MG CAPSULE
55045342109	GABAPENTIN 400MG CAPSULE
55045342200	GABAPENTIN 800MG TABLET
55045342208	GABAPENTIN 800MG TABLET
55045342209	GABAPENTIN 800MG TABLET
55045372301	GABAPENTIN 300MG CAPSULE
55045376506	GABAPENTIN 300MG CAPSULE
55154358004	GABAPENTIN 100 MG CAPSULE
55154358007	GABAPENTIN 100 MG CAPSULE
55154358104	GABAPENTIN 300 MG CAPSULE
55154358107	GABAPENTIN 300 MG CAPSULE
55154358204	GABAPENTIN 400 MG CAPSULE
55154358207	GABAPENTIN 400 MG CAPSULE
55289057010	NEURONTIN 300MG CAPSULE

NDC	Description
55289057030	NEURONTIN 300MG CAPSULE
55289057060	NEURONTIN 300MG CAPSULE
55289084330	NEURONTIN 100MG CAPSULE
55289085030	NEURONTIN 600MG TABLET
55289089830	GABAPENTIN 300MG CAPSULE
55289089845	GABAPENTIN 300MG CAPSULE
55289089860	GABAPENTIN 300MG CAPSULE
55289089883	GABAPENTIN 300MG CAPSULE
55289089886	GABAPENTIN 300MG CAPSULE
55289089890	GABAPENTIN 300MG CAPSULE
55289089893	GABAPENTIN 300MG CAPSULE
55289089894	GABAPENTIN 300MG CAPSULE
55289089898	GABAPENTIN 300 MG CAPSULE
55289089899	GABAPENTIN 300MG CAPSULE
55289093930	GABAPENTIN 100MG CAPSULE
55289093945	GABAPENTIN 100MG CAPSULE
55289093986	GABAPENTIN 100MG CAPSULE
55289093990	GABAPENTIN 100MG CAPSULE
55289093994	GABAPENTIN 100MG CAPSULE
55289095960	GABAPENTIN 600MG TABLET
55289095990	GABAPENTIN 600MG TABLET
55289095998	GABAPENTIN 600MG TABLET
55700000330	GABAPENTIN 800 MG TABLET
55700000360	GABAPENTIN 800 MG TABLET
55700000390	GABAPENTIN 800 MG TABLET
55700027601	GABAPENTIN 100 MG CAPSULE
55700027630	GABAPENTIN 100 MG CAPSULE
55700027660	GABAPENTIN 100 MG CAPSULE
55700027690	GABAPENTIN 100 MG CAPSULE
55700027701	GABAPENTIN 300 MG CAPSULE
55700027730	GABAPENTIN 300 MG CAPSULE
55700027760	GABAPENTIN 300 MG CAPSULE
55700027790	GABAPENTIN 300 MG CAPSULE
55700027830	GABAPENTIN 800 MG TABLET

NDC	Description
55700027860	GABAPENTIN 800 MG TABLET
55700027890	GABAPENTIN 800 MG TABLET
55700029630	GABAPENTIN 600 MG TABLET
55700029660	GABAPENTIN 600 MG TABLET
55700029690	GABAPENTIN 600 MG TABLET
55700029901	GABAPENTIN 300 MG CAPSULE
55700029930	GABAPENTIN 300 MG CAPSULE
55700029960	GABAPENTIN 300 MG CAPSULE
55700029990	GABAPENTIN 300 MG CAPSULE
55700036001	GABAPENTIN 100 MG CAPSULE
55700036030	GABAPENTIN 100 MG CAPSULE
55700036060	GABAPENTIN 100 MG CAPSULE
55700036090	GABAPENTIN 100 MG CAPSULE
55700038630	GABAPENTIN 400 MG CAPSULE
55700038660	GABAPENTIN 400 MG CAPSULE
55700038690	GABAPENTIN 400 MG CAPSULE
55700038990	GABAPENTIN 600 MG TABLET
55700045330	GABAPENTIN 400 MG CAPSULE
55700045360	GABAPENTIN 400 MG CAPSULE
55700045390	GABAPENTIN 400 MG CAPSULE
55700054401	GABAPENTIN 300 MG CAPSULE
55700054430	GABAPENTIN 300 MG CAPSULE
55700054460	GABAPENTIN 300 MG CAPSULE
55700054490	GABAPENTIN 300 MG CAPSULE
55700058401	GABAPENTIN 100 MG CAPSULE
55700058430	GABAPENTIN 100 MG CAPSULE
55700058460	GABAPENTIN 100 MG CAPSULE
55700058490	GABAPENTIN 100 MG CAPSULE
55700068630	GABAPENTIN 600 MG TABLET
55700068660	GABAPENTIN 600 MG TABLET
55700068690	GABAPENTIN 600 MG TABLET
55887017730	GABAPENTIN 400MG CAPSULE
55887027630	GABAPENTIN 400MG TABLET
55887027660	GABAPENTIN 400MG TABLET

NDC	Description
55887027690	GABAPENTIN 400MG TABLET
55887028101	GABAPENTIN 800MG TABLET
55887028130	GABAPENTIN 800MG TABLET
55887028160	GABAPENTIN 800MG TABLET
55887028182	GABAPENTIN 800MG TABLET
55887028186	GABAPENTIN 800MG TABLET
55887028190	GABAPENTIN 800MG TABLET
55887028260	GABAPENTIN 600MG TABLET
55887028290	GABAPENTIN 600MG TABLET
55887032930	GABAPENTIN 100MG CAPSULE
55887032990	GABAPENTIN 100MG CAPSULE
55887033820	GABAPENTIN 300MG CAPSULE
55887033860	GABAPENTIN 300MG CAPSULE
55887033890	GABAPENTIN 300MG CAPSULE
55887053930	NEURONTIN 600MG TABLET
55887053960	NEURONTIN 600MG TABLET
55887053982	NEURONTIN 600MG TABLET
55887053990	NEURONTIN 600MG TABLET
55887054030	NEURONTIN 100MG CAPSULE
55887054060	NEURONTIN 100MG CAPSULE
55887054082	NEURONTIN 100MG CAPSULE
55887054090	NEURONTIN 100MG CAPSULE
55887055120	NEURONTIN 300MG CAPSULE
55887055130	NEURONTIN 300MG CAPSULE
55887055160	NEURONTIN 300MG CAPSULE
55887055190	NEURONTIN 300MG CAPSULE
57866017701	GABAPENTIN 400MG CAPSULE
57866105302	NEURONTIN 300MG CAPSULE
57866105303	NEURONTIN 300MG CAPSULE
57866105304	NEURONTIN 300MG CAPSULE
57866126301	GABAPENTIN 100MG CAPSULE
57866126302	GABAPENTIN 100MG CAPSULE
57866301101	GABAPENTIN 600MG TABLET
57866390501	GABAPENTIN 800MG TABLET

NDC	Description
57866728501	GABAPENTIN 300MG TABLET
57866728502	GABAPENTIN 300MG CAPSULE
57866728504	GABAPENTIN 300MG TABLET
57866728505	GABAPENTIN 300MG TABLET
58016013300	GABAPENTIN 400MG CAPSULE
58016013302	GABAPENTIN 400MG CAPSULE
58016013303	GABAPENTIN 400MG CAPSULE
58016013310	GABAPENTIN 400MG CAPSULE
58016013314	GABAPENTIN 400MG CAPSULE
58016013315	GABAPENTIN 400MG CAPSULE
58016013320	GABAPENTIN 400MG CAPSULE
58016013321	GABAPENTIN 400MG CAPSULE
58016013328	GABAPENTIN 400MG CAPSULE
58016013330	GABAPENTIN 400MG CAPSULE
58016013340	GABAPENTIN 400MG CAPSULE
58016013350	GABAPENTIN 400MG CAPSULE
58016013360	GABAPENTIN 400MG CAPSULE
58016013390	GABAPENTIN 400MG CAPSULE
58016013399	GABAPENTIN 400MG CAPSULE
58016013400	GABAPENTIN 100MG CAPSULE
58016013402	GABAPENTIN 100MG CAPSULE
58016013403	GABAPENTIN 100MG CAPSULE
58016013410	GABAPENTIN 100MG CAPSULE
58016013414	GABAPENTIN 100MG CAPSULE
58016013415	GABAPENTIN 100MG CAPSULE
58016013420	GABAPENTIN 100MG CAPSULE
58016013421	GABAPENTIN 100MG CAPSULE
58016013428	GABAPENTIN 100MG CAPSULE
58016013430	GABAPENTIN 100MG CAPSULE
58016013440	GABAPENTIN 100MG CAPSULE
58016013450	GABAPENTIN 100MG CAPSULE
58016013460	GABAPENTIN 100MG CAPSULE
58016013490	GABAPENTIN 100MG CAPSULE
58016013499	GABAPENTIN 100MG CAPSULE

NDC	Description
58016028500	GABAPENTIN 300MG TABLET
58016028502	GABAPENTIN 300MG TABLET
58016028503	GABAPENTIN 300MG TABLET
58016028510	GABAPENTIN 300MG TABLET
58016028514	GABAPENTIN 300MG TABLET
58016028515	GABAPENTIN 300MG TABLET
58016028520	GABAPENTIN 300MG TABLET
58016028521	GABAPENTIN 300MG TABLET
58016028528	GABAPENTIN 300MG TABLET
58016028530	GABAPENTIN 300MG TABLET
58016028540	GABAPENTIN 300MG TABLET
58016028550	GABAPENTIN 300MG TABLET
58016028560	GABAPENTIN 300MG TABLET
58016028590	GABAPENTIN 300MG TABLET
58016029500	GABAPENTIN 400MG TABLET
58016029502	GABAPENTIN 400MG TABLET
58016029503	GABAPENTIN 400MG TABLET
58016029510	GABAPENTIN 400MG TABLET
58016029514	GABAPENTIN 400MG TABLET
58016029515	GABAPENTIN 400MG TABLET
58016029520	GABAPENTIN 400MG TABLET
58016029521	GABAPENTIN 400MG TABLET
58016029528	GABAPENTIN 400MG TABLET
58016029530	GABAPENTIN 400MG TABLET
58016029540	GABAPENTIN 400MG TABLET
58016029550	GABAPENTIN 400MG TABLET
58016029560	GABAPENTIN 400MG TABLET
58016029590	GABAPENTIN 400MG TABLET
58016029800	GABAPENTIN 300MG CAPSULE
58016029802	GABAPENTIN 300MG CAPSULE
58016029803	GABAPENTIN 300MG CAPSULE
58016029804	GABAPENTIN 300MG CAPSULE
58016029810	GABAPENTIN 300MG CAPSULE
58016029814	GABAPENTIN 300MG CAPSULE

NDC	Description
58016029815	GABAPENTIN 300MG CAPSULE
58016029820	GABAPENTIN 300MG CAPSULE
58016029821	GABAPENTIN 300MG CAPSULE
58016029828	GABAPENTIN 300MG CAPSULE
58016029830	GABAPENTIN 300MG CAPSULE
58016029840	GABAPENTIN 300MG CAPSULE
58016029850	GABAPENTIN 300MG CAPSULE
58016029860	GABAPENTIN 300MG CAPSULE
58016029863	GABAPENTIN 300MG CAPSULE
58016029867	GABAPENTIN 300MG CAPSULE
58016029873	GABAPENTIN 300MG CAPSULE
58016029889	GABAPENTIN 300MG CAPSULE
58016029890	GABAPENTIN 300MG CAPSULE
58016029891	GABAPENTIN 300MG CAPSULE
58016029899	GABAPENTIN 300MG CAPSULE
58016030100	GABAPENTIN 100MG TABLET
58016030102	GABAPENTIN 100MG TABLET
58016030103	GABAPENTIN 100MG TABLET
58016030110	GABAPENTIN 100MG TABLET
58016030114	GABAPENTIN 100MG TABLET
58016030115	GABAPENTIN 100MG TABLET
58016030120	GABAPENTIN 100MG TABLET
58016030121	GABAPENTIN 100MG TABLET
58016030128	GABAPENTIN 100MG TABLET
58016030130	GABAPENTIN 100MG TABLET
58016030140	GABAPENTIN 100MG TABLET
58016030150	GABAPENTIN 100MG TABLET
58016030160	GABAPENTIN 100MG TABLET
58016030190	GABAPENTIN 100MG TABLET
58016031200	GABAPENTIN 600MG TABLET
58016031202	GABAPENTIN 600MG TABLET
58016031203	GABAPENTIN 600MG TABLET
58016031210	GABAPENTIN 600MG TABLET
58016031214	GABAPENTIN 600MG TABLET

NDC	Description
58016031215	GABAPENTIN 600MG TABLET
58016031220	GABAPENTIN 600MG TABLET
58016031221	GABAPENTIN 600MG TABLET
58016031228	GABAPENTIN 600MG TABLET
58016031230	GABAPENTIN 600MG TABLET
58016031240	GABAPENTIN 600MG TABLET
58016031250	GABAPENTIN 600MG TABLET
58016031260	GABAPENTIN 600MG TABLET
58016031273	GABAPENTIN 600MG TABLET
58016031290	GABAPENTIN 600MG TABLET
58016031299	GABAPENTIN 600MG TABLET
58016032000	GABAPENTIN 800MG TABLET
58016032002	GABAPENTIN 800MG TABLET
58016032003	GABAPENTIN 800MG TABLET
58016032010	GABAPENTIN 800MG TABLET
58016032014	GABAPENTIN 800MG TABLET
58016032015	GABAPENTIN 800MG TABLET
58016032020	GABAPENTIN 800MG TABLET
58016032021	GABAPENTIN 800MG TABLET
58016032028	GABAPENTIN 800MG TABLET
58016032030	GABAPENTIN 800MG TABLET
58016032040	GABAPENTIN 800MG TABLET
58016032050	GABAPENTIN 800MG TABLET
58016032060	GABAPENTIN 800MG TABLET
58016032090	GABAPENTIN 800MG TABLET
58016032099	GABAPENTIN 800MG TABLET
58016042700	NEURONTIN 100MG CAPSULE
58016042710	NEURONTIN 100MG CAPSULE
58016042714	NEURONTIN 100MG CAPSULE
58016042715	NEURONTIN 100MG CAPSULE
58016042720	NEURONTIN 100MG CAPSULE
58016042721	NEURONTIN 100MG CAPSULE
58016042728	NEURONTIN 100MG CAPSULE
58016042730	NEURONTIN 100MG CAPSULE

NDC	Description
58016042740	NEURONTIN 100MG CAPSULE
58016042750	NEURONTIN 100MG CAPSULE
58016042760	NEURONTIN 100MG CAPSULE
58016042790	NEURONTIN 100MG CAPSULE
58016043300	NEURONTIN 400MG CAPSULE
58016043310	NEURONTIN 400MG CAPSULE
58016043314	NEURONTIN 400MG CAPSULE
58016043315	NEURONTIN 400MG CAPSULE
58016043320	NEURONTIN 400MG CAPSULE
58016043321	NEURONTIN 400MG CAPSULE
58016043328	NEURONTIN 400MG CAPSULE
58016043330	NEURONTIN 400MG CAPSULE
58016043340	NEURONTIN 400MG CAPSULE
58016043350	NEURONTIN 400MG CAPSULE
58016043360	NEURONTIN 400MG CAPSULE
58016043390	NEURONTIN 400MG CAPSULE
58016048100	NEURONTIN 300MG CAPSULE
58016048110	NEURONTIN 300MG CAPSULE
58016048114	NEURONTIN 300MG CAPSULE
58016048115	NEURONTIN 300MG CAPSULE
58016048120	NEURONTIN 300MG CAPSULE
58016048121	NEURONTIN 300MG CAPSULE
58016048128	NEURONTIN 300MG CAPSULE
58016048130	NEURONTIN 300MG CAPSULE
58016048140	NEURONTIN 300MG CAPSULE
58016048150	NEURONTIN 300MG CAPSULE
58016048160	NEURONTIN 300MG CAPSULE
58016048190	NEURONTIN 300MG CAPSULE
58016048200	NEURONTIN 600MG TABLET
58016048210	NEURONTIN 600MG TABLET
58016048214	NEURONTIN 600MG TABLET
58016048215	NEURONTIN 600MG TABLET
58016048220	NEURONTIN 600MG TABLET
58016048221	NEURONTIN 600MG TABLET

NDC	Description
58016048228	NEURONTIN 600MG TABLET
58016048230	NEURONTIN 600MG TABLET
58016048240	NEURONTIN 600MG TABLET
58016048250	NEURONTIN 600MG TABLET
58016048260	NEURONTIN 600MG TABLET
58016048290	NEURONTIN 600MG TABLET
58016048300	NEURONTIN 800MG TABLET
58016048310	NEURONTIN 800MG TABLET
58016048320	NEURONTIN 800MG TABLET
58016048330	NEURONTIN 800MG TABLET
58016048340	NEURONTIN 800MG TABLET
58016048350	NEURONTIN 800MG TABLET
58016048360	NEURONTIN 800MG TABLET
58016048390	NEURONTIN 800MG TABLET
58517006030	GABAPENTIN 300 MG CAPSULE
58657062001	GABAPENTIN 100 MG CAPSULE
58657062050	GABAPENTIN 100 MG CAPSULE
58657062101	GABAPENTIN 300 MG CAPSULE
58657062150	GABAPENTIN 300 MG CAPSULE
58657062201	GABAPENTIN 400 MG CAPSULE
58657062250	GABAPENTIN 400 MG CAPSULE
58657062301	GABAPENTIN 600 MG TABLET
58657062350	GABAPENTIN 600 MG TABLET
58657062401	GABAPENTIN 800 MG TABLET
58657062450	GABAPENTIN 800 MG TABLET
58864071260	NEURONTIN 100MG CAPSULE
59088073800	GABACAINE 300 MG-5 % KIT
59762403001	GABAPENTIN 100 MG CAPSULE
59762413501	GABAPENTIN 300 MG CAPSULE
59762413505	GABAPENTIN 300 MG CAPSULE
59762424001	GABAPENTIN 400 MG CAPSULE
59762435501	GABAPENTIN 600 MG TABLET
59762446001	GABAPENTIN 800 MG TABLET
59762502301	GABAPENTIN 600MG TABLET

NDC	Description
59762502401	GABAPENTIN 800MG TABLET
59762502501	GABAPENTIN 250 MG/5ML SOLUTION
59762502601	GABAPENTIN 100MG CAPSULE
59762502701	GABAPENTIN 300MG CAPSULE
59762502702	GABAPENTIN 300MG CAPSULE
59762502801	GABAPENTIN 400MG CAPSULE
60429073801	GABAPENTIN 100MG CAPSULE
60429073805	GABAPENTIN 100MG CAPSULE
60429073850	GABAPENTIN 100MG CAPSULE
60429073890	GABAPENTIN 100MG CAPSULE
60429073901	GABAPENTIN 300MG CAPSULE
60429073905	GABAPENTIN 300MG CAPSULE
60429073918	GABAPENTIN 300 MG CAPSULE
60429073927	GABAPENTIN 300 MG CAPSULE
60429073950	GABAPENTIN 300MG CAPSULE
60429073990	GABAPENTIN 300MG CAPSULE
60429074001	GABAPENTIN 400MG CAPSULE
60429074005	GABAPENTIN 400MG CAPSULE
60429074050	GABAPENTIN 400MG CAPSULE
60429074090	GABAPENTIN 400MG CAPSULE
60429078201	GABAPENTIN 600 MG TABLET
60429078205	GABAPENTIN 600 MG TABLET
60429078290	GABAPENTIN 600 MG TABLET
60429078301	GABAPENTIN 800 MG TABLET
60429078305	GABAPENTIN 800 MG TABLET
60429078390	GABAPENTIN 800 MG TABLET
60505011200	GABAPENTIN 100MG CAPSULE
60505011201	GABAPENTIN 100MG CAPSULE
60505011207	GABAPENTIN 100MG CAPSULE
60505011208	GABAPENTIN 100MG CAPSULE
60505011300	GABAPENTIN 300MG CAPSULE
60505011301	GABAPENTIN 300MG CAPSULE
60505011307	GABAPENTIN 300MG CAPSULE
60505011308	GABAPENTIN 300MG CAPSULE

NDC	Description
60505011400	GABAPENTIN 400MG CAPSULE
60505011401	GABAPENTIN 400MG CAPSULE
60505011405	GABAPENTIN 400MG CAPSULE
60505011407	GABAPENTIN 400MG CAPSULE
60505255101	GABAPENTIN 600MG TABLET
60505255105	GABAPENTIN 600MG TABLET
60505255201	GABAPENTIN 800MG TABLET
60505255205	GABAPENTIN 800MG TABLET
60760003590	GABAPENTIN 400 MG CAPSULE
60760003860	GABAPENTIN 800MG TABLET
60760003890	GABAPENTIN 800 MG TABLET
60760003930	GABAPENTIN 300MG CAPSULE
60760003960	GABAPENTIN 300MG CAPSULE
60760003990	GABAPENTIN 300MG CAPSULE
60760003992	GABAPENTIN 300 MG CAPSULE
60760006690	GABAPENTIN 600 MG TABLET
60760006760	GABAPENTIN 800 MG TABLET
60760008830	GABAPENTIN 300 MG CAPSULE
60760008860	GABAPENTIN 300 MG CAPSULE
60760008890	GABAPENTIN 300 MG CAPSULE
60760012360	GABAPENTIN 800 MG TABLET
60760017330	GABAPENTIN 600MG TABLET
60760017390	GABAPENTIN 600MG TABLET
60760017392	GABAPENTIN 600 MG TABLET
60760038390	GABAPENTIN 100 MG CAPSULE
60760055790	GABAPENTIN 400 MG CAPSULE
60760056590	GABAPENTIN 400 MG CAPSULE
60760060560	GABAPENTIN 100 MG CAPSULE
60760062790	GABAPENTIN 100 MG CAPSULE
60760080560	NEURONTIN 300MG CAPSULE
60760082630	GABAPENTIN 800 MG TABLET
60760085730	GABAPENTIN 300 MG CAPSULE
60760085760	GABAPENTIN 300 MG CAPSULE
60760085790	GABAPENTIN 300 MG CAPSULE

NDC	Description
61919008330	GABAPENTIN 400 MG CAPSULE
61919008360	GABAPENTIN 400 MG CAPSULE
61919008372	GABAPENTIN 400 MG CAPSULE
61919008390	GABAPENTIN 400 MG CAPSULE
61919010130	GABAPENTIN 100 MG CAPSULE
61919010160	GABAPENTIN 100 MG CAPSULE
61919010172	GABAPENTIN 100 MG CAPSULE
61919010190	GABAPENTIN 100 MG CAPSULE
61919010230	GABAPENTIN 300 MG CAPSULE
61919010260	GABAPENTIN 300 MG CAPSULE
61919010272	GABAPENTIN 300 MG CAPSULE
61919010290	GABAPENTIN 300 MG CAPSULE
61919010330	GABAPENTIN 600 MG TABLET
61919010360	GABAPENTIN 600 MG TABLET
61919010372	GABAPENTIN 600 MG TABLET
61919010390	GABAPENTIN 600 MG TABLET
61919010490	GABAPENTIN 800 MG TABLET
61919025230	GABAPENTIN 100 MG CAPSULE
61919025260	GABAPENTIN 100 MG CAPSULE
61919025272	GABAPENTIN 100 MG CAPSULE
61919025290	GABAPENTIN 100 MG CAPSULE
61919035030	GABAPENTIN 800 MG TABLET
61919035060	GABAPENTIN 800 MG TABLET
61919035090	GABAPENTIN 800 MG TABLET
61919038730	GABAPENTIN 600 MG TABLET
61919038760	GABAPENTIN 600 MG TABLET
61919038772	GABAPENTIN 600 MG TABLET
61919038786	GABAPENTIN 600 MG TABLET
61919038790	GABAPENTIN 600 MG TABLET
61919041190	GABAPENTIN 300 MG CAPSULE
61919049230	GABAPENTIN 400 MG CAPSULE
61919049260	GABAPENTIN 400 MG CAPSULE
61919049272	GABAPENTIN 400 MG CAPSULE
61919049290	GABAPENTIN 400 MG CAPSULE

NDC	Description
61919056330	GABAPENTIN 600 MG TABLET
61919056360	GABAPENTIN 600 MG TABLET
61919056372	GABAPENTIN 600 MG TABLET
61919056390	GABAPENTIN 600 MG TABLET
61919064030	GABAPENTIN 300 MG CAPSULE
61919064060	GABAPENTIN 300 MG CAPSULE
61919064072	GABAPENTIN 300 MG CAPSULE
61919066030	GABAPENTIN 400 MG CAPSULE
61919066072	GABAPENTIN 400 MG CAPSULE
61919066090	GABAPENTIN 400 MG CAPSULE
61919066190	GABAPENTIN 100 MG CAPSULE
61919083930	GABAPENTIN 300 MG CAPSULE
61919083960	GABAPENTIN 300 MG CAPSULE
61919083971	GABAPENTIN 300 MG CAPSULE
61919083972	GABAPENTIN 300 MG CAPSULE
61919083990	GABAPENTIN 300 MG CAPSULE
61919083999	GABAPENTIN 300 MG CAPSULE
61919098230	GABAPENTIN 300 MG CAPSULE
61919098260	GABAPENTIN 300 MG CAPSULE
61919098271	GABAPENTIN 300 MG CAPSULE
61919098272	GABAPENTIN 300 MG CAPSULE
61919098290	GABAPENTIN 300 MG CAPSULE
62756013702	GABAPENTIN 100MG CAPSULE
62756013705	GABAPENTIN 100MG CAPSULE
62756013802	GABAPENTIN 300MG CAPSULE
62756013805	GABAPENTIN 300MG CAPSULE
62756013902	GABAPENTIN 400MG CAPSULE
62756013905	GABAPENTIN 400MG CAPSULE
62756020201	GABAPENTIN 600MG TABLET
62756020203	GABAPENTIN 600MG TABLET
62756020401	GABAPENTIN 800MG TABLET
62756020403	GABAPENTIN 800MG TABLET
63187000690	GABAPENTIN 600 MG TABLET
63187001030	GABAPENTIN 800 MG TABLET

NDC	Description
63187001060	GABAPENTIN 800 MG TABLET
63187001090	GABAPENTIN 800 MG TABLET
63187003100	GABAPENTIN 300 MG CAPSULE
63187003130	GABAPENTIN 300 MG CAPSULE
63187003190	GABAPENTIN 300 MG CAPSULE
63187005690	GABAPENTIN 400 MG CAPSULE
63187005700	GABAPENTIN 600 MG TABLET
63187005730	GABAPENTIN 600 MG TABLET
63187005790	GABAPENTIN 600 MG TABLET
63187014930	GABAPENTIN 600 MG TABLET
63187014990	GABAPENTIN 600 MG TABLET
63187023160	GABAPENTIN 800 MG TABLET
63187023190	GABAPENTIN 800 MG TABLET
63187024830	GABAPENTIN 100 MG CAPSULE
63187024860	GABAPENTIN 100 MG CAPSULE
63187024890	GABAPENTIN 100 MG CAPSULE
63187037200	GABAPENTIN 300 MG CAPSULE
63187037260	GABAPENTIN 300 MG CAPSULE
63187037290	GABAPENTIN 300 MG CAPSULE
63187039200	GABAPENTIN 100 MG CAPSULE
63187039203	GABAPENTIN 100 MG CAPSULE
63187039230	GABAPENTIN 100 MG CAPSULE
63187039260	GABAPENTIN 100 MG CAPSULE
63187039290	GABAPENTIN 100 MG CAPSULE
63187078590	GABAPENTIN 600 MG TABLET
63187081030	GABAPENTIN 300 MG CAPSULE
63187081060	GABAPENTIN 300 MG CAPSULE
63187081090	GABAPENTIN 300 MG CAPSULE
63187090930	GABAPENTIN 400 MG CAPSULE
63187090990	GABAPENTIN 400 MG CAPSULE
63187098372	GABAPENTIN 400 MG CAPSULE
63187098800	GABAPENTIN 300 MG CAPSULE
63187098860	GABAPENTIN 300 MG CAPSULE
63187098890	GABAPENTIN 300 MG CAPSULE

NDC	Description
63304059201	GABAPENTIN 600MG TABLET
63304059205	GABAPENTIN 600MG TABLET
63304059301	GABAPENTIN 800MG TABLET
63304059305	GABAPENTIN 800MG TABLET
63304062701	GABAPENTIN 100MG CAPSULE
63304062705	GABAPENTIN 100MG CAPSULE
63304062801	GABAPENTIN 300MG CAPSULE
63304062805	GABAPENTIN 300MG CAPSULE
63304062901	GABAPENTIN 400MG CAPSULE
63304062905	GABAPENTIN 400MG CAPSULE
63370009925	GABAPENTIN POWDER
63370009935	GABAPENTIN POWDER
63629157201	GABAPENTIN 100MG CAPSULE
63629157202	GABAPENTIN 100MG CAPSULE
63629157203	GABAPENTIN 100MG CAPSULE
63629157204	GABAPENTIN 100MG CAPSULE
63629157205	GABAPENTIN 100 MG CAPSULE
63629157206	GABAPENTIN 100 MG CAPSULE
63629157207	GABAPENTIN 100 MG CAPSULE
63629157208	GABAPENTIN 100 MG CAPSULE
63629259301	GABAPENTIN 400 MG CAPSULE
63629259302	GABAPENTIN 400 MG CAPSULE
63629259303	GABAPENTIN 400 MG CAPSULE
63629259304	GABAPENTIN 400 MG CAPSULE
63629259305	GABAPENTIN 400 MG CAPSULE
63629259306	GABAPENTIN 400 MG CAPSULE
63629305600	GABAPENTIN 300 MG CAPSULE
63629305601	GABAPENTIN 300MG CAPSULE
63629305602	GABAPENTIN 300MG CAPSULE
63629305603	GABAPENTIN 300MG CAPSULE
63629305604	GABAPENTIN 300MG CAPSULE
63629305605	GABAPENTIN 300MG CAPSULE
63629305606	GABAPENTIN 300 MG CAPSULE
63629305607	GABAPENTIN 300 MG CAPSULE

NDC	Description
63629305608	GABAPENTIN 300 MG CAPSULE
63629305609	GABAPENTIN 300 MG CAPSULE
63629306301	GABAPENTIN 600 MG TABLET
63629306302	GABAPENTIN 600MG TABLET
63629306303	GABAPENTIN 600MG TABLET
63629306304	GABAPENTIN 600MG TABLET
63629306305	GABAPENTIN 600MG TABLET
63629306306	GABAPENTIN 600MG TABLET
63629337501	GABAPENTIN 800MG TABLET
63629337502	GABAPENTIN 800MG TABLET
63629337503	GABAPENTIN 800MG TABLET
63629337504	GABAPENTIN 800MG TABLET
63629337505	GABAPENTIN 800MG TABLET
63629337506	GABAPENTIN 800 MG TABLET
63739023610	GABAPENTIN 300 MG CAPSULE
63739037410	GABAPENTIN 100MG CAPSULE
63739037415	GABAPENTIN 100MG CAPSULE
63739037510	GABAPENTIN 300MG CAPSULE
63739037515	GABAPENTIN 300MG CAPSULE
63739037610	GABAPENTIN 400MG CAPSULE
63739037615	GABAPENTIN 400MG CAPSULE
63739039104	GABAPENTIN 600 MG TABLET
63739039110	GABAPENTIN 600MG TABLET
63739039115	GABAPENTIN 600MG TABLET
63739039210	GABAPENTIN 800MG TABLET
63739039215	GABAPENTIN 800MG TABLET
63739056010	GABAPENTIN 600 MG TABLET
63739059110	GABAPENTIN 100 MG CAPSULE
63739067510	GABAPENTIN 100 MG CAPSULE
63739068910	GABAPENTIN 300 MG CAPSULE
63739069310	GABAPENTIN 400 MG CAPSULE
63739080941	GABAPENTIN 300 MG CAPSULE
63739080942	GABAPENTIN 300 MG CAPSULE
63739080943	GABAPENTIN 300 MG CAPSULE

NDC	Description
63739080945	GABAPENTIN 300 MG CAPSULE
63739080947	GABAPENTIN 300 MG CAPSULE
63739098410	GABAPENTIN 400 MG CAPSULE
63874062901	NEURONTIN 300MG CAPSULE
63874062904	NEURONTIN 300MG CAPSULE
63874062910	NEURONTIN 300MG CAPSULE
63874062914	NEURONTIN 300MG CAPSULE
63874062918	NEURONTIN 300MG CAPSULE
63874062921	NEURONTIN 300MG CAPSULE
63874062928	NEURONTIN 300MG CAPSULE
63874062930	NEURONTIN 300MG CAPSULE
63874062940	NEURONTIN 300MG CAPSULE
63874062950	NEURONTIN 300MG CAPSULE
63874062960	NEURONTIN 300MG CAPSULE
63874062990	NEURONTIN 300MG CAPSULE
63874070601	NEURONTIN 100MG CAPSULE
63874070604	NEURONTIN 100MG CAPSULE
63874070610	NEURONTIN 100MG CAPSULE
63874070614	NEURONTIN 100MG CAPSULE
63874070618	NEURONTIN 100MG CAPSULE
63874070620	NEURONTIN 100MG CAPSULE
63874070621	NEURONTIN 100MG CAPSULE
63874070628	NEURONTIN 100MG CAPSULE
63874070630	NEURONTIN 100MG CAPSULE
63874070640	NEURONTIN 100MG CAPSULE
63874070660	NEURONTIN 100MG CAPSULE
63874070690	NEURONTIN 100MG CAPSULE
63874107300	NEURONTIN 600MG TABLET
63874107301	NEURONTIN 600MG TABLET
63874107302	NEURONTIN 600MG TABLET
63874107303	NEURONTIN 600MG TABLET
63874107304	NEURONTIN 600MG TABLET
63874107305	NEURONTIN 600MG TABLET
63874107306	NEURONTIN 600MG TABLET

NDC	Description
63874107307	NEURONTIN 600MG TABLET
63874107308	NEURONTIN 600MG TABLET
63874107309	NEURONTIN 600MG TABLET
63874110201	GABAPENTIN 100MG CAPSULE
63874110202	GABAPENTIN 100MG CAPSULE
63874110203	GABAPENTIN 100MG CAPSULE
63874110204	GABAPENTIN 100MG CAPSULE
63874110206	GABAPENTIN 100MG CAPSULE
63874110208	GABAPENTIN 100MG CAPSULE
63874110209	GABAPENTIN 100MG CAPSULE
63874110301	GABAPENTIN 300MG CAPSULE
63874110302	GABAPENTIN 300MG CAPSULE
63874110303	GABAPENTIN 300MG CAPSULE
63874110304	GABAPENTIN 300MG CAPSULE
63874110306	GABAPENTIN 300MG CAPSULE
63874110308	GABAPENTIN 300MG CAPSULE
63874110309	GABAPENTIN 300MG CAPSULE
63874110401	GABAPENTIN 400MG CAPSULE
63874110402	GABAPENTIN 400MG CAPSULE
63874110403	GABAPENTIN 400MG CAPSULE
63874110404	GABAPENTIN 400MG CAPSULE
63874110406	GABAPENTIN 400MG CAPSULE
63874110408	GABAPENTIN 400MG CAPSULE
63874110409	GABAPENTIN 400MG CAPSULE
63874112901	GABAPENTIN 800MG TABLET
63874112903	GABAPENTIN 800MG TABLET
63874112906	GABAPENTIN 800MG TABLET
63874112909	GABAPENTIN 800MG TABLET
63874113101	GABAPENTIN 600MG TABLET
63874113103	GABAPENTIN 600MG TABLET
63874113106	GABAPENTIN 600MG TABLET
63874113109	GABAPENTIN 600MG TABLET
64380086706	GABAPENTIN 100 MG CAPSULE
64380086707	GABAPENTIN 100 MG CAPSULE

NDC	Description
64380086806	GABAPENTIN 300 MG CAPSULE
64380086807	GABAPENTIN 300 MG CAPSULE
64380086906	GABAPENTIN 400 MG CAPSULE
64380086907	GABAPENTIN 400 MG CAPSULE
65084037014	GABAPENTIN 300MG CAPSULE
65084037018	GABAPENTIN 300MG CAPSULE
65084037032	GABAPENTIN 300MG CAPSULE
65084037034	GABAPENTIN 300MG CAPSULE
65162010110	GABAPENTIN 100MG CAPSULE
65162010111	GABAPENTIN 100 MG CAPSULE
65162010150	GABAPENTIN 100MG CAPSULE
65162010210	GABAPENTIN 300MG CAPSULE
65162010211	GABAPENTIN 300 MG CAPSULE
65162010250	GABAPENTIN 300MG CAPSULE
65162010310	GABAPENTIN 400MG CAPSULE
65162010350	GABAPENTIN 400MG CAPSULE
65162069890	GABAPENTIN 250 MG/5ML SOLUTION
65243030103	GABAPENTIN 300 MG CAPSULE
65243030106	GABAPENTIN 300MG CAPSULE
65243030109	GABAPENTIN 300MG CAPSULE
65243030118	GABAPENTIN 300MG CAPSULE
65243034406	GABAPENTIN 300 MG CAPSULE
65243034409	GABAPENTIN 300 MG CAPSULE
65243037709	GABAPENTIN 100 MG CAPSULE
65862019801	GABAPENTIN 100 MG CAPSULE
65862019805	GABAPENTIN 100 MG CAPSULE
65862019899	GABAPENTIN 100 MG CAPSULE
65862019901	GABAPENTIN 300 MG CAPSULE
65862019905	GABAPENTIN 300 MG CAPSULE
65862019999	GABAPENTIN 300 MG CAPSULE
65862020001	GABAPENTIN 400 MG CAPSULE
65862020005	GABAPENTIN 400 MG CAPSULE
65862052301	GABAPENTIN 600 MG TABLET
65862052305	GABAPENTIN 600 MG TABLET

NDC	Description
65862052401	GABAPENTIN 800 MG TABLET
65862052405	GABAPENTIN 800 MG TABLET
66267015530	NEURONTIN 300MG CAPSULE
66267015545	NEURONTIN 300MG CAPSULE
66267015560	NEURONTIN 300MG CAPSULE
66267015590	NEURONTIN 300MG CAPSULE
66267015592	NEURONTIN 300MG CAPSULE
66267033930	NEURONTIN 100MG CAPSULE
66267033945	NEURONTIN 100MG CAPSULE
66267033990	NEURONTIN 100MG CAPSULE
66267125900	GABAPENTIN 300MG CAPSULE
66336026630	GABAPENTIN 400MG CAPSULE
66336026690	GABAPENTIN 400MG CAPSULE
66336026694	GABAPENTIN 400MG CAPSULE
66336043930	GABAPENTIN 300MG CAPSULE
66336043960	GABAPENTIN 300MG CAPSULE
66336043990	GABAPENTIN 300MG CAPSULE
66336043994	GABAPENTIN 300MG CAPSULE
66336047130	GABAPENTIN 600MG TABLET
66336047190	GABAPENTIN 600MG TABLET
66336047194	GABAPENTIN 600MG TABLET
66336056730	GABAPENTIN 100MG CAPSULE
66336056760	GABAPENTIN 100MG CAPSULE
66336056790	GABAPENTIN 100MG CAPSULE
66336076290	GABAPENTIN 800MG TABLET
66336076294	GABAPENTIN 800MG TABLET
67544004460	GABAPENTIN 400MG CAPSULE
67544004480	GABAPENTIN 400MG CAPSULE
67544004492	GABAPENTIN 400MG CAPSULE
67544009530	GABAPENTIN 300MG CAPSULE
67544009553	GABAPENTIN 300MG CAPSULE
67544009560	GABAPENTIN 300MG CAPSULE
67544009580	GABAPENTIN 300MG CAPSULE
67544009592	GABAPENTIN 300MG CAPSULE

NDC	Description
67544020060	GABAPENTIN 100MG CAPSULE
67544035330	GABAPENTIN 300MG CAPSULE
67544035353	GABAPENTIN 300MG CAPSULE
67544035360	GABAPENTIN 300MG CAPSULE
67544035370	GABAPENTIN 300MG CAPSULE
67544035380	GABAPENTIN 300MG CAPSULE
67544035392	GABAPENTIN 300MG CAPSULE
67544035394	GABAPENTIN 300 MG CAPSULE
67544035398	GABAPENTIN 300 MG CAPSULE
67544035460	GABAPENTIN 400MG CAPSULE
67544035480	GABAPENTIN 400MG CAPSULE
67544035492	GABAPENTIN 400MG CAPSULE
67544035494	GABAPENTIN 400 MG CAPSULE
67544036160	GABAPENTIN 100MG CAPSULE
67544038530	GABAPENTIN 300MG CAPSULE
67544038553	GABAPENTIN 300MG CAPSULE
67544038560	GABAPENTIN 300MG CAPSULE
67544038570	GABAPENTIN 300MG CAPSULE
67544038580	GABAPENTIN 300MG CAPSULE
67544038592	GABAPENTIN 300MG CAPSULE
67544038660	GABAPENTIN 400MG CAPSULE
67544038680	GABAPENTIN 400MG CAPSULE
67544038692	GABAPENTIN 400MG CAPSULE
67544051830	GABAPENTIN 300 MG CAPSULE
67544051853	GABAPENTIN 300 MG CAPSULE
67544051860	GABAPENTIN 300 MG CAPSULE
67544051870	GABAPENTIN 300 MG CAPSULE
67544051880	GABAPENTIN 300MG CAPSULE
67544051892	GABAPENTIN 300 MG CAPSULE
67544051894	GABAPENTIN 300 MG CAPSULE
67544051898	GABAPENTIN 300 MG CAPSULE
67544079860	GABAPENTIN 100MG CAPSULE
67544079953	GABAPENTIN 300MG CAPSULE
67544080060	GABAPENTIN 400MG CAPSULE

NDC	Description
00677193501	GABAPENTIN 100MG CAPSULE
00677193505	GABAPENTIN 100MG CAPSULE
00677193510	GABAPENTIN 100MG CAPSULE
00677193601	GABAPENTIN 300MG CAPSULE
00677193605	GABAPENTIN 300MG CAPSULE
00677193610	GABAPENTIN 300MG CAPSULE
00677193701	GABAPENTIN 400MG CAPSULE
00677193705	GABAPENTIN 400MG CAPSULE
00677193710	GABAPENTIN 400MG CAPSULE
67877022201	GABAPENTIN 100 MG CAPSULE
67877022205	GABAPENTIN 100 MG CAPSULE
67877022210	GABAPENTIN 100 MG CAPSULE
67877022301	GABAPENTIN 300 MG CAPSULE
67877022305	GABAPENTIN 300 MG CAPSULE
67877022310	GABAPENTIN 300 MG CAPSULE
67877022401	GABAPENTIN 400 MG CAPSULE
67877022405	GABAPENTIN 400 MG CAPSULE
67877022410	GABAPENTIN 400 MG CAPSULE
67877042801	GABAPENTIN 600 MG TABLET
67877042805	GABAPENTIN 600 MG TABLET
67877042901	GABAPENTIN 800 MG TABLET
67877042905	GABAPENTIN 800 MG TABLET
68001000600	GABAPENTIN 600 MG TABLET
68001000603	GABAPENTIN 600 MG TABLET
68001000700	GABAPENTIN 800 MG TABLET
68001000703	GABAPENTIN 800 MG TABLET
68001041100	GABAPENTIN 600 MG TABLET
68001041103	GABAPENTIN 600 MG TABLET
68001041200	GABAPENTIN 800 MG TABLET
68001041203	GABAPENTIN 800 MG TABLET
68071021207	GABAPENTIN 300 MG CAPSULE
68071021214	GABAPENTIN 300 MG CAPSULE
68071021230	GABAPENTIN 300MG CAPSULE
68071021245	GABAPENTIN 300 MG CAPSULE

NDC	Description
68071021260	GABAPENTIN 300MG CAPSULE
68071021284	GABAPENTIN 300 MG CAPSULE
68071021290	GABAPENTIN 300MG CAPSULE
68071022830	GABAPENTIN 100 MG CAPSULE
68071022845	GABAPENTIN 100 MG CAPSULE
68071022884	GABAPENTIN 100 MG CAPSULE
68071022890	GABAPENTIN 100MG CAPSULE
68071029130	GABAPENTIN 400 MG CAPSULE
68071029160	GABAPENTIN 400 MG CAPSULE
68071029184	GABAPENTIN 400 MG CAPSULE
68071029190	GABAPENTIN 400 MG CAPSULE
68071029230	GABAPENTIN 600MG TABLET
68071029260	GABAPENTIN 600MG TABLET
68071029290	GABAPENTIN 600MG TABLET
68071029291	GABAPENTIN 600MG TABLET
68071029330	GABAPENTIN 800MG TABLET
68071029360	GABAPENTIN 800MG TABLET
68071029384	GABAPENTIN 800 MG TABLET
68071029390	GABAPENTIN 800MG TABLET
68071029391	GABAPENTIN 800MG TABLET
68084007901	GABAPENTIN 100MG CAPSULE
68084007908	GABAPENTIN 100MG CAPSULE
68084007911	GABAPENTIN 100MG CAPSULE
68084007965	GABAPENTIN 100MG CAPSULE
68084007990	GABAPENTIN 100MG CAPSULE
68084008001	GABAPENTIN 300MG CAPSULE
68084008008	GABAPENTIN 300MG CAPSULE
68084008011	GABAPENTIN 300MG CAPSULE
68084008065	GABAPENTIN 300MG CAPSULE
68084008090	GABAPENTIN 300MG CAPSULE
68084008101	GABAPENTIN 400MG CAPSULE
68084008108	GABAPENTIN 400MG CAPSULE
68084008111	GABAPENTIN 400MG CAPSULE
68084008165	GABAPENTIN 400MG CAPSULE

NDC	Description
68084008190	GABAPENTIN 400MG CAPSULE
68084012201	GABAPENTIN 600MG TABLET
68084012211	GABAPENTIN 600MG TABLET
68084012285	GABAPENTIN 600MG TABLET
68084012301	GABAPENTIN 800MG TABLET
68084012311	GABAPENTIN 800MG TABLET
68084012385	GABAPENTIN 800MG TABLET
68084056301	GABAPENTIN 300 MG CAPSULE
68084056311	GABAPENTIN 300 MG CAPSULE
68084056365	GABAPENTIN 300 MG CAPSULE
68084059401	GABAPENTIN 100 MG CAPSULE
68084059411	GABAPENTIN 100 MG CAPSULE
68084059465	GABAPENTIN 100 MG CAPSULE
68084059501	GABAPENTIN 400 MG CAPSULE
68084059511	GABAPENTIN 400 MG CAPSULE
68084059565	GABAPENTIN 400 MG CAPSULE
68084062401	GABAPENTIN 600 MG TABLET
68084062411	GABAPENTIN 600 MG TABLET
68084062501	GABAPENTIN 800 MG TABLET
68084062511	GABAPENTIN 800 MG TABLET
68084076201	GABAPENTIN 300 MG CAPSULE
68084076211	GABAPENTIN 300 MG CAPSULE
68084077401	GABAPENTIN 400 MG CAPSULE
68084077411	GABAPENTIN 400 MG CAPSULE
68084078301	GABAPENTIN 100 MG CAPSULE
68084078311	GABAPENTIN 100 MG CAPSULE
68084079701	GABAPENTIN 600 MG TABLET
68084079711	GABAPENTIN 600 MG TABLET
68084080201	GABAPENTIN 800 MG TABLET
68084080211	GABAPENTIN 800 MG TABLET
68115025300	NEURONTIN 100MG CAPSULE
68115025330	NEURONTIN 100MG CAPSULE
68115025360	NEURONTIN 100MG CAPSULE
68115025390	NEURONTIN 100MG CAPSULE

NDC	Description
68115025400	NEURONTIN 300MG CAPSULE
68115025430	NEURONTIN 300MG CAPSULE
68115025445	NEURONTIN 300MG CAPSULE
68115025460	NEURONTIN 300MG CAPSULE
68115025490	NEURONTIN 300MG CAPSULE
68115029200	NEURONTIN 800MG TABLET
68115038500	NEURONTIN 600MG TABLET
68115038560	NEURONTIN 600MG TABLET
68115048400	GABAPENTIN 100MG CAPSULE
68115048430	GABAPENTIN 100MG CAPSULE
68115048490	GABAPENTIN 100MG CAPSULE
68115048500	GABAPENTIN 300MG CAPSULE
68115048530	GABAPENTIN 300MG CAPSULE
68115048560	GABAPENTIN 300MG CAPSULE
68115048590	GABAPENTIN 300MG CAPSULE
68115048593	GABAPENTIN 300MG CAPSULE
68115048597	GABAPENTIN 300MG CAPSULE
68115048599	GABAPENTIN 300MG CAPSULE
68115050130	GABAPENTIN 600MG TABLET
68115050160	GABAPENTIN 600MG TABLET
68115050190	GABAPENTIN 600MG TABLET
68115050197	GABAPENTIN 600MG TABLET
68115050230	GABAPENTIN 800MG TABLET
68115050290	GABAPENTIN 800MG TABLET
68115054500	GABAPENTIN 400MG TABLET
68115072300	NEURONTIN 400MG CAPSULE
68382020401	GABAPENTIN 600 MG TABLET
68382020405	GABAPENTIN 600 MG TABLET
68382020501	GABAPENTIN 800 MG TABLET
68382020505	GABAPENTIN 800 MG TABLET
68387040412	GABAPENTIN 400 MG CAPSULE
68387040460	GABAPENTIN 400 MG CAPSULE
68387040490	GABAPENTIN 400MG CAPSULE
68387040512	GABAPENTIN 600 MG TABLET

NDC	Description
68387040590	GABAPENTIN 600MG TABLET
68387040812	GABAPENTIN 800MG TABLET
68387040860	GABAPENTIN 800 MG TABLET
68387040890	GABAPENTIN 800MG TABLET
68387041010	GABAPENTIN 300MG CAPSULE
68387041018	GABAPENTIN 300MG CAPSULE
68387041030	GABAPENTIN 300MG CAPSULE
68387041045	GABAPENTIN 300MG CAPSULE
68387041060	GABAPENTIN 300MG CAPSULE
68387041090	GABAPENTIN 300MG CAPSULE
68387042012	GABAPENTIN 100MG CAPSULE
68387042030	GABAPENTIN 100MG CAPSULE
68387042045	GABAPENTIN 100MG CAPSULE
68387042090	GABAPENTIN 100 MG CAPSULE
68387042112	GABAPENTIN 600MG TABLET
68387042190	GABAPENTIN 600MG TABLET
68405806826	THERAPENTIN-60 300MG CAPSULE
68405806836	THERAPENTIN-90 300MG CAPSULE
68462012601	GABAPENTIN 600MG TABLET
68462012605	GABAPENTIN 600MG TABLET
68462012701	GABAPENTIN 800MG TABLET
68462012705	GABAPENTIN 800MG TABLET
69097081107	GABAPENTIN 800 MG TABLET
69097081112	GABAPENTIN 800 MG TABLET
69097081207	GABAPENTIN 600 MG TABLET
69097081212	GABAPENTIN 600 MG TABLET
69097081307	GABAPENTIN 100 MG CAPSULE
69097081312	GABAPENTIN 100 MG CAPSULE
69097081407	GABAPENTIN 300 MG CAPSULE
69097081412	GABAPENTIN 300 MG CAPSULE
69097081507	GABAPENTIN 400 MG CAPSULE
69097081512	GABAPENTIN 400 MG CAPSULE
69097094307	GABAPENTIN 300 MG CAPSULE
69097094312	GABAPENTIN 300 MG CAPSULE

NDC	Description
69336010611	GABAPENTIN 300 MG CAPSULE
69367013104	GABAPENTIN 100 MG CAPSULE
69367013106	GABAPENTIN 100 MG CAPSULE
69367013204	GABAPENTIN 300 MG CAPSULE
69367013206	GABAPENTIN 300 MG CAPSULE
69367013304	GABAPENTIN 400 MG CAPSULE
69367013306	GABAPENTIN 400 MG CAPSULE
69367013404	GABAPENTIN 600 MG TABLET
69367013406	GABAPENTIN 600 MG TABLET
69367013504	GABAPENTIN 800 MG TABLET
69367013506	GABAPENTIN 800 MG TABLET
69512010210	GABAPENTIN 300 MG CAPSULE
69677006302	SMARTRX GABAKIT 300MG-4-1% KIT CR-CAP
69677006902	SMARTRX GABA-V KIT 300MG-20-5 KIT CR-CAP
00071040124	NEURONTIN 800MG TABLET
00071041624	NEURONTIN 600MG TABLET
00071042624	NEURONTIN 800MG TABLET
00071051324	NEURONTIN 600MG TABLET
00071080324	NEURONTIN 100MG CAPSULE
00071080340	NEURONTIN 100MG CAPSULE
00071080524	NEURONTIN 300MG CAPSULE
00071080540	NEURONTIN 300MG CAPSULE
00071080624	NEURONTIN 400MG CAPSULE
00071080640	NEURONTIN 400MG CAPSULE
71093011104	GABAPENTIN 600 MG TABLET
71093011105	GABAPENTIN 600 MG TABLET
71093011204	GABAPENTIN 800 MG TABLET
71093011205	GABAPENTIN 800 MG TABLET
71093012004	GABAPENTIN 100 MG CAPSULE
71093012005	GABAPENTIN 100 MG CAPSULE
71093012104	GABAPENTIN 300 MG CAPSULE
71093012105	GABAPENTIN 300 MG CAPSULE
71093012204	GABAPENTIN 400 MG CAPSULE
71093012205	GABAPENTIN 400 MG CAPSULE

NDC	Description
00071201223	NEURONTIN 250MG/5ML SOLUTION
71205006430	GABAPENTIN 400 MG CAPSULE
71205006472	GABAPENTIN 400 MG CAPSULE
71205006490	GABAPENTIN 400 MG CAPSULE
71205016030	GABAPENTIN 800 MG TABLET
71205016090	GABAPENTIN 800 MG TABLET
71205029515	GABAPENTIN 300 MG CAPSULE
71205029530	GABAPENTIN 300 MG CAPSULE
71205029560	GABAPENTIN 300 MG CAPSULE
71205029590	GABAPENTIN 300 MG CAPSULE
71300644001	NEURAPTINE 10 % CREAM PACK
71300644002	NEURAPTINE 10 % CRM MD APL
71300644003	NEURAPTINE 10 % CREAM PACK
71335101201	GABAPENTIN 600 MG TABLET
71335101202	GABAPENTIN 600 MG TABLET
71335101204	GABAPENTIN 600 MG TABLET
71335101206	GABAPENTIN 600 MG TABLET
71335101208	GABAPENTIN 600 MG TABLET
71335101209	GABAPENTIN 600 MG TABLET
71335113202	GABAPENTIN 600 MG TABLET
71335116902	GABAPENTIN 100 MG CAPSULE
71335119701	GABAPENTIN 300 MG CAPSULE
71335119702	GABAPENTIN 300 MG CAPSULE
71335119703	GABAPENTIN 300 MG CAPSULE
71335119704	GABAPENTIN 300 MG CAPSULE
71335119705	GABAPENTIN 300 MG CAPSULE
71335119709	GABAPENTIN 300 MG CAPSULE
71335119804	GABAPENTIN 100 MG CAPSULE
71335120001	GABAPENTIN 600 MG TABLET
71335128702	GABAPENTIN 600 MG TABLET
71335134801	GABAPENTIN 300 MG CAPSULE
71399055105	GABAPENTIN 100 MG CAPSULE
71399055305	GABAPENTIN 300 MG CAPSULE
71399055405	GABAPENTIN 400 MG CAPSULE

NDC	Description
71399055605	GABAPENTIN 600 MG TABLET
71399055805	GABAPENTIN 800 MG TABLET
71610004460	GABAPENTIN 600 MG TABLET
71610004480	GABAPENTIN 600 MG TABLET
71610004492	GABAPENTIN 600 MG TABLET
71610005760	GABAPENTIN 100 MG CAPSULE
71610005780	GABAPENTIN 100 MG CAPSULE
71610005792	GABAPENTIN 100 MG CAPSULE
71610005960	GABAPENTIN 400 MG CAPSULE
71610006030	GABAPENTIN 300 MG CAPSULE
71610006053	GABAPENTIN 300 MG CAPSULE
71610006060	GABAPENTIN 300 MG CAPSULE
71610006070	GABAPENTIN 300 MG CAPSULE
71610006080	GABAPENTIN 300 MG CAPSULE
71610006092	GABAPENTIN 300 MG CAPSULE
71610006094	GABAPENTIN 300 MG CAPSULE
71610006098	GABAPENTIN 300 MG CAPSULE
71610006960	GABAPENTIN 600 MG TABLET
71610006980	GABAPENTIN 600 MG TABLET
71610006992	GABAPENTIN 600 MG TABLET
71610007260	GABAPENTIN 100 MG CAPSULE
71610007280	GABAPENTIN 100 MG CAPSULE
71610007292	GABAPENTIN 100 MG CAPSULE
71610007298	GABAPENTIN 100 MG CAPSULE
71610008830	GABAPENTIN 300 MG CAPSULE
71610008853	GABAPENTIN 300 MG CAPSULE
71610008860	GABAPENTIN 300 MG CAPSULE
71610008870	GABAPENTIN 300 MG CAPSULE
71610008880	GABAPENTIN 300 MG CAPSULE
71610008892	GABAPENTIN 300 MG CAPSULE
71610008894	GABAPENTIN 300 MG CAPSULE
71610008898	GABAPENTIN 300 MG CAPSULE
71610009053	GABAPENTIN 300 MG CAPSULE
71610009060	GABAPENTIN 300 MG CAPSULE

NDC	Description
71610009080	GABAPENTIN 300 MG CAPSULE
71610009092	GABAPENTIN 300 MG CAPSULE
71610009094	GABAPENTIN 300 MG CAPSULE
71610012530	GABAPENTIN 300 MG CAPSULE
71610012553	GABAPENTIN 300 MG CAPSULE
71610012560	GABAPENTIN 300 MG CAPSULE
71610012570	GABAPENTIN 300 MG CAPSULE
71610012580	GABAPENTIN 300 MG CAPSULE
71610012592	GABAPENTIN 300 MG CAPSULE
71610012598	GABAPENTIN 300 MG CAPSULE
71610012660	GABAPENTIN 100 MG CAPSULE
71610012680	GABAPENTIN 100 MG CAPSULE
71610012692	GABAPENTIN 100 MG CAPSULE
71610013560	GABAPENTIN 100 MG CAPSULE
71610013580	GABAPENTIN 100 MG CAPSULE
71610013592	GABAPENTIN 100 MG CAPSULE
71610013598	GABAPENTIN 100 MG CAPSULE
71610014360	GABAPENTIN 300 MG CAPSULE
71610014630	GABAPENTIN 300 MG CAPSULE
71610014653	GABAPENTIN 300 MG CAPSULE
71610014660	GABAPENTIN 300 MG CAPSULE
71610014670	GABAPENTIN 300 MG CAPSULE
71610014680	GABAPENTIN 300 MG CAPSULE
71610014692	GABAPENTIN 300 MG CAPSULE
71610014698	GABAPENTIN 300 MG CAPSULE
71610016660	GABAPENTIN 400 MG CAPSULE
71610016680	GABAPENTIN 400 MG CAPSULE
71610016692	GABAPENTIN 400 MG CAPSULE
71610016694	GABAPENTIN 400 MG CAPSULE
71610018160	GABAPENTIN 400 MG CAPSULE
71610018180	GABAPENTIN 400 MG CAPSULE
71610018530	GABAPENTIN 300 MG CAPSULE
71610018553	GABAPENTIN 300 MG CAPSULE
71610018560	GABAPENTIN 300 MG CAPSULE

NDC	Description
71610018570	GABAPENTIN 300 MG CAPSULE
71610018580	GABAPENTIN 300 MG CAPSULE
71610018592	GABAPENTIN 300 MG CAPSULE
71610018594	GABAPENTIN 300 MG CAPSULE
71610018830	GABAPENTIN 300 MG CAPSULE
71610018853	GABAPENTIN 300 MG CAPSULE
71610018860	GABAPENTIN 300 MG CAPSULE
71610018880	GABAPENTIN 300 MG CAPSULE
71610018892	GABAPENTIN 300 MG CAPSULE
71610018894	GABAPENTIN 300 MG CAPSULE
71610019560	GABAPENTIN 400 MG CAPSULE
71610019592	GABAPENTIN 400 MG CAPSULE
71610019860	GABAPENTIN 400 MG CAPSULE
71610019880	GABAPENTIN 400 MG CAPSULE
71610019894	GABAPENTIN 400 MG CAPSULE
71610021160	GABAPENTIN 300 MG CAPSULE
71610021170	GABAPENTIN 300 MG CAPSULE
71610021180	GABAPENTIN 300 MG CAPSULE
71610021194	GABAPENTIN 300 MG CAPSULE
71610021198	GABAPENTIN 300 MG CAPSULE
71717010210	GABAPENTIN 600 MG TABLET
71717010250	GABAPENTIN 600 MG TABLET
71717010310	GABAPENTIN 800 MG TABLET
71717010350	GABAPENTIN 800 MG TABLET
76282022101	GABAPENTIN 100 MG CAPSULE
76282022105	GABAPENTIN 100 MG CAPSULE
76282022201	GABAPENTIN 300 MG CAPSULE
76282022205	GABAPENTIN 300 MG CAPSULE
76282022301	GABAPENTIN 400 MG CAPSULE
76282022305	GABAPENTIN 400 MG CAPSULE
76282032101	GABAPENTIN 100 MG CAPSULE
76282032105	GABAPENTIN 100 MG CAPSULE
76282032201	GABAPENTIN 300 MG CAPSULE
76282032205	GABAPENTIN 300 MG CAPSULE

NDC	Description
76282032301	GABAPENTIN 400 MG CAPSULE
76282032305	GABAPENTIN 400 MG CAPSULE
76282040501	GABAPENTIN 600 MG TABLET
76282040505	GABAPENTIN 600 MG TABLET
76282040590	GABAPENTIN 600 MG TABLET
76282040601	GABAPENTIN 800 MG TABLET
76282040605	GABAPENTIN 800 MG TABLET
76282040690	GABAPENTIN 800 MG TABLET
76282062705	GABAPENTIN 300 MG CAPSULE
00904563140	GABAPENTIN 100 MG CAPSULE
00904563161	GABAPENTIN 100MG CAPSULE
00904563189	GABAPENTIN 100MG CAPSULE
00904563193	GABAPENTIN 100 MG CAPSULE
00904563240	GABAPENTIN 300 MG CAPSULE
00904563246	GABAPENTIN 300MG CAPSULE
00904563252	GABAPENTIN 300 MG CAPSULE
00904563253	GABAPENTIN 300MG CAPSULE
00904563261	GABAPENTIN 300MG CAPSULE
00904563289	GABAPENTIN 300MG CAPSULE
00904563293	GABAPENTIN 300MG CAPSULE
00904563340	GABAPENTIN 400 MG CAPSULE
00904563361	GABAPENTIN 400MG CAPSULE
00904563389	GABAPENTIN 400MG CAPSULE
00904607861	GABAPENTIN 100 MG CAPSULE
00904607961	GABAPENTIN 300 MG CAPSULE
00904610561	GABAPENTIN 400 MG CAPSULE
00904658661	GABAPENTIN 800 MG TABLET
00904666561	GABAPENTIN 100 MG CAPSULE
00904666661	GABAPENTIN 300 MG CAPSULE
00904666761	GABAPENTIN 400 MG CAPSULE
00904682361	GABAPENTIN 600 MG TABLET
00093103801	GABAPENTIN 100MG CAPSULE
00093103805	GABAPENTIN 100MG CAPSULE
00093103901	GABAPENTIN 300MG CAPSULE

NDC	Description
00093103905	GABAPENTIN 300MG CAPSULE
00093103910	GABAPENTIN 300MG CAPSULE
00093103919	GABAPENTIN 300 MG CAPSULE
00093103993	GABAPENTIN 300 MG CAPSULE
00093104001	GABAPENTIN 400MG CAPSULE
00093104005	GABAPENTIN 400MG CAPSULE
00093444301	GABAPENTIN 600MG TABLET
00093444305	GABAPENTIN 600MG TABLET
00093444310	GABAPENTIN 600MG TABLET
00093444401	GABAPENTIN 800MG TABLET
00093444405	GABAPENTIN 800MG TABLET
00093717301	GABAPENTIN 600MG TABLET
00093717305	GABAPENTIN 600MG TABLET
00093717401	GABAPENTIN 800MG TABLET
00093717405	GABAPENTIN 800MG TABLET
10544041960	TOPIRAMATE 25MG TABLET
10544042060	TOPIRAMATE 50MG TABLET
10544042160	TOPIRAMATE 100MG TABLET
10544048960	TOPIRAMATE 100 MG TABLET
10544048990	TOPIRAMATE 100 MG TABLET
10544062890	TOPIRAMATE 25 MG TABLET
10544084730	TOPIRAMATE 50 MG TABLET
10544084760	TOPIRAMATE 50 MG TABLET
12280002215	TOPAMAX 100MG TABLET
12280029815	TOPAMAX 50MG TABLET
12280029830	TOPAMAX 50MG TABLET
12280029860	TOPAMAX 50MG TABLET
13668003101	TOPIRAMATE 25MG TABLET
13668003105	TOPIRAMATE 25MG TABLET
13668003130	TOPIRAMATE 25MG TABLET
13668003160	TOPIRAMATE 25MG TABLET
13668003171	TOPIRAMATE 25 MG TABLET
13668003174	TOPIRAMATE 25MG TABLET
13668003201	TOPIRAMATE 50MG TABLET

NDC	Description
13668003205	TOPIRAMATE 50MG TABLET
13668003230	TOPIRAMATE 50MG TABLET
13668003260	TOPIRAMATE 50MG TABLET
13668003271	TOPIRAMATE 50 MG TABLET
13668003274	TOPIRAMATE 50MG TABLET
13668003301	TOPIRAMATE 100MG TABLET
13668003305	TOPIRAMATE 100MG TABLET
13668003360	TOPIRAMATE 100MG TABLET
13668003364	TOPIRAMATE 100MG TABLET
13668003371	TOPIRAMATE 100 MG TABLET
13668003401	TOPIRAMATE 200MG TABLET
13668003405	TOPIRAMATE 200MG TABLET
13668003460	TOPIRAMATE 200MG TABLET
13668003471	TOPIRAMATE 200 MG TABLET
13668003477	TOPIRAMATE 200MG TABLET
16252056450	TOPIRAMATE 25MG TABLET
16252056460	TOPIRAMATE 25MG TABLET
16252056550	TOPIRAMATE 50MG TABLET
16252056560	TOPIRAMATE 50MG TABLET
16252056650	TOPIRAMATE 100MG TABLET
16252056660	TOPIRAMATE 100MG TABLET
16252056760	TOPIRAMATE 200MG TABLET
16252056860	TOPIRAMATE 15MG CAP SPRINK
16252056960	TOPIRAMATE 25MG CAP SPRINK
16590022630	TOPAMAX 25MG TABLET
16590022660	TOPAMAX 25MG TABLET
16590022672	TOPAMAX 25MG TABLET
16590022690	TOPAMAX 25MG TABLET
16590022730	TOPAMAX 50MG TABLET
16590022760	TOPAMAX 50MG TABLET
16590022790	TOPAMAX 50MG TABLET
16590022830	TOPAMAX 100MG TABLET
16590022860	TOPAMAX 100MG TABLET
16590022890	TOPAMAX 100MG TABLET

NDC	Description
16590081772	TOPIRAMATE 100 MG TABLET
16590082330	TOPIRAMATE 200 MG TABLET
16590082360	TOPIRAMATE 200 MG TABLET
16590082390	TOPIRAMATE 200 MG TABLET
16590082430	TOPIRAMATE 25 MG TABLET
16590082456	TOPIRAMATE 25 MG TABLET
16590082460	TOPIRAMATE 25 MG TABLET
16590082462	TOPIRAMATE 25 MG TABLET
16590082471	TOPIRAMATE 25 MG TABLET
16590082472	TOPIRAMATE 25 MG TABLET
16590082482	TOPIRAMATE 25 MG TABLET
16590082486	TOPIRAMATE 25 MG TABLET
16590082490	TOPIRAMATE 25 MG TABLET
16590082530	TOPIRAMATE 50 MG TABLET
16590082560	TOPIRAMATE 50 MG TABLET
16590082572	TOPIRAMATE 50 MG TABLET
16590082590	TOPIRAMATE 50 MG TABLET
17772010101	TROKENDI XR 25 MG CAP ER 24H
17772010115	TROKENDI XR 25 MG CAP ER 24H
17772010130	TROKENDI XR 25 MG CAP ER 24H
17772010201	TROKENDI XR 50 MG CAP ER 24H
17772010215	TROKENDI XR 50 MG CAP ER 24H
17772010230	TROKENDI XR 50 MG CAP ER 24H
17772010301	TROKENDI XR 100 MG CAP ER 24H
17772010315	TROKENDI XR 100 MG CAP ER 24H
17772010330	TROKENDI XR 100 MG CAP ER 24H
17772010401	TROKENDI XR 200 MG CAP ER 24H
17772010415	TROKENDI XR 200 MG CAP ER 24H
17772010430	TROKENDI XR 200 MG CAP ER 24H
18837015560	TOPAMAX 25MG TABLET
21695012815	TOPAMAX 25MG TABLET
21695012860	TOPAMAX 25MG TABLET
21695012915	TOPAMAX 50MG TABLET
21695013015	TOPAMAX 100MG TABLET

NDC	Description
21695016230	TOPIRAMATE 25MG TABLET
21695016260	TOPIRAMATE 25MG TABLET
21695016290	TOPIRAMATE 25 MG TABLET
21695020530	TOPIRAMATE 50MG TABLET
21695020560	TOPIRAMATE 50MG TABLET
21695020572	TOPIRAMATE 50 MG TABLET
21695020590	TOPIRAMATE 50MG TABLET
21695034830	TOPIRAMATE 100MG TABLET
21695034860	TOPIRAMATE 100MG TABLET
21695034890	TOPIRAMATE 100 MG TABLET
21695034930	TOPIRAMATE 200MG TABLET
21695034960	TOPIRAMATE 200 MG TABLET
23490900000	TOPAMAX 100MG TABLET
23490900003	TOPAMAX 100MG TABLET
00245071160	TOPIRAGEN 25 MG TABLET
00245071260	TOPIRAGEN 50 MG TABLET
00245071360	TOPIRAGEN 100 MG TABLET
00245071460	TOPIRAGEN 200 MG TABLET
00245107115	QUDEXY XR 25 MG CAP SPR 24
00245107130	QUDEXY XR 25 MG CAP SPR 24
00245107215	QUDEXY XR 50 MG CAP SPR 24
00245107230	QUDEXY XR 50 MG CAP SPR 24
00245107315	QUDEXY XR 200 MG CAP SPR 24
00245107330	QUDEXY XR 200 MG CAP SPR 24
00245107415	QUDEXY XR 100 MG CAP SPR 24
00245107430	QUDEXY XR 100 MG CAP SPR 24
00245107515	QUDEXY XR 150 MG CAP SPR 24
00245107530	QUDEXY XR 150 MG CAP SPR 24
29300011505	TOPIRAMATE 25 MG TABLET
29300011510	TOPIRAMATE 25 MG TABLET
29300011516	TOPIRAMATE 25 MG TABLET
29300011605	TOPIRAMATE 50 MG TABLET
29300011610	TOPIRAMATE 50 MG TABLET
29300011616	TOPIRAMATE 50 MG TABLET

NDC	Description
29300011705	TOPIRAMATE 100 MG TABLET
29300011710	TOPIRAMATE 100 MG TABLET
29300011716	TOPIRAMATE 100 MG TABLET
29300011805	TOPIRAMATE 200 MG TABLET
29300011810	TOPIRAMATE 200 MG TABLET
29300011816	TOPIRAMATE 200 MG TABLET
31722027805	TOPIRAMATE 25 MG TABLET
31722027810	TOPIRAMATE 25MG TABLET
31722027860	TOPIRAMATE 25MG TABLET
31722027905	TOPIRAMATE 50 MG TABLET
31722027910	TOPIRAMATE 50MG TABLET
31722027960	TOPIRAMATE 50MG TABLET
31722028005	TOPIRAMATE 100 MG TABLET
31722028010	TOPIRAMATE 100MG TABLET
31722028060	TOPIRAMATE 100MG TABLET
31722028105	TOPIRAMATE 200 MG TABLET
31722028110	TOPIRAMATE 200MG TABLET
31722028160	TOPIRAMATE 200MG TABLET
33358034156	TOPAMAX 25MG TABLET
35356040130	TOPAMAX 200MG TABLET
35356046930	TOPIRAMATE 25MG TABLET
35356046960	TOPIRAMATE 25MG TABLET
35356046990	TOPIRAMATE 25MG TABLET
35356047030	TOPIRAMATE 50MG TABLET
35356047060	TOPIRAMATE 50MG TABLET
35356047130	TOPIRAMATE 100MG TABLET
35356047160	TOPIRAMATE 100MG TABLET
35356047190	TOPIRAMATE 100 MG TABLET
35356047230	TOPIRAMATE 200MG TABLET
35356047260	TOPIRAMATE 200MG TABLET
00378203505	TOPIRAMATE 15 MG CAP SPRINK
00378203605	TOPIRAMATE 25 MG CAP SPRINK
00378610105	TOPIRAMATE 25MG TABLET
00378610191	TOPIRAMATE 25MG TABLET

NDC	Description
00378610205	TOPIRAMATE 50MG TABLET
00378610291	TOPIRAMATE 50MG TABLET
00378610305	TOPIRAMATE 100MG TABLET
00378610391	TOPIRAMATE 100MG TABLET
00378610505	TOPIRAMATE 200MG TABLET
00378610591	TOPIRAMATE 200MG TABLET
42291051810	TOPIRAMATE 25 MG TABLET
42291051818	TOPIRAMATE 25 MG TABLET
42291051890	TOPIRAMATE 25 MG TABLET
42291051910	TOPIRAMATE 50 MG TABLET
42291051918	TOPIRAMATE 50 MG TABLET
42291051990	TOPIRAMATE 50 MG TABLET
42291052010	TOPIRAMATE 100 MG TABLET
42291052018	TOPIRAMATE 100 MG TABLET
42291052090	TOPIRAMATE 100 MG TABLET
42291052110	TOPIRAMATE 200 MG TABLET
42291052118	TOPIRAMATE 200 MG TABLET
42291052190	TOPIRAMATE 200 MG TABLET
42549061960	TOPIRAMATE 25MG TABLET
42549062060	TOPIRAMATE 50MG TABLET
42549062160	TOPIRAMATE 100MG TABLET
43063009430	TOPIRAMATE 25MG TABLET
43063009460	TOPIRAMATE 25 MG TABLET
43063011430	TOPIRAMATE 50MG TABLET
43063018930	TOPIRAMATE 100 MG TABLET
43063018960	TOPIRAMATE 100 MG TABLET
43063041730	TOPIRAMATE 25 MG TABLET
43063043630	TOPIRAMATE 100 MG TABLET
43063043660	TOPIRAMATE 100 MG TABLET
43063053830	TOPIRAMATE 50 MG TABLET
43063053860	TOPIRAMATE 50 MG TABLET
43063057315	TOPIRAMATE 25 MG TABLET
43063057330	TOPIRAMATE 25 MG TABLET
43063057360	TOPIRAMATE 25 MG TABLET

NDC	Description
43063060530	TOPIRAMATE 100 MG TABLET
43063060560	TOPIRAMATE 100 MG TABLET
43063061230	TOPIRAMATE 50 MG TABLET
43063061260	TOPIRAMATE 50 MG TABLET
43063072907	TOPIRAMATE 100 MG TABLET
43063072921	TOPIRAMATE 100 MG TABLET
43063072928	TOPIRAMATE 100 MG TABLET
43063072930	TOPIRAMATE 100 MG TABLET
43063072960	TOPIRAMATE 100 MG TABLET
43063073407	TOPIRAMATE 50 MG TABLET
43063073421	TOPIRAMATE 50 MG TABLET
43063073430	TOPIRAMATE 50 MG TABLET
43063073460	TOPIRAMATE 50 MG TABLET
43063073515	TOPIRAMATE 25 MG TABLET
43063073530	TOPIRAMATE 25 MG TABLET
43063073560	TOPIRAMATE 25 MG TABLET
43063099730	TOPIRAMATE 50 MG TABLET
43063099760	TOPIRAMATE 50 MG TABLET
43063099830	TOPIRAMATE 25 MG TABLET
43063099860	TOPIRAMATE 25 MG TABLET
43353069530	TOPIRAMATE 25 MG TABLET
43353069553	TOPIRAMATE 25 MG TABLET
43353069560	TOPIRAMATE 25 MG TABLET
43353069570	TOPIRAMATE 25 MG TABLET
43353069580	TOPIRAMATE 25 MG TABLET
43353069630	TOPIRAMATE 100 MG TABLET
43353069645	TOPIRAMATE 100 MG TABLET
43353069653	TOPIRAMATE 100 MG TABLET
43353069660	TOPIRAMATE 100 MG TABLET
43353069680	TOPIRAMATE 100 MG TABLET
43353069715	TOPIRAMATE 200 MG TABLET
43353069730	TOPIRAMATE 200 MG TABLET
43353069760	TOPIRAMATE 200 MG TABLET
43353069780	TOPIRAMATE 200 MG TABLET

NDC	Description
00045063965	TOPAMAX 25MG TABLET
00045064065	TOPAMAX 50MG TABLET
00045064165	TOPAMAX 100MG TABLET
00045064265	TOPAMAX 200MG TABLET
00045064565	TOPAMAX 25MG CAP SPRINK
00045064765	TOPAMAX 15MG CAP SPRINK
47335070713	TOPIRAMATE 25 MG TABLET
47335070786	TOPIRAMATE 25 MG TABLET
47335071013	TOPIRAMATE 50 MG TABLET
47335071086	TOPIRAMATE 50 MG TABLET
47335071113	TOPIRAMATE 100 MG TABLET
47335071186	TOPIRAMATE 100 MG TABLET
47335071213	TOPIRAMATE 200 MG TABLET
47335071286	TOPIRAMATE 200 MG TABLET
49999060501	TOPAMAX 100MG TABLET
49999060515	TOPAMAX 100MG TABLET
49999060530	TOPAMAX 25MG TABLET
49999060560	TOPAMAX 100MG TABLET
49999069801	TOPAMAX 25MG TABLET
49999069815	TOPAMAX 25MG TABLET
49999069830	TOPAMAX 25MG TABLET
49999069860	TOPAMAX 25MG TABLET
49999069890	TOPAMAX 100MG TABLET
49999095560	TOPAMAX 50MG TABLET
50090210200	TOPIRAMATE 25 MG TABLET
50090210201	TOPIRAMATE 25 MG TABLET
50090210202	TOPIRAMATE 25 MG TABLET
50090220300	TOPIRAMATE 50 MG TABLET
50090220301	TOPIRAMATE 50 MG TABLET
50090220302	TOPIRAMATE 50 MG TABLET
50090224800	TOPIRAMATE 100 MG TABLET
50090224802	TOPIRAMATE 100 MG TABLET
50090338900	TOPIRAMATE 100 MG TABLET
50090346100	TOPIRAMATE 50 MG TABLET

NDC	Description
50090346102	TOPIRAMATE 50 MG TABLET
50268075011	TOPIRAMATE 25 MG TABLET
50268075015	TOPIRAMATE 25 MG TABLET
50268075111	TOPIRAMATE 50 MG TABLET
50268075115	TOPIRAMATE 50 MG TABLET
50268075211	TOPIRAMATE 100 MG TABLET
50268075215	TOPIRAMATE 100 MG TABLET
50268075311	TOPIRAMATE 200 MG TABLET
50268075315	TOPIRAMATE 200 MG TABLET
50436994901	TOPIRAMATE 25 MG TABLET
50436994902	TOPIRAMATE 25 MG TABLET
50436994903	TOPIRAMATE 25 MG TABLET
50436995001	TOPIRAMATE 50 MG TABLET
50436995002	TOPIRAMATE 50 MG TABLET
50436995003	TOPIRAMATE 50 MG TABLET
50436995101	TOPIRAMATE 100 MG TABLET
50436995102	TOPIRAMATE 100 MG TABLET
50458063965	TOPAMAX 25MG TABLET
50458064065	TOPAMAX 50MG TABLET
50458064165	TOPAMAX 100MG TABLET
50458064265	TOPAMAX 200MG TABLET
50458064565	TOPAMAX 25MG CAP SPRINK
50458064765	TOPAMAX 15MG CAP SPRINK
51079072601	TOPIRAMATE 25MG TABLET
51079072620	TOPIRAMATE 25MG TABLET
51079072701	TOPIRAMATE 50MG TABLET
51079072720	TOPIRAMATE 50MG TABLET
51079072801	TOPIRAMATE 100MG TABLET
51079072820	TOPIRAMATE 100MG TABLET
52959044101	TOPIRAMATE 25 MG TABLET
52959044160	TOPIRAMATE 25 MG TABLET
52959064330	TOPIRAMATE 100 MG TABLET
52959064360	TOPIRAMATE 100 MG TABLET
52959078060	TOPAMAX 25MG TABLET

NDC	Description
52959099402	TOPIRAMATE 50 MG TABLET
52959099460	TOPIRAMATE 50MG TABLET
54569483100	TOPAMAX 25MG TABLET
54569547300	TOPAMAX 100MG TABLET
54569613700	TOPIRAMATE 25 MG TABLET
54569613701	TOPIRAMATE 25 MG TABLET
54569613702	TOPIRAMATE 25 MG TABLET
54569613800	TOPIRAMATE 50 MG TABLET
54569613801	TOPIRAMATE 50 MG TABLET
54569613802	TOPIRAMATE 50 MG TABLET
54569613900	TOPIRAMATE 100 MG TABLET
54569613901	TOPIRAMATE 100 MG TABLET
54569613902	TOPIRAMATE 100 MG TABLET
54868467200	TOPAMAX 25MG TABLET
54868467201	TOPAMAX 25MG TABLET
54868467202	TOPAMAX 25MG TABLET
54868467203	TOPAMAX 25MG TABLET
54868467400	TOPAMAX 100MG TABLET
54868467401	TOPAMAX 100MG TABLET
54868467402	TOPAMAX 100MG TABLET
54868519000	TOPAMAX 200MG TABLET
54868534300	TOPAMAX 50MG TABLET
54868534301	TOPAMAX 50MG TABLET
54868601400	TOPIRAMATE 100MG TABLET
54868601401	TOPIRAMATE 100MG TABLET
54868601402	TOPIRAMATE 100MG TABLET
54868601500	TOPIRAMATE 200 MG TABLET
54868601501	TOPIRAMATE 200 MG TABLET
54868601600	TOPIRAMATE 25MG TABLET
54868601601	TOPIRAMATE 25MG TABLET
54868601602	TOPIRAMATE 25MG TABLET
54868601603	TOPIRAMATE 25 MG TABLET
54868601700	TOPIRAMATE 50MG TABLET
54868601701	TOPIRAMATE 50MG TABLET

NDC	Description
54868601702	TOPIRAMATE 50 MG TABLET
55045307601	TOPAMAX 25MG TABLET
55045307606	TOPAMAX 25MG TABLET
55045312406	TOPAMAX 100MG TABLET
55045312408	TOPAMAX 100MG TABLET
55045396401	TOPIRAMATE 50MG TABLET
55289043330	TOPAMAX 50MG TABLET
55289049730	TOPAMAX 100MG TABLET
55289090130	TOPAMAX 25MG TABLET
55700013460	TOPIRAMATE 200 MG TABLET
55700017930	TOPIRAMATE 50 MG TABLET
55700018330	TOPIRAMATE 100 MG TABLET
55700018360	TOPIRAMATE 100 MG TABLET
55700018390	TOPIRAMATE 100 MG TABLET
55700021030	TOPIRAMATE 50 MG TABLET
55700021060	TOPIRAMATE 50 MG TABLET
55700021730	TOPIRAMATE 100 MG TABLET
55700021760	TOPIRAMATE 100 MG TABLET
55700021790	TOPIRAMATE 100 MG TABLET
55700022630	TOPIRAMATE 200 MG TABLET
55700022660	TOPIRAMATE 200 MG TABLET
55700022727	TOPIRAMATE 25 MG TABLET
55700022730	TOPIRAMATE 25 MG TABLET
55700022760	TOPIRAMATE 25 MG TABLET
55700022790	TOPIRAMATE 25 MG TABLET
55700022830	TOPIRAMATE 50 MG TABLET
55700022860	TOPIRAMATE 50 MG TABLET
55700022890	TOPIRAMATE 50 MG TABLET
55700059627	TOPIRAMATE 25 MG TABLET
55700059630	TOPIRAMATE 25 MG TABLET
55700059660	TOPIRAMATE 25 MG TABLET
55700059690	TOPIRAMATE 25 MG TABLET
55887018630	TOPAMAX 50MG TABLET
55887018660	TOPAMAX 50MG TABLET

NDC	Description
55887018690	TOPAMAX 50MG TABLET
55887048930	TOPAMAX 100MG TABLET
55887048960	TOPAMAX 100MG TABLET
55887048990	TOPAMAX 100MG TABLET
55887051730	TOPAMAX 25MG TABLET
55887051760	TOPAMAX 25MG TABLET
55887051782	TOPAMAX 25MG TABLET
55887051790	TOPAMAX 25MG TABLET
57866018501	TOPAMAX 100MG TABLET
57866018502	TOPAMAX 100MG TABLET
57866019001	TOPAMAX 25MG TABLET
57866556102	TOPAMAX 50MG TABLET
58016004700	TOPAMAX 200MG TABLET
58016004730	TOPAMAX 200MG TABLET
58016004760	TOPAMAX 200MG TABLET
58016004790	TOPAMAX 200MG TABLET
58016047800	TOPAMAX 25MG TABLET
58016047810	TOPAMAX 25MG TABLET
58016047830	TOPAMAX 25MG TABLET
58016047840	TOPAMAX 25MG TABLET
58016047860	TOPAMAX 25MG TABLET
58016047890	TOPAMAX 25MG TABLET
58016062600	TOPAMAX 15MG CAP SPRINK
58016062630	TOPAMAX 15MG CAP SPRINK
58016062660	TOPAMAX 15MG CAP SPRINK
58016062690	TOPAMAX 15MG CAP SPRINK
58016096100	TOPAMAX 100MG TABLET
58016096130	TOPAMAX 100MG TABLET
58016096160	TOPAMAX 100MG TABLET
58016096190	TOPAMAX 100MG TABLET
59762103001	TOPIRAMATE 25MG TABLET
59762103101	TOPIRAMATE 50MG TABLET
59762103201	TOPIRAMATE 100MG TABLET
59762103301	TOPIRAMATE 200MG TABLET

NDC	Description
60429076905	TOPIRAMATE 25MG TABLET
60429076910	TOPIRAMATE 25 MG TABLET
60429076960	TOPIRAMATE 25MG TABLET
60429077005	TOPIRAMATE 50MG TABLET
60429077010	TOPIRAMATE 50 MG TABLET
60429077060	TOPIRAMATE 50MG TABLET
60429077105	TOPIRAMATE 100MG TABLET
60429077110	TOPIRAMATE 100 MG TABLET
60429077160	TOPIRAMATE 100MG TABLET
60429077205	TOPIRAMATE 200MG TABLET
60429077210	TOPIRAMATE 200 MG TABLET
60429077260	TOPIRAMATE 200MG TABLET
60505276005	TOPIRAMATE 25MG TABLET
60505276006	TOPIRAMATE 25MG TABLET
60505276105	TOPIRAMATE 50MG TABLET
60505276106	TOPIRAMATE 50MG TABLET
60505276205	TOPIRAMATE 100MG TABLET
60505276206	TOPIRAMATE 100MG TABLET
60505276305	TOPIRAMATE 200MG TABLET
60505276306	TOPIRAMATE 200MG TABLET
60687010832	TOPIRAMATE 25 MG CAP SPRINK
60687010833	TOPIRAMATE 25 MG CAP SPRINK
60760009460	TOPIRAMATE 50 MG TABLET
60760009490	TOPIRAMATE 50 MG TABLET
60760027890	TOPIRAMATE 25 MG TABLET
60760027990	TOPIRAMATE 50 MG TABLET
60760028060	TOPIRAMATE 100 MG TABLET
60760063930	TOPAMAX 25MG TABLET
60760063960	TOPAMAX 25MG TABLET
60760063990	TOPAMAX 25MG TABLET
60760064130	TOPAMAX 100MG TABLET
60760064160	TOPAMAX 100MG TABLET
60760064190	TOPAMAX 100MG TABLET
61919017260	TOPIRAMATE 50 MG TABLET

NDC	Description
61919017272	TOPIRAMATE 50 MG TABLET
61919017290	TOPIRAMATE 50 MG TABLET
61919018960	TOPIRAMATE 50 MG TABLET
61919021372	TOPIRAMATE 100 MG TABLET
61919036960	TOPIRAMATE 50 MG TABLET
61919043960	TOPIRAMATE 100 MG TABLET
61919067930	TOPIRAMATE 25 MG TABLET
61919067960	TOPIRAMATE 25 MG TABLET
61919067972	TOPIRAMATE 25 MG TABLET
61919067990	TOPIRAMATE 25 MG TABLET
61919081730	TOPIRAMATE 100 MG TABLET
61919081760	TOPIRAMATE 100 MG TABLET
61919082430	TOPIRAMATE 25 MG TABLET
61919082460	TOPIRAMATE 25 MG TABLET
61919082490	TOPIRAMATE 25 MG TABLET
61919082530	TOPIRAMATE 50 MG TABLET
61919082560	TOPIRAMATE 50 MG TABLET
61919082590	TOPIRAMATE 50 MG TABLET
62541020130	QSYMIA 3.75-23 MG CPMP 24HR
62541020230	QSYMIA 7.5MG-46MG CPMP 24HR
62541020330	QSYMIA 11.25-69MG CPMP 24HR
62541020430	QSYMIA 15 MG-92MG CPMP 24HR
62756070713	TOPIRAMATE 25MG TABLET
62756070786	TOPIRAMATE 25MG TABLET
62756071013	TOPIRAMATE 50MG TABLET
62756071086	TOPIRAMATE 50MG TABLET
62756071113	TOPIRAMATE 100MG TABLET
62756071186	TOPIRAMATE 100MG TABLET
62756071213	TOPIRAMATE 200MG TABLET
62756071286	TOPIRAMATE 200MG TABLET
63187006030	TOPIRAMATE 100 MG TABLET
63187011830	TOPIRAMATE 25 MG TABLET
63187011860	TOPIRAMATE 25 MG TABLET
63187022830	TOPIRAMATE 50 MG TABLET

NDC	Description
63187022890	TOPIRAMATE 50 MG TABLET
63187023090	TOPIRAMATE 100 MG TABLET
63187028360	TOPIRAMATE 100 MG TABLET
63187047960	TOPIRAMATE 50 MG TABLET
63187069630	TOPIRAMATE 100 MG TABLET
63187069660	TOPIRAMATE 100 MG TABLET
63187069690	TOPIRAMATE 100 MG TABLET
63187075807	TOPIRAMATE 50 MG TABLET
63187075830	TOPIRAMATE 50 MG TABLET
63187075890	TOPIRAMATE 50 MG TABLET
63187077330	TOPIRAMATE 25 MG TABLET
63187077360	TOPIRAMATE 25 MG TABLET
63187077390	TOPIRAMATE 25 MG TABLET
63187080190	TOPIRAMATE 100 MG TABLET
63187096330	TOPIRAMATE 200 MG TABLET
63629329401	TOPIRAMATE 100 MG TABLET
63629329402	TOPIRAMATE 100 MG TABLET
63629329403	TOPIRAMATE 100 MG TABLET
63629329404	TOPIRAMATE 100 MG TABLET
63629329405	TOPIRAMATE 100 MG TABLET
63629329406	TOPIRAMATE 100 MG TABLET
63629329407	TOPIRAMATE 100 MG TABLET
63629336502	TOPAMAX 50MG TABLET
63629399401	TOPIRAMATE 25 MG TABLET
63629399402	TOPIRAMATE 25 MG TABLET
63629399403	TOPIRAMATE 25 MG TABLET
63629399501	TOPIRAMATE 50 MG TABLET
63629399502	TOPIRAMATE 50 MG TABLET
63874112806	TOPAMAX 25MG TABLET
64376011901	TOPIRAMATE 25 MG TABLET
64376011910	TOPIRAMATE 25 MG TABLET
64376012001	TOPIRAMATE 50 MG TABLET
64376012010	TOPIRAMATE 50 MG TABLET
64376012101	TOPIRAMATE 100 MG TABLET

NDC	Description
64376012110	TOPIRAMATE 100 MG TABLET
64376012201	TOPIRAMATE 200 MG TABLET
65862017160	TOPIRAMATE 25MG TABLET
65862017260	TOPIRAMATE 50MG TABLET
65862017360	TOPIRAMATE 100MG TABLET
65862017460	TOPIRAMATE 200MG TABLET
67253075110	TOPIRAMATE 25MG TABLET
67253075111	TOPIRAMATE 25MG TABLET
67253075210	TOPIRAMATE 50MG TABLET
67253075211	TOPIRAMATE 50MG TABLET
67253075310	TOPIRAMATE 100MG TABLET
67253075311	TOPIRAMATE 100MG TABLET
67253075410	TOPIRAMATE 200MG TABLET
67544047782	TOPAMAX 25MG TABLET
67544047787	TOPAMAX 25MG TABLET
67544102899	TOPAMAX 200MG TABLET
68071080830	TOPIRAMATE 25 MG TABLET
68071080860	TOPIRAMATE 25 MG TABLET
68071081030	TOPIRAMATE 200 MG TABLET
68071081130	TOPIRAMATE 50 MG TABLET
68071081160	TOPIRAMATE 50 MG TABLET
68071081330	TOPIRAMATE 100 MG TABLET
68084034201	TOPIRAMATE 25MG TABLET
68084034211	TOPIRAMATE 25MG TABLET
68084034301	TOPIRAMATE 50 MG TABLET
68084034311	TOPIRAMATE 50MG TABLET
68084034321	TOPIRAMATE 50MG TABLET
68084034401	TOPIRAMATE 100MG TABLET
68084034411	TOPIRAMATE 100MG TABLET
68084034511	TOPIRAMATE 200MG TABLET
68084034521	TOPIRAMATE 200MG TABLET
68115045615	TOPAMAX 25MG TABLET
68115045630	TOPAMAX 25MG TABLET
68115091060	TOPAMAX 200MG TABLET

NDC	Description
68115091860	TOPAMAX 25MG TABLET
68115092760	TOPAMAX 100MG TABLET
68258300001	TOPIRAMATE 25MG TABLET
68258300101	TOPIRAMATE 50MG TABLET
68258705606	TOPIRAMATE 100 MG TABLET
68258904301	TOPAMAX 25MG TABLET
68258904401	TOPAMAX 100MG TABLET
68258914601	TOPAMAX 15MG CAP SPRINK
68382000414	TOPIRAMATE 15MG CAP SPRINK
68382000514	TOPIRAMATE 25 MG CAP SPRINK
68382013805	TOPIRAMATE 25MG TABLET
68382013814	TOPIRAMATE 25MG TABLET
68382013905	TOPIRAMATE 50MG TABLET
68382013914	TOPIRAMATE 50MG TABLET
68382014005	TOPIRAMATE 100MG TABLET
68382014014	TOPIRAMATE 100MG TABLET
68382014105	TOPIRAMATE 200MG TABLET
68382014114	TOPIRAMATE 200MG TABLET
68387055512	TOPAMAX 25MG TABLET
68387055560	TOPAMAX 25MG TABLET
68387055630	TOPAMAX 100MG TABLET
68387055890	TOPIRAMATE 25MG TABLET
68387055930	TOPIRAMATE 100 MG TABLET
68387055960	TOPIRAMATE 100 MG TABLET
68387055990	TOPIRAMATE 100MG TABLET
68387056060	TOPIRAMATE 200 MG TABLET
68387056090	TOPIRAMATE 200 MG TABLET
68462010810	TOPIRAMATE 25MG TABLET
68462010860	TOPIRAMATE 25MG TABLET
68462010910	TOPIRAMATE 100MG TABLET
68462010960	TOPIRAMATE 100MG TABLET
68462011010	TOPIRAMATE 200MG TABLET
68462011060	TOPIRAMATE 200MG TABLET
68462015310	TOPIRAMATE 50MG TABLET

NDC	Description
68462015360	TOPIRAMATE 50MG TABLET
69097012203	TOPIRAMATE 25 MG TABLET
69097012212	TOPIRAMATE 25 MG TABLET
69097012215	TOPIRAMATE 25 MG TABLET
69097012303	TOPIRAMATE 50 MG TABLET
69097012312	TOPIRAMATE 50 MG TABLET
69097012315	TOPIRAMATE 50 MG TABLET
69097012403	TOPIRAMATE 100 MG TABLET
69097012412	TOPIRAMATE 100 MG TABLET
69097012415	TOPIRAMATE 100 MG TABLET
69097012503	TOPIRAMATE 200 MG TABLET
69097012512	TOPIRAMATE 200 MG TABLET
69097012515	TOPIRAMATE 200 MG TABLET
69097081603	TOPIRAMATE 25 MG TABLET
69097081615	TOPIRAMATE 25 MG TABLET
69097081703	TOPIRAMATE 50 MG TABLET
69097081715	TOPIRAMATE 50 MG TABLET
69097081803	TOPIRAMATE 100 MG TABLET
69097081815	TOPIRAMATE 100 MG TABLET
69097081903	TOPIRAMATE 200 MG TABLET
69097081915	TOPIRAMATE 200 MG TABLET
70934013330	TOPIRAMATE 50 MG TABLET
70934014930	TOPIRAMATE 25 MG TABLET
71205019590	TOPIRAMATE 100 MG TABLET
71205020230	TOPIRAMATE 25 MG TABLET
71205021430	TOPIRAMATE 25 MG TABLET
71205021460	TOPIRAMATE 25 MG TABLET
71205021490	TOPIRAMATE 25 MG TABLET
71335106401	TOPIRAMATE 50 MG TABLET
71335106402	TOPIRAMATE 50 MG TABLET
71335106403	TOPIRAMATE 50 MG TABLET
71335106405	TOPIRAMATE 50 MG TABLET
71335106407	TOPIRAMATE 50 MG TABLET
71335114301	TOPIRAMATE 100 MG TABLET

NDC	Description
71335114302	TOPIRAMATE 100 MG TABLET
71335114303	TOPIRAMATE 100 MG TABLET
71335114304	TOPIRAMATE 100 MG TABLET
71335114701	TOPIRAMATE 50 MG TABLET
71335114702	TOPIRAMATE 50 MG TABLET
71335114703	TOPIRAMATE 50 MG TABLET
71335114705	TOPIRAMATE 50 MG TABLET
71610019330	TOPIRAMATE 50 MG TABLET
71610019353	TOPIRAMATE 50 MG TABLET
71610019360	TOPIRAMATE 50 MG TABLET
71610019380	TOPIRAMATE 50 MG TABLET
72789000430	TOPIRAMATE 100 MG TABLET
00781227560	TOPIRAMATE 15MG CAP SPRINK
00781227660	TOPIRAMATE 25 MG CAP SPRINK
00832070715	TOPIRAMATE 25 MG TABLET
00832070815	TOPIRAMATE 50 MG TABLET
00832070915	TOPIRAMATE 100 MG TABLET
00832071015	TOPIRAMATE 200 MG TABLET
00832107115	TOPIRAMATE ER 25 MG CAP SPR 24
00832107130	TOPIRAMATE ER 25 MG CAP SPR 24
00832107215	TOPIRAMATE ER 50 MG CAP SPR 24
00832107230	TOPIRAMATE ER 50 MG CAP SPR 24
00832107315	TOPIRAMATE ER 200 MG CAP SPR 24
00832107330	TOPIRAMATE ER 200 MG CAP SPR 24
00832107415	TOPIRAMATE ER 100 MG CAP SPR 24
00832107430	TOPIRAMATE ER 100 MG CAP SPR 24
00832107515	TOPIRAMATE ER 150 MG CAP SPR 24
00832107530	TOPIRAMATE ER 150 MG CAP SPR 24
00904601604	TOPIRAMATE 25MG TABLET
00904601704	TOPIRAMATE 50MG TABLET
00904601804	TOPIRAMATE 100MG TABLET
00093015506	TOPIRAMATE 25MG TABLET
00093015510	TOPIRAMATE 25MG TABLET
00093721906	TOPIRAMATE 100MG TABLET

NDC	Description
00093721910	TOPIRAMATE 100MG TABLET
00093722006	TOPIRAMATE 200MG TABLET
00093722010	TOPIRAMATE 200MG TABLET
00093733506	TOPIRAMATE 15MG CAP SPRINK
00093733606	TOPIRAMATE 25MG CAP SPRINK
00093754006	TOPIRAMATE 50MG TABLET
00093754010	TOPIRAMATE 50MG TABLET
00102344501	VALPROIC ACID 250 MG CAPSULE
10370051010	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
10370051050	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
10370051110	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
10370051150	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
00115691101	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
00115691102	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
00115692201	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
00115692202	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
11845018501	VALPROIC ACID 250 MG CAPSULE
00121067505	VALPROIC ACID 250MG/5ML SYRUP
00121067516	VALPROIC ACID 250MG/5ML SYRUP
00121135000	VALPROIC ACID 500MG/10ML SOLUTION
00121135010	VALPROIC ACID 500MG/10ML SOLUTION
00121467500	VALPROIC ACID 250 MG/5ML SOLUTION
00121467505	VALPROIC ACID 250MG/5ML SYRUP
00121467510	VALPROIC ACID 500MG/10ML SOLUTION
00121467540	VALPROIC ACID 250 MG/5ML SOLUTION
00121467555	VALPROIC ACID 250 MG/5ML SYRUP
12280030800	DEPAKOTE ER 500MG TAB.SR 24H
12280030815	DEPAKOTE ER 500MG TAB.SR 24H
12280030830	DEPAKOTE ER 500MG TAB.SR 24H
00143963701	VALPROATE SODIUM 500 MG/5ML VIAL
00143963710	VALPROATE SODIUM 500 MG/5ML VIAL
00143978501	VALPROATE SODIUM 500 MG/5ML VIAL
00143978510	VALPROATE SODIUM 500 MG/5ML VIAL
16590058730	DEPAKOTE 250 MG TABLET DR

NDC	Description
16590058760	DEPAKOTE 250 MG TABLET DR
16590058772	DEPAKOTE 250 MG TABLET DR
16590058790	DEPAKOTE 250 MG TABLET DR
16590064830	DIVALPROEX SODIUM 500 MG TABLET DR
16590064860	DIVALPROEX SODIUM 500 MG TABLET DR
16590064890	DIVALPROEX SODIUM 500 MG TABLET DR
16590080930	DIVALPROEX SODIUM 250 MG TABLET DR
16590080960	DIVALPROEX SODIUM 250 MG TABLET DR
16590080990	DIVALPROEX SODIUM 250 MG TABLET DR
16714048401	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
16714048402	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
16714048501	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
16714048502	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
16714051101	DIVALPROEX SODIUM 125MG TABLET DR
16714051201	DIVALPROEX SODIUM 250MG TABLET DR
16714051202	DIVALPROEX SODIUM 250MG TABLET DR
16714051301	DIVALPROEX SODIUM 500MG TABLET DR
16714051302	DIVALPROEX SODIUM 500MG TABLET DR
17236035301	VALPROIC ACID 250 MG CAPSULE
17236084316	VALPROIC ACID 250 MG/5ML SOLUTION
00182175401	VALPROIC ACID 250MG CAPSULE
00182177901	VALPROIC ACID 250 MG CAPSULE
00182191601	DIVALPROEX SODIUM 125 MG TABLET DR
00182191701	DIVALPROEX SODIUM 250 MG TABLET DR
00182191801	DIVALPROEX SODIUM 500 MG TABLET DR
00182611540	VALPROIC ACID 250MG/5ML SYRUP
21695016315	DEPAKOTE ER 500MG TAB.SR 24H
21695035930	DEPAKOTE ER 250MG TAB.SR 24H
21695041700	VALPROIC ACID 250MG CAPSULE
21695041730	VALPROIC ACID 250MG CAPSULE
21695041760	VALPROIC ACID 250MG CAPSULE
21695065460	ZONISAMIDE 50 MG CAPSULE
21695081760	DIVALPROEX SODIUM 125MG TABLET DR
21695081830	DIVALPROEX SODIUM 250 MG TABLET DR

NDC	Description
21695081860	DIVALPROEX SODIUM 250MG TABLET DR
21695081930	DIVALPROEX SODIUM 500 MG TABLET DR
21695081960	DIVALPROEX SODIUM 500MG TABLET DR
21695081990	DIVALPROEX SODIUM 500 MG TABLET DR
00228245510	VALPROIC ACID 250MG CAPSULE
00245018001	DIVALPROEX SODIUM 125MG TABLET DR
00245018011	DIVALPROEX SODIUM 125MG TABLET DR
00245018015	DIVALPROEX SODIUM 125MG TABLET DR
00245018089	DIVALPROEX SODIUM 125MG TABLET DR
00245018101	DIVALPROEX SODIUM 250MG TABLET DR
00245018111	DIVALPROEX SODIUM 250MG TABLET DR
00245018115	DIVALPROEX SODIUM 250MG TABLET DR
00245018189	DIVALPROEX SODIUM 250MG TABLET DR
00245018201	DIVALPROEX SODIUM 500MG TABLET DR
00245018211	DIVALPROEX SODIUM 500MG TABLET DR
00245018215	DIVALPROEX SODIUM 500MG TABLET DR
00245018289	DIVALPROEX SODIUM 500MG TABLET DR
29300013801	DIVALPROEX SODIUM 125 MG TABLET DR
29300013805	DIVALPROEX SODIUM 125 MG TABLET DR
29300013901	DIVALPROEX SODIUM 250 MG TABLET DR
29300013905	DIVALPROEX SODIUM 250 MG TABLET DR
29300014001	DIVALPROEX SODIUM 500 MG TABLET DR
29300014005	DIVALPROEX SODIUM 500 MG TABLET DR
00302759901	VALPROIC ACID 250 MG CAPSULE
00304164001	VALPROIC ACID 250 MG CAPSULE
00304169898	VALPROIC ACID 250 MG/5ML SOLUTION
00304202201	DIVALPROEX SODIUM 125 MG TABLET DR
00304202301	DIVALPROEX SODIUM 250 MG TABLET DR
00304202401	DIVALPROEX SODIUM 500 MG TABLET DR
00306254780	VALPROIC ACID 250 MG CAPSULE
31722022801	ZONISAMIDE 100 MG CAPSULE
00032412001	DEPROIC 250 MG CAPSULE
33358010030	DEPAKOTE 250MG TABLET DR
33358010060	DEPAKOTE 250MG TABLET DR

NDC	Description
00349868601	DIVALPROEX SODIUM 125 MG TABLET DR
00349868701	DIVALPROEX SODIUM 250 MG TABLET DR
00349868801	DIVALPROEX SODIUM 500 MG TABLET DR
00349873501	VALPROIC ACID 250MG CAPSULE
00349873505	VALPROIC ACID 250 MG CAPSULE
35356014390	ZONISAMIDE 100 MG CAPSULE
35356034500	DEPAKOTE ER 250MG TAB.SR 24H
35356038630	DIVALPROEX SODIUM 125MG TABLET DR
35356061390	DIVALPROEX SODIUM 500 MG TABLET DR
35356061460	DIVALPROEX SODIUM 250 MG TABLET DR
35470057801	VALPROIC ACID 250 MG CAPSULE
35470102304	VALPROIC ACID 250 MG/5ML SOLUTION
00364082201	VALPROIC ACID 250MG CAPSULE
00364213916	VALPROIC ACID 250MG/5ML SYRUP
00378047201	DIVALPROEX SODIUM 250MG TAB.SR 24H
00378047205	DIVALPROEX SODIUM 250MG TAB.SR 24H
00378047277	DIVALPROEX SODIUM ER 250 MG TAB.SR 24H
00378047301	DIVALPROEX SODIUM 500MG TAB.SR 24H
00378047305	DIVALPROEX SODIUM 500MG TAB.SR 24H
00378047377	DIVALPROEX SODIUM ER 500 MG TAB.SR 24H
00378104301	DIVALPROEX SODIUM 125MG TABLET DR
00378104401	DIVALPROEX SODIUM 250MG TABLET DR
00378104501	DIVALPROEX SODIUM 500MG TABLET DR
00378104505	DIVALPROEX SODIUM 500 MG TABLET DR
00378800801	DIVALPROEX SODIUM 125 MG CAP SPRINK
00378800805	DIVALPROEX SODIUM 125 MG CAP SPRINK
38245063307	VALPROIC ACID 250MG/5ML SYRUP
00405389016	VALPROIC ACID 250MG/5ML SYRUP
00405509401	VALPROIC ACID 250MG CAPSULE
42254041760	ZONISAMIDE 50 MG CAPSULE
42291084401	VALPROIC ACID 250 MG CAPSULE
00426862116	VALPROIC ACID 250 MG/5ML SOLUTION
43063029530	DIVALPROEX SODIUM ER 500 MG TAB SR 24H
43063057514	ZONISAMIDE 25 MG CAPSULE

NDC	Description
43063057530	ZONISAMIDE 25 MG CAPSULE
43063093230	ZONISAMIDE 25 MG CAPSULE
43353008553	VALPROIC ACID 250 MG CAPSULE
43353008560	VALPROIC ACID 250 MG CAPSULE
43353008570	VALPROIC ACID 250 MG CAPSULE
43353008580	VALPROIC ACID 250 MG CAPSULE
43353008590	VALPROIC ACID 250 MG CAPSULE
43353010753	VALPROIC ACID 250 MG CAPSULE
43353010760	VALPROIC ACID 250 MG CAPSULE
43353010770	VALPROIC ACID 250 MG CAPSULE
43353010780	VALPROIC ACID 250 MG CAPSULE
43353010790	VALPROIC ACID 250 MG CAPSULE
43353010794	VALPROIC ACID 250 MG CAPSULE
43353027953	VALPROIC ACID 250 MG CAPSULE
43353027960	VALPROIC ACID 250 MG CAPSULE
43353027970	VALPROIC ACID 250 MG CAPSULE
43353027980	VALPROIC ACID 250 MG CAPSULE
43353027990	VALPROIC ACID 250 MG CAPSULE
43353027994	VALPROIC ACID 250 MG CAPSULE
43353031053	DEPAKOTE ER 500 MG TAB ER 24H
43353031060	DEPAKOTE ER 500 MG TAB ER 24H
43353031070	DEPAKOTE ER 500 MG TAB ER 24H
43353031080	DEPAKOTE ER 500 MG TAB ER 24H
43353054730	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
43353054753	DIVALPROEX SODIUM ER 500 MG TAB SR 24H
43353054760	DIVALPROEX SODIUM ER 500 MG TAB.SR 24H
43353054770	DIVALPROEX SODIUM ER 500 MG TAB SR 24H
43353054775	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
43353054780	DIVALPROEX SODIUM ER 500 MG TAB SR 24H
43353092853	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
43353092860	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
43353092870	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
00472021016	VALPROIC ACID 250MG/5ML SYRUP
47202135701	VALPROIC ACID 250 MG/5ML SOLUTION

NDC	Description
47202265401	VALPROIC ACID 250 MG CAPSULE
47202265402	VALPROIC ACID 250 MG CAPSULE
47202285701	VALPROIC ACID 250 MG CAPSULE
47202297701	DIVALPROEX SODIUM 125 MG TABLET DR
47202297801	DIVALPROEX SODIUM 250 MG TABLET DR
47202297901	DIVALPROEX SODIUM 500 MG TABLET DR
00472025116	VALPROIC ACID 250MG/5ML SYRUP
49727091702	VALPROIC ACID 250 MG CAPSULE
49884012501	VALPROIC ACID 250 MG CAPSULE
49884012504	VALPROIC ACID 250 MG CAPSULE
49884012505	VALPROIC ACID 250 MG CAPSULE
49999032230	VALPROIC ACID 250MG CAPSULE
49999087400	DEPAKOTE 500MG TABLET DR
49999087460	DEPAKOTE 500MG TABLET DR
49999087500	DEPAKOTE ER 500MG TAB.SR 24H
49999087560	DEPAKOTE ER 500MG TAB.SR 24H
49999094100	DEPAKOTE 250MG TABLET DR
49999094130	DEPAKOTE 250MG TABLET DR
49999094230	DEPAKOTE SPRINKLE 125MG CAP SPRINK
50090200700	DIVALPROEX SODIUM 250 MG TABLET DR
50090315600	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
50111085201	VALPROIC ACID 250MG CAPSULE
50268025811	DIVALPROEX SODIUM 125 MG CAP SPRINK
50268025813	DIVALPROEX SODIUM 125 MG CAP SPRINK
50383079205	VALPROIC ACID 250 MG/5ML SOLUTION
50383079206	VALPROIC ACID 250 MG/5ML SOLUTION
50383079207	VALPROIC ACID 250 MG/5ML SOLUTION
50383079210	VALPROIC ACID 500MG/10ML SOLUTION
50383079212	VALPROIC ACID 500MG/10ML SOLUTION
50383079216	VALPROIC ACID 250MG/5ML SYRUP
50436997601	DIVALPROEX SODIUM 500 MG TABLET DR
50962022605	VALPROIC ACID 250MG/5ML SYRUP
50962022660	VALPROIC ACID 250MG/5ML SYRUP
50962022661	VALPROIC ACID 250MG/5ML SYRUP

NDC	Description
50962023157	VALPROIC ACID 250MG CAPSULE
51079029801	VALPROIC ACID 250MG CAPSULE
51079029808	VALPROIC ACID 250 MG CAPSULE
51079029820	VALPROIC ACID 250MG CAPSULE
51079029840	VALPROIC ACID 250 MG CAPSULE
51079029850	VALPROIC ACID 250 MG CAPSULE
51079029856	VALPROIC ACID 250MG CAPSULE
51079047401	DIVALPROEX SODIUM 250MG TABLET DR
51079047408	DIVALPROEX SODIUM 250 MG TABLET DR
51079047420	DIVALPROEX SODIUM 250MG TABLET DR
51079047501	DIVALPROEX SODIUM 500MG TABLET DR
51079047508	DIVALPROEX SODIUM 500MG TABLET DR
51079047520	DIVALPROEX SODIUM 500MG TABLET DR
51079065410	VALPROIC ACID 250 MG/5ML SOLUTION
51079076501	DIVALPROEX SODIUM 125 MG CAP SPRINK
51079076508	DIVALPROEX SODIUM 125 MG CAP SPRINK
51079076530	DIVALPROEX SODIUM 125 MG CAP SPRINK
51079076556	DIVALPROEX SODIUM 125 MG CAP SPRINK
51079076601	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
51079076608	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
51079076701	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
51079076708	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
51079076730	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
51079076756	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
51129462302	DEPAKOTE ER 500MG TAB.SR 24H
51432046903	VALPROIC ACID 250 MG CAPSULE
51432056103	DIVALPROEX SODIUM 125 MG TABLET DR
51432056303	DIVALPROEX SODIUM 500 MG TABLET DR
51432056305	DIVALPROEX SODIUM 500 MG TABLET DR
51432056403	DIVALPROEX SODIUM 250 MG TABLET DR
51432056405	DIVALPROEX SODIUM 250 MG TABLET DR
51432067020	VALPROIC ACID 250 MG/5ML SOLUTION
51641030464	DEPA-SYRUP 250 MG/5ML SOLUTION
51641030476	DEPA-SYRUP 250 MG/5ML SOLUTION

NDC	Description
52446049921	VALPROIC ACID 250 MG CAPSULE
52446089858	VALPROIC ACID 250 MG/5ML SOLUTION
52544042616	VALPROIC ACID 250MG/5ML SYRUP
52555032501	VALPROIC ACID 250MG CAPSULE
52555032505	VALPROIC ACID 250 MG CAPSULE
52555066701	VALPROIC ACID 250MG CAPSULE
52555068801	VALPROIC ACID 250MG CAPSULE
52584012501	VALPROIC ACID 250 MG CAPSULE
52584018801	VALPROIC ACID 250 MG CAPSULE
00527540770	VALPROIC ACID 250 MG/5ML SOLUTION
52959014242	DEPAKOTE 125MG TABLET DR
52959067160	VALPROIC ACID 250MG CAPSULE
00536239085	VALPROIC ACID 250MG/5ML SYRUP
00536447701	VALPROIC ACID 250MG CAPSULE
00536477901	VALPROIC ACID 250 MG CAPSULE
00536477905	VALPROIC ACID 250 MG CAPSULE
54274021810	VALPROIC ACID 250 MG CAPSULE
54274021830	VALPROIC ACID 250 MG CAPSULE
54274038316	VALPROIC ACID 250 MG/5ML SOLUTION
54429319401	VALPROIC ACID 250MG CAPSULE
54569026100	DEPAKOTE 250MG TABLET DR
54569026101	DEPAKOTE 250MG TABLET DR
54569026102	DEPAKOTE 250 MG TABLET DR
54569026103	DEPAKOTE 250MG TABLET DR
54569026104	DEPAKOTE 250MG TABLET DR
54569026200	DEPAKOTE 500MG TABLET DR
54569026201	DEPAKOTE 500MG TABLET DR
54569026202	DEPAKOTE 500 MG TABLET DR
54569413400	DEPAKOTE 125MG TABLET DR
54569413401	DEPAKOTE 125MG TABLET DR
54569623300	DIVALPROEX SODIUM ER 500 MG TAB SR 24H
54868120801	DEPAKOTE 250MG TABLET DR
54868120803	DEPAKOTE 250MG TABLET DR
54868120804	DEPAKOTE 250MG TABLET DR

NDC	Description
54868120805	DEPAKOTE 250MG TABLET DR
54868120806	DEPAKOTE 250MG TABLET DR
54868168901	VALPROIC ACID 250MG CAPSULE
54868168902	VALPROIC ACID 250MG CAPSULE
54868168903	VALPROIC ACID 250MG CAPSULE
54868254401	DEPAKOTE 500MG TABLET DR
54868254403	DEPAKOTE 500MG TABLET DR
54868254404	DEPAKOTE 500MG TABLET DR
54868428500	VALPROIC ACID 250MG/5ML SYRUP
54868495900	DEPAKOTE ER 500MG TAB.SR 24H
54868495901	DEPAKOTE ER 500MG TAB.SR 24H
54868552500	DEPAKOTE ER 250MG TAB.SR 24H
54868552501	DEPAKOTE ER 250MG TAB.SR 24H
54868607200	DIVALPROEX SODIUM 500 MG TABLET DR
54868607201	DIVALPROEX SODIUM 500 MG TABLET DR
54868607202	DIVALPROEX SODIUM 500 MG TABLET DR
54868607203	DIVALPROEX SODIUM 500 MG TABLET DR
54868608801	DIVALPROEX SODIUM ER 500 MG TAB.SR 24H
54868608802	DIVALPROEX SODIUM ER 500 MG TAB SR 24H
55045248408	DEPAKOTE 250MG TABLET DR
55111052901	DIVALPROEX SODIUM 125MG TABLET DR
55111053001	DIVALPROEX SODIUM 250MG TABLET DR
55111053101	DIVALPROEX SODIUM 500MG TABLET DR
55111053201	DIVALPROEX SODIUM 125MG CAP SPRINK
55111053205	DIVALPROEX SODIUM 125MG CAP SPRINK
55111053301	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
55111053305	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
55111053401	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
55111053405	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
55289040430	DEPAKOTE ER 500MG TAB.SR 24H
55289099130	DEPAKOTE SPRINKLE 125MG CAP SPRINK
55390000710	VALPROATE SODIUM 100MG/ML VIAL
55700005114	DIVALPROEX SODIUM 500 MG TABLET DR
55700005130	DIVALPROEX SODIUM 500 MG TABLET DR

NDC	Description
55700005160	DIVALPROEX SODIUM 500 MG TABLET DR
55700005190	DIVALPROEX SODIUM 500 MG TABLET DR
55700008730	DIVALPROEX SODIUM 250 MG TABLET DR
55700008760	DIVALPROEX SODIUM 250 MG TABLET DR
55700009860	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
55700009960	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
55700011530	VALPROIC ACID 250 MG CAPSULE
55700011560	VALPROIC ACID 250 MG CAPSULE
56126010611	VALPROIC ACID 250MG CAPSULE
57237004601	DIVALPROEX SODIUM 125 MG TABLET DR
57237004605	DIVALPROEX SODIUM 125 MG TABLET DR
57237004701	DIVALPROEX SODIUM 250 MG TABLET DR
57237004705	DIVALPROEX SODIUM 250 MG TABLET DR
57237004801	DIVALPROEX SODIUM 500 MG TABLET DR
57237004805	DIVALPROEX SODIUM 500 MG TABLET DR
57237010601	DIVALPROEX SODIUM 125 MG TABLET DR
57237010605	DIVALPROEX SODIUM 125 MG TABLET DR
57480048401	VALPROIC ACID 250MG CAPSULE
57664012434	VALPROIC ACID 250 MG/5ML SOLUTION
57866447701	VALPROIC ACID 250MG CAPSULE
57866639102	DEPAKOTE 500MG TABLET DR
00580137301	VALPROIC ACID 250 MG CAPSULE
58016008500	VALPROIC ACID 250MG CAPSULE
58016008530	VALPROIC ACID 250MG CAPSULE
58016008560	VALPROIC ACID 250MG CAPSULE
58016008590	VALPROIC ACID 250MG CAPSULE
58016068700	DEPAKOTE 250MG TABLET DR
58016068730	DEPAKOTE 250MG TABLET DR
58016068760	DEPAKOTE 250MG TABLET DR
58016068790	DEPAKOTE 250MG TABLET DR
58016077430	DEPAKOTE 500MG TABLET DR
58016077460	DEPAKOTE 500MG TABLET DR
58016077490	DEPAKOTE 500MG TABLET DR
00580172501	DIVALPROEX SODIUM 250 MG TABLET DR

NDC	Description
00580172601	DIVALPROEX SODIUM 500 MG TABLET DR
58469447730	VALPROIC ACID 250 MG CAPSULE
58864063030	DEPAKOTE 250MG TABLET DR
58864063060	DEPAKOTE 250MG TABLET DR
58864063098	DEPAKOTE 250MG TABLET DR
58864080530	DEPAKOTE 500MG TABLET DR
58864080560	DEPAKOTE 500MG TABLET DR
58864081350	DIVALPROEX SODIUM 500MG TABLET DR
58864082960	VALPROIC ACID 250MG CAPSULE
00591042616	VALPROIC ACID 250MG/5ML SYRUP
00591401201	VALPROIC ACID 250MG CAPSULE
59762130301	DIVALPROEX SODIUM 125 MG TABLET DR
59762130401	DIVALPROEX SODIUM 250 MG TABLET DR
59762130501	DIVALPROEX SODIUM 500 MG TABLET DR
00603184058	VALPROIC ACID 250MG/5ML SYRUP
00603184158	VALPROIC ACID 250MG/5ML SYRUP
00603344121	DIVALPROEX SODIUM 125 MG TABLET DR
00603344125	DIVALPROEX SODIUM 125 MG TABLET DR
00603344221	DIVALPROEX SODIUM 250 MG TABLET DR
00603344228	DIVALPROEX SODIUM 250 MG TABLET DR
00603344321	DIVALPROEX SODIUM 500 MG TABLET DR
00603344328	DIVALPROEX SODIUM 500 MG TABLET DR
00603633421	VALPROIC ACID 250MG CAPSULE
60429024601	VALPROIC ACID 250 MG CAPSULE
60432062116	VALPROIC ACID 250MG/5ML SYRUP
60505306501	DIVALPROEX SODIUM 125MG TABLET DR
60505306601	DIVALPROEX SODIUM 250MG TABLET DR
60505306605	DIVALPROEX SODIUM 250MG TABLET DR
60505306701	DIVALPROEX SODIUM 500MG TABLET DR
60505306705	DIVALPROEX SODIUM 500MG TABLET DR
60687021111	DIVALPROEX SODIUM 125 MG TABLET DR
60687021121	DIVALPROEX SODIUM 125 MG TABLET DR
61392015730	VALPROIC ACID 250MG CAPSULE
61392015731	VALPROIC ACID 250MG CAPSULE

NDC	Description
61392015732	VALPROIC ACID 250MG CAPSULE
61392015739	VALPROIC ACID 250MG CAPSULE
61392015745	VALPROIC ACID 250MG CAPSULE
61392015751	VALPROIC ACID 250MG CAPSULE
61392015754	VALPROIC ACID 250MG CAPSULE
61392015760	VALPROIC ACID 250MG CAPSULE
61392015790	VALPROIC ACID 250MG CAPSULE
61392015791	VALPROIC ACID 250MG CAPSULE
00615132529	VALPROIC ACID 250MG CAPSULE
00615132543	VALPROIC ACID 250MG CAPSULE
00615132553	VALPROIC ACID 250MG CAPSULE
00615132563	VALPROIC ACID 250MG CAPSULE
00615132565	VALPROIC ACID 250MG CAPSULE
61919064830	DIVALPROEX SODIUM 500 MG TABLET DR
61919064860	DIVALPROEX SODIUM 500 MG TABLET DR
61919080960	DIVALPROEX SODIUM 250 MG TABLET DR
62584089401	VALPROIC ACID 250MG CAPSULE
62756079613	DIVALPROEX SODIUM 125MG TABLET DR
62756079688	DIVALPROEX SODIUM 125MG TABLET DR
62756079713	DIVALPROEX SODIUM 250MG TABLET DR
62756079788	DIVALPROEX SODIUM 250MG TABLET DR
62756079813	DIVALPROEX SODIUM 500MG TABLET DR
62756079888	DIVALPROEX SODIUM 500MG TABLET DR
62756087388	VALPROIC ACID 250 MG CAPSULE
63187074260	DIVALPROEX SODIUM 250 MG TABLET DR
63187074360	DIVALPROEX SODIUM 500 MG TABLET DR
63323049401	VALPROATE SODIUM 500 MG/5ML VIAL
63323049405	VALPROATE SODIUM 100MG/ML VIAL
63323049416	VALPROATE SODIUM 500 MG/5ML VIAL
63629337001	DEPAKOTE ER 500 MG TAB.SR 24H
63629337002	DEPAKOTE ER 500MG TAB.SR 24H
63629337003	DEPAKOTE ER 500 MG TAB.SR 24H
63629427801	DIVALPROEX SODIUM 500 MG TABLET DR
63629427802	DIVALPROEX SODIUM 500 MG TABLET DR

NDC	Description
63629427803	DIVALPROEX SODIUM 500 MG TABLET DR
63739025101	VALPROIC ACID 250MG CAPSULE
63739025102	VALPROIC ACID 250MG CAPSULE
63739025103	VALPROIC ACID 250MG CAPSULE
63739025110	VALPROIC ACID 250MG CAPSULE
63739025115	VALPROIC ACID 250MG CAPSULE
63739055310	DIVALPROEX SODIUM 250 MG TABLET DR
63739055410	DIVALPROEX SODIUM 500 MG TABLET DR
64679072401	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
64679072402	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
64679072403	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
64679072501	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
64679072502	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
64679072503	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
64679097301	DIVALPROEX SODIUM 125MG TABLET DR
64679097401	DIVALPROEX SODIUM 250MG TABLET DR
64679097402	DIVALPROEX SODIUM 250MG TABLET DR
64679097501	DIVALPROEX SODIUM 500MG TABLET DR
64679097502	DIVALPROEX SODIUM 500MG TABLET DR
65162075510	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
65162075550	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
65162075710	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
65162075750	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
65862040101	DIVALPROEX SODIUM 125 MG TABLET DR
65862040105	DIVALPROEX SODIUM 125 MG TABLET DR
65862040201	DIVALPROEX SODIUM 250 MG TABLET DR
65862040205	DIVALPROEX SODIUM 250 MG TABLET DR
65862040301	DIVALPROEX SODIUM 500 MG TABLET DR
65862040305	DIVALPROEX SODIUM 500 MG TABLET DR
65862059401	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
65862059499	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
65862059501	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
65862059505	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
66336005190	DEPAKOTE ER 500MG TAB.SR 24H

NDC	Description
00665412006	VALPROIC ACID 250MG CAPSULE
67544028053	DEPAKOTE 500MG TABLET DR
67544028060	DEPAKOTE 500MG TABLET DR
67544034853	VALPROIC ACID 250MG CAPSULE
67544034860	VALPROIC ACID 250MG CAPSULE
67544034865	VALPROIC ACID 250 MG CAPSULE
67544034870	VALPROIC ACID 250 MG CAPSULE
67544034880	VALPROIC ACID 250 MG CAPSULE
67544034890	VALPROIC ACID 250 MG CAPSULE
67544034894	VALPROIC ACID 250 MG CAPSULE
67544047953	VALPROIC ACID 250 MG CAPSULE
67544047960	VALPROIC ACID 250 MG CAPSULE
67544047970	VALPROIC ACID 250 MG CAPSULE
67544047980	VALPROIC ACID 250 MG CAPSULE
67544047990	VALPROIC ACID 250 MG CAPSULE
67544047994	VALPROIC ACID 250 MG CAPSULE
67544090495	DEPAKOTE ER 250MG TAB.SR 24H
67544134680	DEPAKOTE ER 500MG TAB.SR 24H
00677107901	VALPROIC ACID 250MG CAPSULE
00677107933	VALPROIC ACID 250 MG/5ML SOLUTION
00677115533	VALPROIC ACID 250MG/5ML SYRUP
68001010500	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
68001010503	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
68001010600	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
68001010603	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
68071077530	DIVALPROEX SODIUM 250 MG TABLET DR
68084031001	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
68084031011	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
68084031301	DIVALPROEX SODIUM 125MG CAP SPRINK
68084031311	DIVALPROEX SODIUM 125MG CAP SPRINK
68084031401	DIVALPROEX SODIUM 250MG TABLET DR
68084031411	DIVALPROEX SODIUM 250MG TABLET DR
68084031501	DIVALPROEX SODIUM 500MG TABLET DR
68084031511	DIVALPROEX SODIUM 500MG TABLET DR

NDC	Description
68084031601	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
68084031611	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
68084031701	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
68084031711	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
68084041501	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
68084041511	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
68084063911	ZONISAMIDE 100 MG CAPSULE
68084063965	ZONISAMIDE 100 MG CAPSULE
68084077601	DIVALPROEX SODIUM 250 MG TABLET DR
68084077611	DIVALPROEX SODIUM 250 MG TABLET DR
68084077635	DIVALPROEX SODIUM 250 MG TABLET DR
68084077695	DIVALPROEX SODIUM 250 MG TABLET DR
68084078201	DIVALPROEX SODIUM 500 MG TABLET DR
68084078211	DIVALPROEX SODIUM 500 MG TABLET DR
68084078232	DIVALPROEX SODIUM 500 MG TABLET DR
68084078233	DIVALPROEX SODIUM 500 MG TABLET DR
68084078261	DIVALPROEX SODIUM 500 MG TABLET DR
68094019358	VALPROIC ACID 250MG/5ML SYRUP
68094019359	VALPROIC ACID 250MG/5ML SYRUP
68094019361	VALPROIC ACID 250MG/5ML SYRUP
68094019362	VALPROIC ACID 250MG/5ML SYRUP
68094070159	VALPROIC ACID 500MG/10ML SOLUTION
68094070161	VALPROIC ACID 250MG/5ML SYRUP
68094070162	VALPROIC ACID 250MG/5ML SYRUP
68115037300	DEPAKOTE 500MG TABLET DR
68115037315	DEPAKOTE 500MG TABLET DR
68115037330	DEPAKOTE 500MG TABLET DR
68115037360	DEPAKOTE 500MG TABLET DR
68115037390	DEPAKOTE 500MG TABLET DR
68115046700	DEPAKOTE ER 250MG TAB.SR 24H
68115046730	DEPAKOTE ER 250MG TAB.SR 24H
68180026501	DIVALPROEX SODIUM 125MG TABLET DR
68180026601	DIVALPROEX SODIUM 250MG TABLET DR
68180026602	DIVALPROEX SODIUM 250MG TABLET DR

NDC	Description
68180026701	DIVALPROEX SODIUM 500MG TABLET DR
68180026702	DIVALPROEX SODIUM 500MG TABLET DR
68258103101	DEPAKOTE ER 500MG TAB.SR 24H
68382003101	DIVALPROEX SODIUM 125 MG TABLET DR
68382003105	DIVALPROEX SODIUM 125 MG TABLET DR
68382003201	DIVALPROEX SODIUM 250 MG TABLET DR
68382003205	DIVALPROEX SODIUM 250 MG TABLET DR
68382003301	DIVALPROEX SODIUM 500 MG TABLET DR
68382003305	DIVALPROEX SODIUM 500 MG TABLET DR
68382010601	DIVALPROEX SODIUM 125MG CAP SPRINK
68382010610	DIVALPROEX SODIUM 125MG CAP SPRINK
68382031401	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
68382031405	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
68382031501	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
68382031505	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
68968312501	STAVZOR 125MG CAPSULE DR
68968325001	STAVZOR 250MG CAPSULE DR
68968350001	STAVZOR 500MG CAPSULE DR
69097086107	ZONISAMIDE 100 MG CAPSULE
69387010701	VALPROIC ACID 250 MG CAPSULE
69452015020	VALPROIC ACID 250 MG CAPSULE
00701062116	MYPROIC ACID 250 MG/5ML SOLUTION
71610003030	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
71610003060	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
71610003075	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
71610003080	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
71610003092	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
71610003160	DIVALPROEX SODIUM 250 MG TABLET DR
71610003253	DIVALPROEX SODIUM 500 MG TABLET DR
71610003260	DIVALPROEX SODIUM 500 MG TABLET DR
71610020153	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610020160	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610020170	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610020530	DIVALPROEX SODIUM ER 500 MG TAB ER 24H

NDC	Description
71610020553	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610020560	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610020570	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610020575	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610020580	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610024953	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610024960	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610024970	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610028930	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
71610028960	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
71610028975	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
71610031153	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610031160	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
71610031170	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
00719129210	DIVALPROEX SODIUM 125 MG TABLET DR
00719129310	DIVALPROEX SODIUM 250 MG TABLET DR
00719129410	DIVALPROEX SODIUM 500 MG TABLET DR
00719198910	VALPROIC ACID 250 MG CAPSULE
00719199110	VALPROIC ACID 250 MG CAPSULE
00719486783	VALPROIC ACID 250 MG/5ML SOLUTION
72189001030	VALPROIC ACID 250 MG CAPSULE
00074156410	DEPAICON 100MG/ML VIAL
00074382611	DEPAKOTE ER 250MG TAB.SR 24H
00074382613	DEPAKOTE ER 250MG TAB.SR 24H
00074568111	DEPAKENE 250MG CAPSULE
00074568113	DEPAKENE 250MG CAPSULE
00074568216	DEPAKENE 250MG/5ML SYRUP
00074611411	DEPAKOTE SPRINKLE 125MG CAP SPRINK
00074611413	DEPAKOTE SPRINKLE 125MG CAP SPRINK
00074621211	DEPAKOTE 125MG TABLET DR
00074621213	DEPAKOTE 125MG TABLET DR
00074621411	DEPAKOTE 250MG TABLET DR
00074621413	DEPAKOTE 250MG TABLET DR
00074621453	DEPAKOTE 250MG TABLET DR

NDC	Description
00074621511	DEPAKOTE 500MG TABLET DR
00074621513	DEPAKOTE 500MG TABLET DR
00074621553	DEPAKOTE 500MG TABLET DR
00074712611	DEPAKOTE ER 500MG TAB.SR 24H
00074712613	DEPAKOTE ER 500MG TAB.SR 24H
00074712653	DEPAKOTE ER 500MG TAB.SR 24H
00781121701	DIVALPROEX SODIUM 125MG TABLET DR
00781121801	DIVALPROEX SODIUM 250MG TABLET DR
00781121805	DIVALPROEX SODIUM 250MG TABLET DR
00781121901	DIVALPROEX SODIUM 500MG TABLET DR
00781121905	DIVALPROEX SODIUM 500MG TABLET DR
00781220301	VALPROIC ACID 250MG CAPSULE
00781224301	DIVALPROEX SODIUM 125 MG CAP SPRINK
00781670116	VALPROIC ACID 250MG/5ML SYRUP
00814824014	VALPROIC ACID 250 MG CAPSULE
00832031011	VALPROIC ACID 250 MG CAPSULE
00832100700	VALPROIC ACID 250MG CAPSULE
00832100800	VALPROIC ACID 250MG CAPSULE
00832100811	VALPROIC ACID 250 MG CAPSULE
00832712211	DIVALPROEX SODIUM 125 MG TABLET DR
00832712215	DIVALPROEX SODIUM 125 MG TABLET DR
00832712301	DIVALPROEX SODIUM 250 MG TABLET DR
00832712311	DIVALPROEX SODIUM 250 MG TABLET DR
00832712315	DIVALPROEX SODIUM 250 MG TABLET DR
00832712389	DIVALPROEX SODIUM 250 MG TABLET DR
00832712401	DIVALPROEX SODIUM 500 MG TABLET DR
00832712411	DIVALPROEX SODIUM 500 MG TABLET DR
00832712415	DIVALPROEX SODIUM 500 MG TABLET DR
00832712489	DIVALPROEX SODIUM 500 MG TABLET DR
00832862116	VALPROIC ACID 250 MG/5ML SOLUTION
00839718006	VALPROIC ACID 250MG CAPSULE
00839719569	VALPROIC ACID 250MG/5ML SYRUP
00839756706	DIVALPROEX SODIUM 125 MG TABLET DR
00839756806	DIVALPROEX SODIUM 250 MG TABLET DR

NDC	Description
00839756812	DIVALPROEX SODIUM 250 MG TABLET DR
00839756906	DIVALPROEX SODIUM 500 MG TABLET DR
00839756912	DIVALPROEX SODIUM 500 MG TABLET DR
00839784006	VALPROIC ACID 250MG CAPSULE
00904159060	DIVALPROEX SODIUM 125 MG TABLET DR
00904159160	DIVALPROEX SODIUM 250 MG TABLET DR
00904159260	DIVALPROEX SODIUM 500 MG TABLET DR
00904210040	DALPRO 250 MG CAPSULE
00904210060	DALPRO 250 MG CAPSULE
00904210070	DALPRO 250 MG CAPSULE
00904210160	VALPROIC ACID 250MG CAPSULE
00904210316	VALPROIC ACID 250MG/5ML SYRUP
00904599061	DIVALPROEX SODIUM ER 250MG TAB.SR 24H
00904607361	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
00904636345	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
00904636361	DIVALPROEX SODIUM ER 250 MG TAB ER 24H
00904636445	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
00904636461	DIVALPROEX SODIUM ER 500 MG TAB ER 24H
00904661561	DIVALPROEX SODIUM 125 MG CAP DR SPR
00904686061	DIVALPROEX SODIUM 250 MG TABLET DR
00904686190	DIVALPROEX SODIUM 500 MG TABLET DR
00904776560	VALPROIC ACID 250MG CAPSULE
00093063201	VALPROIC ACID 250 MG CAPSULE
00093734001	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
00093734005	DIVALPROEX SODIUM ER 500MG TAB.SR 24H
00093743901	DIVALPROEX SODIUM 125MG TABLET DR
00093744001	DIVALPROEX SODIUM 250MG TABLET DR
00093744005	DIVALPROEX SODIUM 250MG TABLET DR
00093744101	DIVALPROEX SODIUM 500MG TABLET DR
00093744105	DIVALPROEX SODIUM 500MG TABLET DR
00093963316	VALPROIC ACID 250MG/5ML SYRUP
15330010301	ZONISAMIDE 25MG CAPSULE
15330010401	ZONISAMIDE 50MG CAPSULE
15330010501	ZONISAMIDE 100MG CAPSULE

NDC	Description
16590025230	ZONEGRAN 100MG CAPSULE
16590025260	ZONEGRAN 100MG CAPSULE
16590025290	ZONEGRAN 100MG CAPSULE
16590072460	ZONISAMIDE 25 MG CAPSULE
00185019301	ZONISAMIDE 25MG CAPSULE
00185019901	ZONISAMIDE 50MG CAPSULE
00185020001	ZONISAMIDE 100MG CAPSULE
21695015560	ZONISAMIDE 100MG CAPSULE
21695015590	ZONISAMIDE 100 MG CAPSULE
21695065460	ZONISAMIDE 50 MG CAPSULE
31722022801	ZONISAMIDE 100 MG CAPSULE
33358037130	ZONEGRAN 100MG CAPSULE
33358037160	ZONEGRAN 100MG CAPSULE
35356009301	ZONISAMIDE 25MG CAPSULE
35356009330	ZONISAMIDE 25MG CAPSULE
35356009360	ZONISAMIDE 25MG CAPSULE
35356009390	ZONISAMIDE 25MG CAPSULE
35356009430	ZONISAMIDE 50MG CAPSULE
35356014000	ZONEGRAN 100MG CAPSULE
35356014030	ZONEGRAN 100MG CAPSULE
35356014060	ZONEGRAN 100MG CAPSULE
35356014330	ZONISAMIDE 100MG CAPSULE
35356014360	ZONISAMIDE 100MG CAPSULE
35356014390	ZONISAMIDE 100 MG CAPSULE
00378672501	ZONISAMIDE 25MG CAPSULE
00378672601	ZONISAMIDE 50MG CAPSULE
00378672701	ZONISAMIDE 100MG CAPSULE
00378672705	ZONISAMIDE 100MG CAPSULE
42254041760	ZONISAMIDE 50 MG CAPSULE
43063057514	ZONISAMIDE 25 MG CAPSULE
43063057530	ZONISAMIDE 25 MG CAPSULE
43063093230	ZONISAMIDE 25 MG CAPSULE
00440876091	ZONISAMIDE 25MG CAPSULE
00440876160	ZONISAMIDE 50MG CAPSULE

NDC	Description
00440876191	ZONISAMIDE 50MG CAPSULE
00440876230	ZONISAMIDE 100MG CAPSULE
00440876260	ZONISAMIDE 100MG CAPSULE
00440876291	ZONISAMIDE 100MG CAPSULE
50268081515	ZONISAMIDE 100 MG CAPSULE
50268081611	ZONISAMIDE 100 MG CAPSULE
50268081615	ZONISAMIDE 100 MG CAPSULE
51079076801	ZONISAMIDE 100 MG CAPSULE
51079076820	ZONISAMIDE 100MG CAPSULE
51407013701	ZONISAMIDE 25 MG CAPSULE
51407013801	ZONISAMIDE 50 MG CAPSULE
51407013901	ZONISAMIDE 100 MG CAPSULE
52959089900	ZONEGRAN 100MG CAPSULE
52959089930	ZONEGRAN 100MG CAPSULE
53489061701	ZONISAMIDE 25MG CAPSULE
53489061801	ZONISAMIDE 50MG CAPSULE
53489061901	ZONISAMIDE 100MG CAPSULE
53489061905	ZONISAMIDE 100MG CAPSULE
00054010520	ZONISAMIDE 100MG CAPSULE
00054010525	ZONISAMIDE 100MG CAPSULE
00054010529	ZONISAMIDE 100MG CAPSULE
54569656000	ZONISAMIDE 100 MG CAPSULE
54868578900	ZONISAMIDE 100MG CAPSULE
54868578901	ZONISAMIDE 100 MG CAPSULE
54868622100	ZONISAMIDE 50 MG CAPSULE
55045307506	ZONEGRAN 100MG CAPSULE
55045307508	ZONEGRAN 100MG CAPSULE
55111028801	ZONISAMIDE 100MG CAPSULE
55111040201	ZONISAMIDE 25MG CAPSULE
55111040301	ZONISAMIDE 50MG CAPSULE
00555082702	ZONISAMIDE 25MG CAPSULE
00555082902	ZONISAMIDE 100MG CAPSULE
55700020430	ZONISAMIDE 100 MG CAPSULE
55700020460	ZONISAMIDE 100 MG CAPSULE

NDC	Description
55700020490	ZONISAMIDE 100 MG CAPSULE
55700032530	ZONISAMIDE 25 MG CAPSULE
55887054630	ZONEGRAN 100MG CAPSULE
55887054660	ZONEGRAN 100MG CAPSULE
55887054682	ZONEGRAN 100MG CAPSULE
55887054690	ZONEGRAN 100MG CAPSULE
58016002000	ZONISAMIDE 100MG CAPSULE
58016002030	ZONISAMIDE 100MG CAPSULE
58016002060	ZONISAMIDE 100MG CAPSULE
58016002090	ZONISAMIDE 100MG CAPSULE
58016063600	ZONEGRAN 25MG CAPSULE
58016063630	ZONEGRAN 25MG CAPSULE
58016063660	ZONEGRAN 25MG CAPSULE
58016063690	ZONEGRAN 25MG CAPSULE
58016065000	ZONEGRAN 50MG CAPSULE
58016065030	ZONEGRAN 50MG CAPSULE
58016065060	ZONEGRAN 50MG CAPSULE
58016065090	ZONEGRAN 50MG CAPSULE
59075068010	ZONEGRAN 100MG CAPSULE
59075068110	ZONEGRAN 25MG CAPSULE
59075068210	ZONEGRAN 50MG CAPSULE
59212068010	ZONEGRAN 100 MG CAPSULE
59212068110	ZONEGRAN 25 MG CAPSULE
60505254501	ZONISAMIDE 25MG CAPSULE
60505254601	ZONISAMIDE 50MG CAPSULE
60505254701	ZONISAMIDE 100MG CAPSULE
60687023001	ZONISAMIDE 100 MG CAPSULE
60687023011	ZONISAMIDE 100 MG CAPSULE
60687023065	ZONISAMIDE 100 MG CAPSULE
61919053960	ZONISAMIDE 100 MG CAPSULE
61919077530	ZONISAMIDE 100 MG CAPSULE
61919091760	ZONISAMIDE 100 MG CAPSULE
62756025802	ZONISAMIDE 25MG CAPSULE
62756025902	ZONISAMIDE 50MG CAPSULE

NDC	Description
62756026002	ZONISAMIDE 100MG CAPSULE
62856068010	ZONEGRAN 100MG CAPSULE
62856068110	ZONEGRAN 25MG CAPSULE
62856068210	ZONEGRAN 50MG CAPSULE
63187089730	ZONISAMIDE 100 MG CAPSULE
63304099201	ZONISAMIDE 100MG CAPSULE
63629329301	ZONISAMIDE 100 MG CAPSULE
63629329302	ZONISAMIDE 100 MG CAPSULE
64679094501	ZONISAMIDE 25MG CAPSULE
64679094601	ZONISAMIDE 50MG CAPSULE
64679099001	ZONISAMIDE 100MG CAPSULE
64720017710	ZONISAMIDE 25MG CAPSULE
64720017810	ZONISAMIDE 50MG CAPSULE
64720017910	ZONISAMIDE 100MG CAPSULE
64720017950	ZONISAMIDE 100MG CAPSULE
68001024200	ZONISAMIDE 25 MG CAPSULE
68001024300	ZONISAMIDE 50 MG CAPSULE
68001024400	ZONISAMIDE 100 MG CAPSULE
68001024403	ZONISAMIDE 100 MG CAPSULE
68084000811	ZONISAMIDE 100 MG CAPSULE
68084000865	ZONISAMIDE 100 MG CAPSULE
68084018301	ZONISAMIDE 100MG CAPSULE
68084018311	ZONISAMIDE 100MG CAPSULE
68084019001	ZONISAMIDE 25MG CAPSULE
68084019011	ZONISAMIDE 25MG CAPSULE
68084019101	ZONISAMIDE 50MG CAPSULE
68084019111	ZONISAMIDE 50MG CAPSULE
68084063911	ZONISAMIDE 100 MG CAPSULE
68084063965	ZONISAMIDE 100 MG CAPSULE
68115090900	ZONEGRAN 100MG CAPSULE
68115090960	ZONEGRAN 100MG CAPSULE
68387065060	ZONISAMIDE 100MG CAPSULE
68462012801	ZONISAMIDE 25MG CAPSULE
68462012805	ZONISAMIDE 25MG CAPSULE

NDC	Description
68462012901	ZONISAMIDE 50MG CAPSULE
68462012905	ZONISAMIDE 50MG CAPSULE
68462013001	ZONISAMIDE 100MG CAPSULE
68462013005	ZONISAMIDE 100MG CAPSULE
69097086107	ZONISAMIDE 100 MG CAPSULE
76282022801	ZONISAMIDE 100 MG CAPSULE
00904595661	ZONISAMIDE 100MG CAPSULE
00093716201	ZONISAMIDE 100MG CAPSULE
00093750801	ZONISAMIDE 25MG CAPSULE
00093750901	ZONISAMIDE 50MG CAPSULE

Appendix D. Inpatient Constipation and Serious Complications of Constipation Codes

Inpatient constipation codes

Code	Code type	Code description	Setting
K59.0	ICD-10-CM diagnosis	Constipation	1 IP / 1 ED
K59.00	ICD-10-CM diagnosis	Constipation, unspecified	1 IP / 1 ED
K59.01	ICD-10-CM diagnosis	Slow transit constipation	1 IP / 1 ED
K59.02	ICD-10-CM diagnosis	Outlet dysfunction constipation	1 IP / 1 ED
K59.03	ICD-10-CM diagnosis	Drug induced constipation	1 IP / 1 ED
K59.04	ICD-10-CM diagnosis	Chronic idiopathic constipation	1 IP / 1 ED
K59.09	ICD-10-CM diagnosis	Other constipation	1 IP / 1 ED

Abbreviations: ICD-10-CM: International Classification of Diseases, 10th Revision, Clinical Modification; IP: inpatient, ED: emergency department

Serious complications of constipation codes

Code	Code type	Code description	Setting
K56.41	ICD-10-CM diagnosis	Fecal impaction	1 IP / 1 ED
K56.49	ICD-10-CM diagnosis	Other impaction of intestine	1 IP / 1 ED
K56.60	ICD-10-CM diagnosis	Unspecified intestinal obstruction	1 IP / 1 ED
K56.600	ICD-10-CM diagnosis	Partial intestinal obstruction, unspecified as to cause	1 IP / 1 ED
K56.601	ICD-10-CM diagnosis	Complete intestinal obstruction, unspecified as to cause	1 IP / 1 ED
K56.609	ICD-10-CM diagnosis	Unspecified intestinal obstruction, unspecified as to partial versus complete obstruction	1 IP / 1 ED
K59.39	ICD-10-CM diagnosis	Other megacolon	1 IP / 1 ED
K62.2	ICD-10-CM diagnosis	Anal prolapse	1 IP / 1 ED
K62.3	ICD-10-CM diagnosis	Rectal prolapse	1 IP / 1 ED
K60.2	ICD-10-CM diagnosis	Anal fissure, unspecified	1 IP / 1 ED
K60.3	ICD-10-CM diagnosis	Anal fistula	1 IP / 1 ED
K60.4	ICD-10-CM diagnosis	Rectal fistula	1 IP / 1 ED
K60.5	ICD-10-CM diagnosis	Anorectal fistula	1 IP / 1 ED
K62.6	ICD-10-CM diagnosis	Ulcer of anus and rectum	1 IP / 1 ED
K56.0	ICD-10-CM diagnosis	Paralytic ileus	1 IP / 1 ED
K56.7	ICD-10-CM diagnosis	Ileus, unspecified	1 IP / 1 ED

Abbreviations: ICD-10-CM: International Classification of Diseases, 10th Revision, Clinical Modification; IP: inpatient, ED: emergency department